<PAGE>
- - - --------------------------------------------------------------------------------
- - - --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------------
FORM 10
GENERAL FORM FOR REGISTRATION OF SECURITIES
PURSUANT TO SECTION 12(B) OR 12(G) OF
THE SECURITIES EXCHANGE ACT OF 1934
------------------------
ALLEGIANCE CORPORATION
(Exact name of registrant as specified in its charter)
DELAWARE XX-XXXXXXX
(State or other jurisdiction of (IRS Employer Identification No.)
incorporation or organization)
ONE BAXTER PARKWAY, DEERFIELD, ILLINOIS 60015
(Address of principal executive offices) (Zip Code)
Securities to be registered pursuant to Section 12(b) of the Act:
TITLE OF EACH CLASS NAME OF EACH EXCHANGE ON WHICH
TO BE SO REGISTERED EACH CLASS IS TO BE REGISTERED
- - - -------------------------------------- --------------------------------------
Common Stock, $1.00 par value New York Stock Exchange
Series A Junior Participating New York Stock Exchange
Preferred Stock Purchase Rights
(Currently traded with common stock)
Securities to be registered pursuant to Section 12(g) of the Act: None
- - - --------------------------------------------------------------------------------
- - - --------------------------------------------------------------------------------
<PAGE>
[LOGO]
Baxter International Inc.
One Baxter Parkway
Deerfield, Illinois 60015
847.948.2000
, 1996
To all Baxter International Inc. Stockholders:
I am pleased to inform you that on , 1996, Baxter's Board of
Directors declared a stock dividend to achieve a distribution of all the
outstanding shares of common stock of Allegiance Corporation to all Baxter
stockholders of record on September , 1996.
Allegiance Corporation is a new company, formed initially as a wholly owned
subsidiary of Baxter, that will own and operate the United States distribution,
surgical and respiratory therapy products and health-care cost management
services operations presently conducted by Baxter. When the distribution is
completed, Allegiance and Baxter will be able to focus more sharply on their
respective core businesses: high-tech medical specialties for Baxter; and
health-care distribution, products and cost management services for Allegiance.
Following the distribution, Allegiance Corporation will be an independent
publicly-owned company.
If you are a Baxter stockholder of record at the close of business on
September , 1996, the record date for the distribution, you will receive one
share of Allegiance common stock for every [six] shares of Baxter common stock
you own. Allegiance stock certificates will be distributed beginning ,
1996. No action is required on your part to receive your Allegiance stock.
The attached Information Statement, which is being mailed to all Baxter
stockholders, describes the distribution in detail and contains important
information about Allegiance, including financial statements.
We expect that Allegiance's common stock will be listed and traded on the
New York Stock Exchange and that its stock symbol will be " ."
Sincerely,
Vernon R. Loucks Jr.
CHAIRMAN OF THE BOARD OF DIRECTORS
AND CHIEF EXECUTIVE OFFICER
<PAGE>
[LOGO]
ALLEGIANCE CORPORATION
1430 WAUKEGAN ROAD
MCGAW PARK, ILLINOIS 60085
, 1996
Dear Stockholder:
It is my pleasure to welcome you as a stockholder of Allegiance Corporation.
We are America's largest provider of health-care products and cost-management
services. Our mission is to help hospitals and others throughout the health-care
field fulfill their mission of serving patients. We will succeed by focusing on
three things: providing high-quality products, excellent service and innovative
ways of managing costs.
I invite you to learn more about Allegiance in the attached Information
Statement. We are a new public company, but we have been serving health care for
more than 70 years. We bring to the marketplace a great base of experience,
breadth of capabilities, commitment to service, strong customer relationships
and financial strength. In 1995, we recorded net revenues of approximately $4.5
billion.
The health-care marketplace is increasingly competitive and cost-conscious.
This presents an opportunity for Allegiance, which enjoys leading positions in
the distribution and manufacturing of health-care products, and in providing a
range of cost-management services. More important, we are the only company that
integrates these capabilities to address one of the most significant challenges
facing health-care professionals: the need to control costs and improve the
quality of patient care at the same time.
Our management team is eager to distinguish Allegiance by continued
leadership and solid financial performance. We are pleased that you will
participate in our mission as a stockholder of Allegiance Corporation.
Sincerely,
Lester B. Knight
CHAIRMAN OF THE BOARD AND
CHIEF EXECUTIVE OFFICER
<PAGE>
Subject to completion, dated June 28, 1996
INFORMATION STATEMENT
[LOGO]
ALLEGIANCE CORPORATION
COMMON STOCK
(PAR VALUE $1.00 PER SHARE)
This Information Statement is being furnished to stockholders of Baxter
International Inc. in connection with the Distribution by Baxter to its
stockholders of all the outstanding shares of common stock of its wholly-owned
subsidiary, Allegiance Corporation.
It is expected that the Distribution will be made on , 1996, to
holders of record of Baxter common stock on , 1996, on the basis of one
share of common stock of Allegiance Corporation for every shares of common
stock of Baxter International Inc. No consideration will be required to be paid
by stockholders of Baxter for the shares of common stock of Allegiance
Corporation to be distributed, nor will they be required to surrender or
exchange shares of common stock of Baxter International Inc. or take any other
action in order to receive common stock of Allegiance Corporation. Application
has been made to list the common stock of Allegiance Corporation on the New York
Stock Exchange under the symbol " ."
In reviewing this Information Statement, you should carefully consider the
matters described under the caption "RISK FACTORS." Neither Baxter nor
Allegiance will receive any cash or other proceeds from the Distribution.
------------------------
NO VOTE OF STOCKHOLDERS IS REQUIRED IN CONNECTION WITH THE DISTRIBUTION.
WE ARE NOT ASKING YOU FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND US A
PROXY.
------------------------
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES
AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE
COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON THE
ACCURACY OR ADEQUACY OF THIS INFORMATION STATEMENT. ANY
REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
THIS INFORMATION STATEMENT DOES NOT CONSTITUTE AN OFFER TO SELL OR THE
SOLICITATION OF AN OFFER TO BUY ANY SECURITIES. ANY SUCH OFFERING MAY
ONLY BE MADE BY MEANS OF A SEPARATE PROSPECTUS PURSUANT TO AN
EFFECTIVE REGISTRATION STATEMENT AND OTHERWISE IN
COMPLIANCE WITH APPLICABLE LAW.
THE DATE OF THIS INFORMATION STATEMENT IS , 1996.
<PAGE>
AVAILABLE INFORMATION
Allegiance has filed with the Securities and Exchange Commission (the
"Commission") a Registration Statement on Form 10 (as amended, the "Registration
Statement") under the Securities Exchange Act of 1934, as amended and the rules
promulgated thereunder (the "Exchange Act"), with respect to its common stock
and preferred stock purchase rights. This Information Statement does not contain
all of the information in the Registration Statement and the related exhibits
and schedule. Statements in this Information Statement as to the contents of any
contract, agreement or other document are summaries only and are not necessarily
complete. For complete information as to these matters, refer to the applicable
exhibit or schedule to the Registration Statement. The Registration Statement
and the related exhibits and schedule filed by Allegiance with the Commission
may be inspected and copied at the public reference facilities maintained by the
Commission at Room 1024, 450 Fifth Street, N.W., Washington, D.C. 20549, as well
as at the Regional Offices of the Commission at Citicorp Center, 500 West
Madison Street, Suite 1400, Chicago, Illinois 60661 and 7 World Trade Center,
13th Floor, New York, New York 10048. Copies of such information may be obtained
by mail from the Public Reference Branch of the Commission at 450 Fifth Street,
N.W., Washington, D.C. 20549, at prescribed rates. In addition, electronic
copies of the Registration Statement and all related exhibits and schedule may
be accessed on the world wide web via the Commission's EDGAR database at its
website (http://www.sec.gov/edgarhp.htm).
Following the Distribution, Allegiance will be required to comply with the
reporting requirements of the Exchange Act and will file annual, quarterly and
other reports with the Commission. Allegiance will also be subject to the proxy
solicitation requirements of the Exchange Act and, accordingly, will furnish
audited financial statements to its stockholders in connection with its annual
meeting of stockholders. Allegiance also intends to furnish quarterly reports
for the first three quarters of each fiscal year containing unaudited financial
information.
NO PERSON IS AUTHORIZED BY BAXTER OR ALLEGIANCE TO GIVE ANY INFORMATION OR TO
MAKE ANY REPRESENTATIONS OTHER THAN THOSE CONTAINED IN THIS INFORMATION
STATEMENT, AND, IF GIVEN OR MADE, SUCH INFORMATION OR REPRESENTATIONS
MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED.
2
<PAGE>
SUMMARY
THIS IS A SUMMARY. IT IS QUALIFIED BY THE MORE DETAILED INFORMATION
(INCLUDING FINANCIAL INFORMATION AND RELATED NOTES) IN THIS INFORMATION
STATEMENT, WHICH SHOULD BE READ IN ITS ENTIRETY. CAPITALIZED TERMS IN THIS
SUMMARY NOT DEFINED HERE ARE DEFINED ELSEWHERE IN THIS INFORMATION STATEMENT.
THE DISTRIBUTION
<TABLE>
<S> <C>
DISTRIBUTING COMPANY.............. Baxter International Inc., a Delaware corporation
("Baxter").
SHARES TO BE DISTRIBUTED.......... Approximately [45],000,000 shares of common stock, par
value $1.00 per share, of Allegiance Corporation, a
Delaware corporation ("Allegiance"), along with
associated preferred stock purchase rights. The
Allegiance common stock and such rights are collectively
referred to as the "Allegiance Stock", representing all
of the Allegiance Stock outstanding on the Record Date,
based on approximately [272] million shares of common
stock of Baxter ("Baxter Stock") expected to be
outstanding on the Record Date. See "DESCRIPTION OF
ALLEGIANCE CAPITAL STOCK."
ALLEGIANCE; BUSINESS OF
DISTRIBUTED COMPANY.............. Through its subsidiaries, Allegiance is America's
largest provider of health-care products and
cost-management services. On or before the Distribution
Date, Baxter will transfer to Allegiance specified
assets and liabilities that comprise the Allegiance
Business. On and after the Distribution Date, Allegiance
will be an independent publicly held company. See
"ALLEGIANCE BUSINESS" and "ALLEGIANCE PRO-FORMA
FINANCIAL INFORMATION."
REASONS FOR THE DISTRIBUTION...... The Distribution will enable Allegiance and Baxter each
to align its reporting structure, cost structure,
culture, and management process in support of its basic
mission. It will enable management of Allegiance to
focus more precisely on cost management service
initiatives, integrated with offerings of products
manufactured by Allegiance, Baxter and others. The
Distribution will enable Allegiance to more easily form
alliances with companies manufacturing products
competitive with Baxter products and to define its own
investment vision and raise capital without competition
for funds from Baxter's technology businesses. Meanwhile
Baxter management will focus on creating innovative
medical specialty products and on expanding sales
outside the United States. The Distribution will allow
investors to better evaluate the merits of Allegiance
and the remaining Baxter businesses, enhancing the
likelihood that each will achieve appropriate market
recognition for its performance.
DISTRIBUTION RATIO................ Expected to be one share of Allegiance Stock for every
[six] shares of Baxter Stock. See "THE DISTRIBUTION --
MANNER OF EFFECTING THE DISTRIBUTION."
</TABLE>
3
<PAGE>
<TABLE>
<S> <C>
FRACTIONAL SHARES OF ALLEGIANCE
STOCK............................ No fractional shares of Allegiance Stock will be
distributed. A cash payment will be made to Baxter
stockholders otherwise entitled to a fractional share of
Allegiance Stock as a result of the Distribution. The
amount of such payment will depend upon the prices at
which the fractional shares are sold by the Distribution
Agent in the open market on or around the Distribution
Date. See "THE DISTRIBUTION -- MANNER OF EFFECTING THE
DISTRIBUTION."
RISK FACTORS...................... The businesses of Allegiance are subject to certain
risks, and Allegiance Stock will be subject to those
same risks. Stockholders should carefully consider the
matters described under "RISK FACTORS."
BUSINESSES RETAINED BY BAXTER..... After the Distribution, Baxter will continue to operate
its high-technology medical specialties products
businesses.
DISTRIBUTION AGENT................ The First Chicago Trust Company of New York
RECORD DATE....................... The close of business on September , 1996 (the "Record
Date").
DISTRIBUTION DATE................. The close of business on , 1996 (the
"Distribution Date"). On the Distribution Date, the
Distribution Agent will begin distribution of
certificates for Allegiance Stock to holders of Baxter
Stock on the Record Date. Baxter stockholders will not
be required to make any payment or to take any other
action to receive their Allegiance Stock. See "THE
DISTRIBUTION -- MANNER OF EFFECTING THE DISTRIBUTION."
FEDERAL INCOME TAX CONSEQUENCES... In March 1996, Baxter applied for a tax ruling (the "Tax
Ruling") from the U.S. Internal Revenue Service (the
"IRS") to the effect, among other things, that the
receipt of Allegiance Stock by stockholders of Baxter in
the Distribution will qualify under Section 355 of the
Internal Revenue Code of 1986, as amended (the "Code").
The Distribution is contingent upon receipt of a Tax
Ruling (or a favorable opinion of counsel as to tax
matters) on or prior to , 1996. See "THE
DISTRIBUTION -- CERTAIN FEDERAL INCOME TAX CONSEQUENCES
OF THE DISTRIBUTION."
</TABLE>
4
<PAGE>
<TABLE>
<S> <C>
RELATIONSHIP BETWEEN BAXTER AND
ALLEGIANCE AFTER THE
DISTRIBUTION..................... Allegiance and Baxter will pursue independent but
mutually supportive courses. Each will have its own
strategies and interests, while recognizing the
advantages of working together. Allegiance will have
significant continuing relationships with Baxter as an
agent, distributor, customer and supplier for a wide
array of health-care products and services, and for
certain administrative support services. Allegiance will
be Baxter's primary agent in distributing Baxter's
intravenous solutions, cardiovascular devices and other
products in the United States and will provide to Baxter
certain administrative services including credit and
collection, accounts payable, information technology and
telecommunications. Baxter will distribute Allegiance's
products in many countries around the world and will
provide various administrative services to Allegiance.
Neither company will have an ownership interest in the
other; Allegiance will be an independent public company.
See "ARRANGEMENTS BETWEEN BAXTER AND ALLEGIANCE."
ALLEGIANCE DIVIDEND POLICY........ The payment and level of cash dividends by Allegiance
after the Distribution will be based upon a number of
factors, including the operating results, cash-flow and
financial requirements of Allegiance. It is anticipated
that, following the Distribution, Allegiance will pay
quarterly cash dividends which, on an annual basis, will
initially be within a range of approximately $. to
$. per share. Allegiance expects that its initial
dividend rate, combined with Baxter's continuing
dividend rate, will aggregate $1.21 per share, which
equals Baxter's current quarterly dividend rate,
annualized. However, no formal action with respect to
any such dividend has been declared, and the declaration
and payment of dividends is at the discretion of
Allegiance's board of directors (the "Allegiance
Board"). See "THE DISTRIBUTION -- LISTING AND TRADING OF
ALLEGIANCE COMMON STOCK."
</TABLE>
5
<PAGE>
<TABLE>
<S> <C>
ALLEGIANCE BORROWINGS............. Prior to the Distribution Date, Allegiance will incur
indebtedness of approximately $1,200 million from
unsecured credit facilities with banks, short-term debt
and new term debt issuances. Approximately $1,160
million of this indebtedness will be used to repay
intercompany debt to Baxter and fund distributions from
Allegiance's foreign operations to Baxter. The remaining
$40 million will be used for initial working capital
requirements. Working capital of $40 million represents
the best estimate of the level of working capital
required related to negotiated agreements with Baxter.
As of the Distribution Date, a final working capital
amount will be determined pursuant to various
operational factors. Allegiance anticipates that it will
convert a significant portion of its initial debt to
longer term fixed rate debt, contingent upon acceptable
market conditions. The debt that is not converted will
be managed as part of a short-term loan portfolio
supported by a long-term credit facility. Management
expects that Allegiance's senior debt will be investment
grade.
ALLEGIANCE STOCK LISTING.......... Application has been made to list the Allegiance Stock
on the New York Stock Exchange under the symbol " ."
See "THE DISTRIBUTION -- LISTING AND TRADING OF
ALLEGIANCE COMMON STOCK."
</TABLE>
6
<PAGE>
SELECTED HISTORICAL FINANCIAL DATA
The following table sets forth selected financial information with respect
to Allegiance. Selected unaudited historical financial information for the three
months ended March 31, 1996 and 1995 includes all adjustments, consisting only
of normal recurring accruals that are considered necessary for a fair
presentation of combined operating results for such interim periods. Results for
the interim periods are not necessarily indicative of results for the full year.
Historical financial information may not be indicative of Allegiance's
performance as an independent company. The information set forth below should be
read in conjunction with "Management's Discussion and Analysis of Financial
Condition and Results of Operations" and the "Combined Financial Statements" and
related notes thereto found elsewhere in this Information Statement. Historical
per share data for net income and dividends, and the ratio of earnings to fixed
charges have not been presented because Allegiance was not incorporated until
June 1996, and did not have significant interest expense for the periods
presented below. Pro-forma long term debt and net income per share data are
presented elsewhere in this Information Statement.
SELECTED HISTORICAL FINANCIAL DATA (A)
<TABLE>
<CAPTION>
THREE MONTHS ENDED
MARCH 31, YEARS ENDED DECEMBER 31,
-------------------- -----------------------------------------------------
1996 1995 1995 1994 1993 1992 1991
--------- --------- --------- --------- --------- --------- ---------
(IN MILLIONS)
<S> <C> <C> <C> <C> <C> <C> <C>
INCOME STATEMENT DATA:
Net sales................................ $ 1,115 $ 1,226 $ 4,922 $ 5,109 $ 5,019 $ 4,861 $ 4,402
Gross profit............................. 226 279 1,044 1,378 1,406 1,512 1,448
Restructuring charges (b)................ -- -- 76 -- 484 -- --
Income before income taxes, depreciation
and amortization........................ 87 110 641 561 67 548 546
Income (loss) before income taxes........ 50 69 476 338 (154) 352 366
Net income (loss) (b) (c)................ $ 31 $ 42 $ 273 $ 215 $ (73) $ 243 $ 250
BALANCE SHEET DATA:
Total Assets............................. $ 3,437 $ 3,769 $ 3,444 $ 4,031 $ 4,590 $ 4,287 $ 4,089
</TABLE>
- - - ------------------------
(a) See Note 1 to "Notes to the Combined Financial Statements" and "Management's
Discussion and Analysis of Financial Condition and Results of Operations"
for discussions of the impact of certain divestitures on Allegiance's
revenues and expenses.
(b) See Note 4 to "Notes to the Combined Financial Statements" and "Management's
Discussion and Analysis of Financial Condition and Results of Operations"
for additional information related to the restructuring charges of $76
million and $484 million that were recorded in 1995 and 1993, respectively.
(c) Net loss for 1993 reflects the impact of a charge equal to $5 million, net
of tax, resulting from the adoption of Statement of Financial Accounting
Standards No. 112, "Employers Accounting for Postemployment Benefits."
7
<PAGE>
SUPPLEMENTARY FINANCIAL DATA
Allegiance's historical results of operations include revenues and expenses
related to certain divested businesses. The Industrial and Life Sciences
division was sold in September 1995 and the diagnostics manufacturing businesses
were sold in December 1994. See Notes 1 and 3 to "Notes to the Combined
Financial Statements" for additional information related to these divestitures.
The following table presents selected supplementary financial data for
Allegiance excluding the revenue and expenses associated with these divested
businesses.
SUPPLEMENTARY FINANCIAL DATA
<TABLE>
<CAPTION>
THREE MONTHS ENDED
MARCH 31, YEARS ENDED DECEMBER 31,
-------------------- -------------------------------
1996 1995 1995 1994 1993
--------- --------- --------- --------- ---------
(IN MILLIONS)
<S> <C> <C> <C> <C> <C>
(UNAUDITED)
Net sales..................................................... $ 1,115 $ 1,108 $ 4,575 $ 4,314 $ 4,249
Gross profit.................................................. 226 242 950 1,003 1,004
Restructuring charge.......................................... -- -- -- -- 304
Income before income taxes, depreciation and amortization..... 87 93 410 481 182
Income (loss) before income taxes............................. 50 52 245 258 (39)
Income (loss)(a).............................................. 31 33 151 157 (26)
</TABLE>
- - - ------------------------
(a) Income (loss) for 1993 excludes the impact of a charge equal to $5 million,
net of tax, resulting from the adoption of Statement of Financial Accounting
Standards No. 112, "Employers Accounting for Postemployment Benefits."
8
<PAGE>
RISK FACTORS
Certain statements in this Information Statement constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward looking statements involve known and unknown risks,
including, but not limited to, general economic and business conditions,
competition, changing trends in customer profiles, changes in governmental
regulations, and unfavorable foreign currency fluctuations. Although Allegiance
believes that its expectations with respect to the forward looking statements
are based upon reasonable assumptions within the bounds of its knowledge of its
business and operations, there can be no assurance that actual results,
performance or achievements of Allegiance will not differ materially from any
future results, performance or achievements expressed or implied by such forward
looking statements.
UNITED STATES HEALTH-CARE ENVIRONMENT
The United States health-care system continues to undergo fundamental
change. Competition for patients among health-care providers continues to
intensify. Increasingly, providers are looking for ways to better manage costs
in areas such as materials handling, supply utilization, product standardization
for specific procedures and capital expenditures.
Accelerating cost pressures on hospitals in the United States are resulting
in increased out-patient and alternate-site health-care service delivery and a
focus on cost-effectiveness and quality. These forces increasingly shape the
demand for, and supply of, medical care. Many private health-care payors are
providing incentives for consumers to seek lower cost care outside the hospital.
Many corporations' employee health plans have been restructured to provide
financial incentives for patients to utilize the most cost-effective forms of
treatment (managed care programs, such as health maintenance organizations, have
become more common), and physicians have been encouraged to provide more
cost-effective treatments. In the past, Allegiance's distribution network has
been focused on traditional distribution to hospitals.
The future financial success of health-care product and service companies,
such as Allegiance, will depend on their ability to work with health-care
providers to help them enhance their competitiveness and to distribute products
to alternate sites as treatment moves outside the hospital. Allegiance
management believes it can help its customers achieve savings in the total
health-care system by automating supply-ordering procedures, optimizing
distribution networks, improving utilization and materials management and
achieving economies through product and procedure standardization, and
performing certain non-clinical services on an outsourced basis. Allegiance
management further believes that its strategy of providing unmatched service to
its health-care customers and achieving the best overall cost in its delivery of
health-care products and services is compatible with any anticipated realignment
of the United States health-care system that may ultimately occur. If customers
do not respond favorably to the Allegiance strategy, these changes could have a
material effect on Allegiance's business, results of operations and financial
condition.
UNITED STATES COMPETITION
The changing health-care environment in recent years has led to increasingly
intense competition among health-care suppliers. Competition is focused on
price, service and product performance. Pressure in these areas is expected to
continue. There has been substantial consolidation in Allegiance's customer base
and among its competitors. In recent years, Allegiance's overall price increases
have been below the Consumer Price Index, and industry trends and competition
may inhibit Allegiance's ability to increase prices, and may continue to depress
Allegiance's margins in the future. These trends are expected to continue.
In part through its previously announced and ongoing restructuring program,
Allegiance plans to continue to increase its efforts to minimize costs and
better meet accelerating price competition. Allegiance believes that its cost
position will continue to benefit from improvements in manufacturing technology
and increased economies of scale. Allegiance continues to improve the quality of
its products and services. If Allegiance is unsuccessful in maintaining its
service and quality levels while
9
<PAGE>
decreasing costs, the competitive environment may have a material adverse effect
on Allegiance's business, results of operations and financial condition. See
"ALLEGIANCE BUSINESS -- COMPETITION."
REVENUES FROM CUSTOMERS PURCHASING THROUGH BUYING GROUPS
For the last three years, as a percentage of total revenue, sales to
customers which are members of two large hospital buying groups, Premier and
VHA, comprised 27 per cent and 16 per cent respectively in 1995, 23 per cent and
13 per cent respectively in 1994, and 23 per cent and 13 per cent respectively
in 1993. Loss of the contracts with either or both of these buying groups could
have a material adverse effect on the business, results of operations and
financial condition of Allegiance. However, some member hospitals in each group
are free to purchase from the vendors of their choice. Management of Allegiance
believes that its relationships with its larger customers are excellent. No
other buying group or single customer currently accounts for more than five per
cent of Allegiance's revenue. See "ALLEGIANCE BUSINESS -- CONTRACTUAL
ARRANGEMENTS; BUYING GROUPS."
POTENTIAL TAXABILITY
The Distribution, though intended to be free from United States federal
income tax as of the Distribution Date, could be rendered taxable as a result of
subsequent actions or events. Allegiance has agreed not to undertake specified
actions and has agreed that under specified circumstances it will indemnify
Baxter for taxes, liabilities and associated expenses incurred as a result of
any such actions or events. See "ARRANGEMENTS BETWEEN BAXTER AND ALLEGIANCE --
REORGANIZATION AGREEMENT."
FINANCIAL LEVERAGE
In connection with the Distribution, Allegiance will borrow, on an unsecured
basis, approximately $1.2 billion. This indebtedness is reflected in the pro
forma financial information presented elsewhere in this Information Statement.
Such indebtedness may limit Allegiance's future financial flexibility. See
"MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION -- LIQUIDITY AND
CAPITAL RESOURCES" and "ALLEGIANCE PRO-FORMA FINANCIAL INFORMATION."
MUTUAL DISTRIBUTION ARRANGEMENTS
Allegiance and Baxter will enter into various agency and distribution
arrangements pursuant to which Allegiance will distribute certain Baxter
products in the United States and Baxter will distribute Allegiance products
internationally. The initial terms of these agreements range from three to five
years. Although the present intention of Allegiance and Baxter is that these
distribution arrangements continue as long as the relationship between the
parties is mutually beneficial, no assurance can be given that these
arrangements will be extended beyond their original expiration dates or will not
be terminated prior to their original terms. See "ARRANGEMENTS BETWEEN BAXTER
AND ALLEGIANCE -- AGENCY SERVICES AND DISTRIBUTION AGREEMENTS."
DEPENDENCE ON ADMINISTRATIVE SERVICES
After the Distribution, Allegiance and Baxter will rely on each other for
the provision of certain administrative services. See "ARRANGEMENTS BETWEEN
BAXTER AND ALLEGIANCE." Such services will be provided, pursuant to contractual
arrangements that can be terminated by either party upon no more than 12 months
notice, at rates intended to approximate the cost of providing such services. No
assurance can be given that such arrangements will continue in the future, that
the cost of arranging substitute service either internally or from a third party
would not increase the cost to the service recipient, or that a service provider
will not be forced to absorb a greater share of its fixed overhead costs in the
event of a termination of these arrangements.
10
<PAGE>
NO OPERATING HISTORY AS AN INDEPENDENT COMPANY
Allegiance does not have an operating history as an independent public
company. While Allegiance has been profitable as part of Baxter, there is no
assurance that as a stand-alone company profits will continue at the same level.
See "COMBINED FINANCIAL STATEMENTS."
NO PRIOR MARKET FOR ALLEGIANCE COMMON STOCK
There has been no prior trading market for Allegiance Stock and there can be
no assurance as to the prices at which the Allegiance Stock will trade before or
after the Distribution Date. Until the Allegiance Stock is fully distributed and
an orderly market develops, the prices at which the Allegiance Stock trades may
fluctuate significantly. Prices for the Allegiance Stock will be determined in
the trading markets and may be influenced by many factors, including the depth
and liquidity of the market for Allegiance Stock, investor perceptions of
Allegiance and its business, Allegiance's dividend policy, and general economic
and market conditions. See "THE DISTRIBUTION -- LISTING AND TRADING OF
ALLEGIANCE COMMON STOCK."
ALLEGIANCE DIVIDEND POLICY
The payment and level of cash dividends by Allegiance after the Distribution
will be based upon a number of factors, including the operating results,
cash-flow and financial requirements of Allegiance. However, no formal action
with respect to any such dividend has been declared, and the declaration and
payment of dividends is at the discretion of the Allegiance Board.
EFFECTS ON STOCK
After the Distribution, the Baxter Stock will continue to be listed and
traded on the NYSE and certain other stock exchanges. As a result of the
Distribution, the trading prices of Baxter Stock will likely be lower than the
trading prices of Baxter Stock immediately prior to the Distribution. The
combined trading prices of Baxter Stock and Allegiance Stock after the
Distribution may be less than, equal to or greater than the trading prices of
Baxter Stock immediately prior to the Distribution. Until the market has fully
analyzed the Allegiance Business, the prices at which the Allegiance Stock
trades may fluctuate significantly. In addition, until the market has fully
analyzed the operations of Baxter without the Allegiance Business, the prices at
which the Baxter Stock trades may fluctuate significantly.
CERTAIN ANTI-TAKEOVER EFFECTS
The Certificate of Incorporation, By-laws and Rights Agreement and the
General Corporation Law of the State of Delaware ("Delaware Law") contain
several provisions that could make more difficult a change of control of
Allegiance in a transaction not approved by the Allegiance Board. In addition,
the Allegiance Board will adopt certain other programs, plans and agreements
with its management and/or employees that may make such a change of control more
expensive. In addition, certain agreements between Baxter and Allegiance may
have anti-takeover effects. See "CERTAIN ANTI-TAKEOVER EFFECTS OF CERTAIN
PROVISIONS OF THE CERTIFICATE OF INCORPORATION, BY-LAWS AND STATE LAW,"
"DESCRIPTION OF ALLEGIANCE CAPITAL STOCK," "ALLEGIANCE MANAGEMENT -- CHANGE OF
CONTROL PLAN" and "ARRANGEMENTS BETWEEN BAXTER AND ALLEGIANCE."
GOVERNMENT REGULATION
Significant aspects of Allegiance's businesses are subject to state and
federal statutes and regulations governing, among other things, reimbursement
under federal and state medical assistance programs, medical waste disposal,
dispensing of controlled substances, and workplace health and safety. In
addition, most of the products manufactured or sold by Allegiance in the United
States are subject to regulation by the Food and Drug Administration ("FDA"), as
well as by other federal and state agencies. The FDA has the power to seize
adulterated or misbranded drugs and devices or to require the manufacturer to
remove them from the market and the power to publicize relevant facts. In the
past, Baxter has removed products from the United States market that were found
not to meet acceptable standards. This may occur with respect to Allegiance in
the future. Product regulatory laws
11
<PAGE>
exist in most other countries where Allegiance will do business. There can be no
assurance that federal or state governments will not impose additional
restrictions or adopt interpretations of existing laws that could materially
adversely affect Allegiance's business, results of operations or financial
condition. See "ALLEGIANCE BUSINESS -- GOVERNMENT REGULATION."
BACKGROUND
On November 27, 1995, the Board of Directors of Baxter (the "Baxter Board")
authorized management to proceed with a plan to separate Baxter into two
companies by means of a spin-off of its Allegiance Business (as defined below).
The spin-off will be effected through a distribution (the "Distribution") to
holders of Baxter Stock of all of the outstanding shares of Allegiance Stock. At
the time of the Distribution, Allegiance and its subsidiaries will own the
assets, liabilities and operations, which prior to the date of the Distribution
(the "Distribution Date") comprised Baxter's United States health-care
distribution, surgical and respiratory therapy products and health-care cost
management businesses (the "Allegiance Business"). See "ALLEGIANCE BUSINESS." On
the Distribution Date, Baxter will effect the Distribution by delivering all of
the outstanding shares of Allegiance Stock to the First Chicago Trust Company of
New York, as the distribution agent (the "Distribution Agent") for distribution
to the holders of record of Baxter Stock at the close of business on
September , 1996 (the "Record Date"). Allegiance's principal executive offices
are located at One Baxter Parkway, Deerfield, Illinois 60015 until September ,
1996 (thereafter, at 1430 Waukegan Road, McGaw Park, Illinois 60085). Unless the
context otherwise indicates, as used in this Information Statement the term
"Allegiance" means the Allegiance Business of Baxter for periods prior to the
Distribution Date and Allegiance Corporation and its consolidated subsidiaries
for the periods following the Distribution Date, and all references to "Baxter"
include Baxter International Inc. and its consolidated subsidiaries as of the
relevant date.
Stockholders of Baxter with inquiries relating to the Distribution prior to
the Distribution Date should contact the Distribution Agent, telephone number
(212) - or Baxter International Inc., Baxter Investor Relations
Department, One Baxter Parkway, Deerfield, Illinois 60015, telephone number
(847) 948-4550. After the Distribution Date, stockholders of Allegiance with
inquiries relating to the Distribution or their investment in Allegiance should
contact Allegiance, Corporate Secretary's Department, 1430 Waukegan Road, McGaw
Park, Illinois 60085, telephone number (847) -
or [ ], Allegiance's transfer agent and
registrar, at , telephone number ( )
- .
ALLEGIANCE
Allegiance Corporation is America's largest provider of health-care products
and cost-management services for hospitals and other health-care providers.
Allegiance was formed in June, 1996 as a wholly owned subsidiary of Baxter
consisting of Baxter's U.S. distribution, surgical and respiratory-therapy
products, and health-care cost-management services operations. These integrated
businesses recorded total sales of approximately $4.5 billion in 1995.
Management believes Allegiance, with its size, breadth of product line, customer
relationships, growing array of cost-management services, and financial
strength, is well-positioned competitively for the increasingly cost-conscious
health-care marketplace.
Allegiance's mission is to align its objectives with those of its customers
- - - -- to help hospitals and others throughout the health-care field fulfill their
mission of serving patients. Allegiance intends to achieve this goal by
providing high-quality products, excellent service and new ways of managing
costs.
12
<PAGE>
THE DISTRIBUTION
REASONS FOR THE DISTRIBUTION
The Distribution is intended to increase the long-term value of Baxter
stockholders' investment.
The Distribution will enable each company to align its reporting structure,
cost structure, culture, and management processes in support of its basic
mission and strategy. For example, Allegiance will focus on its mission of
helping customers manage total costs and improving quality in the managed care
environment. Baxter, for example, will develop measurement and reward systems to
encourage intelligent risk-taking and reward entrepreneurship more comparably to
its technology competitors.
From an Allegiance perspective, the Distribution will enable its management
to more precisely focus on cost management and service initiatives while
building on strong positions within self-manufactured products and distribution.
Allegiance will provide integrated solutions that include many different product
offerings within the context of a comprehensive process that reduces overall
cost and improves total quality as defined by its customers. These products may
be Allegiance products, Baxter products or products of other health-care
companies. The Distribution will provide Allegiance with flexibility to serve a
broader range of customers, AS THEY WOULD LIKE TO BE SERVED. Baxter will be a
preferred supplier to Allegiance, and if customers want to continue buying the
total Baxter package of services and products, they can do so. If, however, a
customer does not want an offering integrated with Baxter products, that will be
available also. As a stand-alone company Allegiance will be able to more easily
form alliances with companies manufacturing products that compete with Baxter
products, without the competitive limitations imposed by ownership by Baxter.
Allegiance will also be able to define its own investment vision and raise
capital on an equal footing with its direct competitors, without competition for
funds from Baxter's technology businesses. This will allow Allegiance to make
investments in logistics, manufacturing, information systems, and cost
management processes required to succeed in the managed care environment.
From a Baxter perspective, the Distribution will enable its management to
better focus on creating innovative medical specialty products and on expanding
sales outside the United States. These two strategic thrusts are intended to
drive its growth. The common links among its businesses will be shared
technical, clinical and regulatory competencies; manufacturing and global sales
and distribution platforms; and market relationships.
From a market perspective, the Distribution will allow investors to better
evaluate the merits of Allegiance and the remaining Baxter businesses, enhancing
the likelihood that each will achieve appropriate market recognition for its
performance. The Distribution will afford stockholders of Baxter the option of
continuing their investment in either the Baxter Stock or Allegiance Stock or
both, depending on their investment objectives, and the separate reporting of
the results of the Allegiance Business and the remaining Baxter businesses
should create a framework for increased and more precisely focused equity
research coverage of both companies by the investment community.
MANNER OF EFFECTING THE DISTRIBUTION
The Distribution is expected to be declared by the Baxter Board on
, 1996 and will be made on the Distribution Date to stockholders of
record of Baxter as of the close of business on the Record Date. On or prior to
the Distribution Date, share certificates for Allegiance Stock will be delivered
to the Distribution Agent. Commencing on the Distribution Date, the Distribution
Agent will begin mailing such share certificates to holders of Baxter Stock as
of the close of business on the Record Date on the basis of one share of
Allegiance Stock for every [six] shares of Baxter Stock held on the Record Date.
All such shares of Allegiance Stock will be fully paid and non-assessable and
holders thereof will not be entitled to preemptive rights. See "DESCRIPTION OF
ALLEGIANCE CAPITAL STOCK -- ALLEGIANCE COMMON STOCK." No certificates or scrip
representing fractional shares of Allegiance Stock will be issued to Baxter
stockholders as part of the Distribution. The Distribution Agent will aggregate
fractional shares into whole shares of Allegiance Stock and sell them in the
open market at then prevailing prices on behalf of holders who otherwise would
be
13
<PAGE>
entitled to receive fractional shares, and such persons will receive instead a
check in payment for the amount of their allocable share of the total sale
proceeds. See "-- CERTAIN FEDERAL INCOME TAX CONSEQUENCES OF THE DISTRIBUTION."
Such sales are expected to be made as soon as practicable after the mailing of
the Allegiance Stock to Baxter stockholders. Baxter will bear the cost of any
commissions incurred in connection with such sales.
NO HOLDER OF BAXTER STOCK WILL BE REQUIRED TO PAY ANY CASH OR OTHER
CONSIDERATION FOR THE SHARES OF ALLEGIANCE STOCK TO BE DISTRIBUTED OR TO
SURRENDER OR EXCHANGE SHARES OF BAXTER STOCK OR TO TAKE ANY OTHER ACTION IN
ORDER TO RECEIVE ALLEGIANCE STOCK.
CERTAIN FEDERAL INCOME TAX CONSEQUENCES OF THE DISTRIBUTION
Baxter has applied for a ruling (the "Tax Ruling") from the United States
Internal Revenue Service (the "IRS") to the effect, among other things, that the
Distribution will qualify under Section 355 of the Internal Revenue Code of
1986, as amended (the "Code") and, accordingly, that under United States federal
income tax law:
1. No income, gain or loss will be recognized by a holder of Baxter
Stock solely as a result of the receipt of Allegiance Stock pursuant to the
Distribution;
2. In general, no gain or loss will be recognized by Baxter or
Allegiance as a result of the Distribution;
3. The tax basis of Baxter Stock held by a Baxter stockholder
immediately prior to the Distribution will be apportioned (based upon
relative market values on the Distribution Date) between such Baxter Stock
and the Allegiance Stock received (including any fractional share interest
deemed received) by such stockholder pursuant to the Distribution; and
4. Assuming that Baxter Stock is held as a capital asset on the
Distribution Date, the holding period for the Allegiance Stock received
pursuant to the Distribution by a holder of Baxter Stock will include the
period during which such Baxter Stock has been held.
If a Tax Ruling has not been issued by the IRS by the date when the Baxter
Board meets formally to set the Record Date and the Distribution Date, the
Baxter Board may decide to effect the Distribution in reliance on an opinion of
tax counsel or to delay the Distribution until the IRS has granted the requested
Tax Ruling.
If the Distribution does not qualify under Section 355 of the Code, then:
(i) Baxter will recognize taxable gain on the Distribution and (ii) each holder
of Baxter Stock who receives shares of Allegiance Stock pursuant to the
Distribution will be treated as having received a taxable dividend.
The Distribution, though intended to be free from United States federal
income tax as of the Distribution Date, could be rendered taxable as a result of
subsequent actions or events, some of which are within Allegiance's control.
Allegiance has agreed not to undertake such actions and has agreed that under
specified circumstances it will indemnify Baxter for taxes, liabilities, and
associated expenses incurred as a result of specified actions or events. See
"ARRANGEMENTS BETWEEN BAXTER AND ALLEGIANCE -- REORGANIZATION AGREEMENT."
A holder of Baxter Stock who receives cash in lieu of a fractional share
interest in Allegiance Stock will be treated as if such fractional share
interest had been received as part of the Distribution and then sold.
Accordingly, gain or loss will be recognized for United States federal income
tax purposes measured by the difference, if any, between the amount of cash
received and the tax basis allocable (as described above) to such holder's
fractional share interest. Such gain or loss will be capital gain or loss to the
holder, provided that the Baxter Stock has been held as a capital asset on the
Distribution Date.
Stockholders are urged to consult their own tax advisors as to the
particular consequences to them of the Distribution, including the application
of state, local and non-U.S. tax laws.
THE FOREGOING IS ONLY A SUMMARY OF CERTAIN UNITED STATES FEDERAL INCOME TAX
CONSEQUENCES OF THE DISTRIBUTION UNDER CURRENT LAW AND IS INTENDED FOR
14
<PAGE>
GENERAL INFORMATION ONLY. EACH STOCKHOLDER SHOULD CONSULT HIS OR HER TAX ADVISOR
AS TO THE PARTICULAR CONSEQUENCES OF THE DISTRIBUTION TO SUCH STOCKHOLDER,
INCLUDING THE APPLICATION OF STATE, LOCAL AND NON-U.S. TAX LAWS, AND AS TO
POSSIBLE CHANGES IN TAX LAWS THAT MAY AFFECT THE TAX CONSEQUENCES DESCRIBED
ABOVE. THIS SUMMARY MAY NOT BE APPLICABLE TO STOCKHOLDERS WHO RECEIVED THEIR
ALLEGIANCE STOCK PURSUANT TO THE EXERCISE OF OPTIONS OR OTHERWISE AS
COMPENSATION (INCLUDING HOLDERS OF RESTRICTED STOCK) OR WHO ARE NOT CITIZENS OR
RESIDENTS OF THE UNITED STATES.
LISTING AND TRADING OF ALLEGIANCE COMMON STOCK
An application has been filed for listing the Allegiance Stock on the NYSE.
Allegiance initially will have approximately 74,000 stockholders of record,
based on the number of record holders of Baxter Stock as of June 1, 1996. The
transfer agent and registrar for Allegiance Stock will be
. For certain information regarding
certain options to purchase Allegiance Stock that will be granted after the
Distribution, see "ALLEGIANCE MANAGEMENT -- COMPENSATION OF EXECUTIVE OFFICERS."
Shares of Allegiance Stock distributed to Baxter stockholders in the
Distribution will be freely transferable, except for shares received by persons
who may be deemed to be "affiliates" of Allegiance under the Securities Act of
1933, as amended, and the rules promulgated thereunder (the "Securities Act").
Persons who may be deemed to be affiliates of Allegiance after the Distribution
generally include individuals or entities that control, are controlled by, or
are under common control with, Allegiance, and may include certain officers and
directors of Allegiance as well as principal stockholders of Allegiance, if any.
Persons who are affiliates of Allegiance will be permitted to sell their shares
of Allegiance Stock only pursuant to an effective registration statement under
the Securities Act or an exemption from the registration requirements of the
Securities Act, such as the exemption afforded by Rule 144 promulgated
thereunder.
FUTURE MANAGEMENT OF ALLEGIANCE
Following the Distribution, Allegiance will have substantially the same
operating management as the Allegiance Business currently has. See "ALLEGIANCE
MANAGEMENT -- EXECUTIVE OFFICERS."
OPINIONS OF FINANCIAL ADVISOR
Baxter has engaged CS First Boston Corporation ("CS First Boston") as a
financial advisor in connection with the Distribution.
CS First Boston has delivered to the Baxter Board its written opinions,
dated , 1996 to the effect that: (i) the Distribution will not have
a material adverse effect on the financial viability of New Baxter (which term
shall be deemed to refer to Baxter as constituted immediately following the
Distribution) or Allegiance, as the case may be, during the period immediately
following the Distribution through the end of fiscal year 1998 (the period for
which CS First Boston was provided forecasts), and (ii) the Distribution is fair
to the stockholders of Baxter from a financial point of view.
The term "financial viability" for purposes of these opinions, means and
refers exclusively to the ability of New Baxter or Allegiance, as the case may
be, to finance its currently anticipated operating and capital requirements (as
projected in the financial forecasts provided to CS First Boston by Baxter and
Allegiance) following the Distribution.
Each of CS First Boston's opinions is based upon, among other things, CS
First Boston's review of (i) publicly available business and financial
information relating to Baxter, New Baxter and Allegiance and financial
information contained in the Information Statement in the form provided to it
which it deemed relevant to its review, (ii) financial forecasts provided to CS
First Boston, and other information provided by Baxter prior to the date of each
of the opinions, (iii) discussions with Baxter and Allegiance management
regarding the business and prospects of Baxter, New Baxter and Allegiance, (iv)
comparisons of financial and stock market data of Baxter, and financial data of
New Baxter and Allegiance with similar data for other publicly held companies in
similar businesses, (v) the financial
15
<PAGE>
terms of other transactions similar to the Distribution that have recently been
effected, (vi) prevailing market conditions, and (vii) other information,
financial studies, analyses and investigations and financial, economic and
market criteria that CS First Boston has deemed relevant.
In each opinion, CS First Boston states that it has not assumed any
responsibility for independent verification of any of the foregoing information
(including the information contained in the Information Statement in the form
provided to it) and has relied on its being complete and accurate in all
material respects. Each opinion further states that, with respect to the
financial forecasts reviewed by CS First Boston, the management of Baxter has
advised CS First Boston that such financial forecasts have been reasonably
prepared on bases reflecting the best currently available estimates and
judgments of management as to the future financial performance of New Baxter and
Allegiance. CS First Boston has assumed no responsibility for, and has expressed
no view as to, such financial forecasts or the assumptions on which they were
based.
Each of CS First Boston's opinions states that CS First Boston has assumed
that (i) no income, gain or loss will be recognized to Baxter, New Baxter or
Allegiance for U.S. federal or state income tax purposes as a result of the
Distribution and (ii) with the exception of the receipt of (x) cash in lieu of
fractional shares of Allegiance Stock and (y) Allegiance Stock distributed with
respect to restricted shares of Baxter Stock held by Baxter employees, the
receipt of Allegiance Stock in the Distribution will be tax-free for U.S.
federal and state income tax purposes to the stockholders of Baxter.
Each CS First Boston opinion is subject to the limitations that CS First
Boston neither made any independent evaluation or appraisal of the assets or
liabilities (contingent or otherwise) of Baxter or Allegiance nor has CS First
Boston been furnished with any such appraisal and that each such opinion is
based on financial, economic, monetary and market conditions as they exist and
can be evaluated on the date of each such opinion. CS First Boston's opinions do
not represent an opinion as to what the market value of the securities of
Allegiance or New Baxter actually will be following the consummation of the
Distribution.
The full text of each of CS First Boston's opinions, each of which set forth
the assumptions made, matters considered and limits on the review undertaken,
will be filed as exhibits to the Registration Statement of which this
Information Statement is a part. The summary of the opinions of CS First Boston
set forth in this Information Statement is qualified in its entirety by
reference to the full text of such opinions.
In arriving at its financial opinions, CS First Boston did not attribute any
particular weight to any analysis or factor considered in reaching its
conclusions, but rather made qualitative judgments as to the significance and
relevance of each analysis and factor. CS First Boston's analyses included
review of other publicly held companies in businesses similar to New Baxter and
Allegiance. CS First Boston analyzed these companies primarily with respect to
operating and trading performance, including such factors as market valuation,
sales, operating income, cash flow and net income, and compared that information
with pro forma and projected operating information relating to Allegiance and
New Baxter. CS First Boston has also reviewed the financial terms of other
transactions similar to the Distribution that recently have been effected,
including (but not limited to) such factors as the debt to equity ratio, book
value and capital structure of the distributed companies, and compared that
information with pro forma data relating to Allegiance and New Baxter.
CS First Boston will receive customary fees, including reimbursement of
expenses, for its services as financial advisor related to the Distribution, a
portion of which is contingent upon the consummation of the Distribution. Baxter
also has agreed to indemnify CS First Boston against certain liabilities and
expenses in connection with its services as financial advisor.
CS First Boston and its affiliates have acted, and may in the future act, as
an underwriter for, and have participated as members of underwriting syndicates
with respect to, offerings of Baxter securities, and CS First Boston has
effected securities transactions for Baxter and performed financial
16
<PAGE>
advisory services in connection with certain acquisitions and dispositions by
Baxter. CS First Boston has received fees from Baxter in the past for these
services. CS First Boston may in the future serve as an underwriter of
Allegiance securities.
ARRANGEMENTS BETWEEN BAXTER AND ALLEGIANCE
For the purpose of governing certain of the ongoing relationships between
Baxter and Allegiance after the Distribution, and to provide mechanisms for an
orderly transfer of the Allegiance Business from Baxter to Allegiance and
facilitate an orderly transition to the status of two separate, publicly traded
companies, Baxter and Allegiance will enter into the various agreements
described in this section. The agreements summarized below have been, or will
be, filed as exhibits to the Registration Statement or an amendment thereto, of
which this Information Statement is a part, and the following summaries are
qualified in their entirety by reference to the agreements as filed.
It is expected that Allegiance and Baxter will pursue independent but
mutually supportive courses. Each will have its own strategies and interests,
while recognizing the advantages of working together. Allegiance, however, will
have significant continuing relationships with Baxter as an agent, distributor,
customer and supplier for a wide array of health-care products and services, and
for certain administrative support services. Allegiance will be Baxter's primary
agent in distributing Baxter's intravenous solutions, cardiovascular devices and
other products in the United States and will provide to Baxter certain
administrative services including credit and collection, accounts payable,
information technology and telecommunications. Baxter will distribute
Allegiance's products in many countries around the world and will provide
various administrative services to Allegiance. Baxter will have no ownership
interest in Allegiance, and Allegiance will be an independent public company.
REORGANIZATION AGREEMENT
Baxter and Allegiance will enter into an Agreement and Plan of
Reorganization (the "Reorganization Agreement") providing for, among other
things, the principal corporate transactions required to effect the separation
of the Allegiance Business from the remaining Baxter businesses and the
Distribution, and certain other agreements governing the relationship between
Baxter and Allegiance with respect to or in consequence of the Distribution.
Pursuant to the Reorganization Agreement, Baxter will transfer to Allegiance
substantially all of the assets, and Allegiance will assume substantially all of
the corresponding liabilities, of the Allegiance Business. See "ALLEGIANCE
BUSINESS." The assets of the Allegiance Business will be transferred to
Allegiance on an "as is, where is" basis and no representations or warranties
will be made by Baxter with respect thereto other than certain product-related
indemnities.
Subject to certain exceptions, the Reorganization Agreement will provide for
certain cross-indemnities (including an indemnity of Baxter by Allegiance with
respect to certain guarantees by Baxter in connection with certain Allegiance
agreements and certain financial guarantees) principally designed to place
financial responsibility for the liabilities of the Allegiance Business with
Allegiance and financial responsibility for the obligations and liabilities of
Baxter's retained businesses and its other subsidiaries with Baxter.
Specifically, Allegiance has agreed to assume liability for, and to indemnify
Baxter against, any and all liabilities associated with the Allegiance Business,
including any litigation, proceedings or claims relating to the products and
operations thereof whether or not the underlying basis for such litigation,
proceeding or claim arose prior to or after the Distribution Date. See "LEGAL
PROCEEDINGS."
The Reorganization Agreement will also provide that Allegiance will assume
all environmental liabilities that arise from or are attributable to the
operations of the Allegiance Business, including, but not limited to, off-site
waste disposal liabilities. Allegiance also has agreed to indemnify Baxter
against any and all such environmental liabilities. Baxter has agreed to
indemnify Allegiance against any and all environmental liabilities associated
with the retained Baxter businesses. In addition, the Reorganization Agreement
provides that each of Baxter and Allegiance will indemnify the other in the
event of certain liabilities arising under the Exchange Act.
17
<PAGE>
The Reorganization Agreement will provide, among other things, that, in
order to avoid potentially adverse tax consequences relating to the
Distribution, for a period of two years after the Distribution Allegiance will
not: (i) cease to engage in an active trade or business within the meaning of
the Code; (ii) issue or redeem any share of stock of Allegiance, except for
certain issuances and redemptions for the benefit of Allegiance's employees or
to effect acquisitions by Allegiance in the ordinary course of business or in
connection with the issuance of any convertible debt by Allegiance or in
accordance with the requirements for permitted purchases of Allegiance Stock as
set forth in section 4.05(1)(b) of Revenue Procedure 96-30 issued by the IRS; or
(iii) liquidate or merge with any other corporation, unless, with respect to
(i), (ii) or (iii) above, either (a) an opinion is obtained from counsel to
Baxter, or (b) a ruling is obtained from the IRS, in either case to the effect
that such act or event will not adversely affect the federal income tax
consequences of the Distribution to Baxter, its stockholders who receive
Allegiance Stock or Allegiance. Allegiance expects that these limitations will
not significantly constrain its activities or its ability to respond to
unanticipated developments. See "THE DISTRIBUTION -- CERTAIN FEDERAL INCOME TAX
CONSEQUENCES OF THE DISTRIBUTION."
The Reorganization Agreement will also provide that if, as a result of
certain transactions occurring after the Distribution Date involving either the
stock or assets of either Allegiance or any of its subsidiaries, or any
combination thereof, the Distribution fails to qualify as tax-free under the
provisions of Section 355 of the Code, Allegiance shall indemnify Baxter for all
taxes, liabilities, and associated expenses, including penalties and interest,
incurred as a result of such failure of the Distribution to qualify under
Section 355 of the Code. The Reorganization Agreement will further provide that
if the Distribution fails to qualify as tax-free under the provisions of Section
355 of the Code, other than as a result of a transaction occurring after the
Distribution Date involving either the stock or assets of Allegiance or any of
its subsidiaries, or any combination thereof, then Allegiance shall not be
liable for such taxes, liabilities, or expenses. See "THE DISTRIBUTION --
CERTAIN FEDERAL INCOME TAX CONSEQUENCES OF THE DISTRIBUTION."
The Reorganization Agreement will also provide for the allocation of
benefits between Baxter and Allegiance under existing insurance policies after
the Distribution Date for claims made or occurrences prior to the Distribution
Date and sets forth procedures for the administration of insured claims. In
addition, the Reorganization Agreement provides that Baxter will use its
reasonable efforts to maintain directors' and officers' insurance at
substantially the level of Baxter's current directors' and officers' insurance
policy for a period of three years with respect to the directors and officers of
Baxter who will become directors and officers of Allegiance as of the
Distribution Date for acts relating to periods prior to the Distribution Date.
The Reorganization Agreement will provide that prior to the Distribution
Date the Certificate of Incorporation and By-laws of Allegiance will be
substantially in the forms attached hereto as Annexes A and B, respectively, and
that as of the Distribution Date the directors of Allegiance will be the persons
named in " ALLEGIANCE MANAGEMENT -- BOARD OF DIRECTORS."
The Reorganization Agreement will also provide that each of Baxter and
Allegiance will be granted access to certain records and information in the
possession of the other, and requires the retention by Baxter and Allegiance,
for a period of ten years following the Distribution, of the information in its
possession relating to the other, and, thereafter, requires that prior notice of
the intention to dispose of such information be given by the party in possession
thereof.
The Reorganization Agreement will also address the treatment of employee
benefit matters and other compensation arrangements for certain former and
current Allegiance employees and their beneficiaries and dependents, as well as
certain former employees of certain former Allegiance businesses and their
beneficiaries and dependents (collectively, the "Allegiance Participants").
These provisions of the Reorganization Agreement contemplate that Allegiance
will establish certain profit-sharing, retirement savings and welfare plans (the
"Allegiance Plans") effective on the Distribution Date. The Reorganization
Agreement will provide that the account balances (including outstanding loans)
of all Allegiance Participants in the Baxter International Inc. and Subsidiaries
Incentive
18
<PAGE>
Investment Plan (the "IIP"), and the plan assets related to such liabilities
will be transferred to Allegiance's new retirement savings plan. The
Reorganization Agreement will also generally provide that, after the
Distribution Date, Allegiance will assume all liabilities for benefits under any
welfare plans related to Allegiance Participants, other than certain claims
incurred on or before the Distribution Date. Moreover, the Reorganization
Agreement will provide that, effective as of the Distribution Date, Allegiance
will become responsible for all other liabilities to Allegiance Participants
(including unfunded supplemental retirement benefits), other than certain
accruals under the Baxter Defined Benefit Excess Plan.
Finally, the Reorganization Agreement provides that the Distribution will
not be made until all of the following conditions are satisfied or waived by the
Baxter Board in its sole discretion: (i) the receipt of the Tax Ruling or an
acceptable opinion of tax counsel as to the tax-free status of the Distribution;
(ii) final approval by the Baxter Board of the Distribution; (iii) receipt of
all material consents required to effect the Distribution; (iv) the Registration
Statement being declared effective; (v) the Allegiance Board, composed of the
persons identified herein as the Allegiance directors, being duly elected; (vi)
the receipt of the opinions of CS First Boston described under "THE DISTRIBUTION
- - - -- OPINIONS OF FINANCIAL ADVISOR"; (vii) the Allegiance Stock being approved for
listing on the NYSE; (viii) the transactions contemplated by the Reorganization
Agreement in connection with the organization of Allegiance and the separation
of the Allegiance Business and the Baxter remaining businesses being consummated
in all material respects; (ix) Baxter and Allegiance having entered into each of
the agreements, instruments, understandings, assignments and other arrangements
to be entered into in connection with the transactions contemplated by the
Reorganization Agreement, including, without limitation, any conveyance
documents, any Interim Services Agreement (as defined below), and the Tax
Sharing Agreement, and each such agreement being in full force and effect; (x)
the execution of definitive agreements relating to Allegiance's credit
facilities; and (xi) no action shall have been instituted or threatened before
any court or administrative body to restrain, enjoin or otherwise prevent the
Distribution and no order, injunction or decree having been issued by any court
of competent jurisdiction or other legal restraint or prohibition preventing
consummation of the Distribution being in effect. Even if all the conditions are
satisfied, the Reorganization Agreement may be terminated and the Distribution
abandoned by the Baxter Board, in its sole discretion, without the approval of
the Baxter stockholders, at any time prior to the Distribution Date.
TAX SHARING AGREEMENT
Baxter and Allegiance will enter into a tax sharing agreement (the "Tax
Sharing Agreement") which allocates tax liabilities and responsibility for tax
audits for periods prior to, and subsequent to the Distribution Date. The Tax
Sharing Agreement will also allocate consolidated alternative minimum tax and
other tax credit carry-forwards as of the Distribution Date between Baxter and
Allegiance.
AGENCY, SERVICES AND DISTRIBUTION AGREEMENTS
As of October 1, 1996, Baxter's principal domestic operating subsidiary,
Baxter Healthcare Corporation ("BHC"), and an Allegiance subsidiary will enter
into an Agency, Services and Distribution Agreement (the "Domestic Distribution
Agreements") for each of Baxter's four primary domestic business units, I.V.
Systems, Renal, Cardiovascular, and Biotechnology, pursuant to which Baxter will
supply products to Allegiance, and Allegiance, as agent for Baxter, will provide
physical distribution and various sales and sales support services to Baxter.
The Domestic Distribution Agreements cover substantially all of the existing
products of each of the foregoing business units.
In most instances, Allegiance will act as Baxter's agent for the physical
distribution of Baxter's products in return for a fee. In such situations,
Baxter will maintain the contractual relationship with the customer, will manage
sales, order-taking, and billing and collections, and will retain title to the
products until shipment to the ultimate customer. In certain situations,
Allegiance will act as a full-service, value-added distributor for Baxter
products with a direct contractual relationship with the ultimate customer. In
these situations, Allegiance will provide additional sales, sales support, and
other customer and product-related services to the customer and will purchase
the products from Baxter at specified prices less a discount approximating the
fee described above. Such additional
19
<PAGE>
services may include aggregating Baxter's products with others to be sold as
"kits" for a given medical procedure or other cost management services which
assist the customer in reducing product consumption, improving utilization of
assets, improving logistics, and reducing or eliminating operating costs.
The initial term of the Domestic Distribution Agreements range from three
years (Renal and Biotechnology) to five years (I.V. Systems and Cardiovascular).
The agreements may be renewed upon expiration upon the mutual agreement of the
parties. In the event of a Change In Control of one of the parties to the
Domestic Distribution Agreements or certain of their affiliates, the other party
to such agreement will have the right, subject to certain notice periods and
other restrictions, to terminate all, or in certain cases only the affected
portion, of such agreement prior to its normal expiration. In the case of a
Change In Control involving a competitor of the non-affected party, the notice
period required for termination may be shorter than if such a competitor was not
involved. For purposes of these agreements, a "Change In Control" includes the
acquisition of more than 30 per cent of the stock of either party or one of
their affiliates, certain mergers or consolidations involving either party or
one of their affiliates, the acquisition by either party of certain significant
subsidiaries, and, in the case of an affiliate of either of the parties, the
disposition of substantially all of its business and assets.
Under the Domestic Distribution Agreements, Baxter is required within the
Territory to distribute all covered I.V. Systems and Cardiovascular products
(including any line extensions of such products) through Allegiance, subject to
certain exceptions. In addition, Allegiance may not market, promote or solicit
orders for any product that competes with any covered I.V. Systems or
Cardiovascular product. Allegiance may however take orders for, stock and sell
competing products in response to customer requests. For purposes of the
Domestic Distribution Agreements, the "Territory" is defined as the 50 states
comprising the United States of America and the District of Columbia.
Allegiance's right to distribute the covered products is limited to the
Territory.
The compensation received by Allegiance under the Domestic Distribution
Agreements generally will approximate or be based upon the internal business
unit revenue and expense allocations that were in effect between the Baxter
business units and the Allegiance Business prior to the date of the
Distribution. Similarly, the service levels and performance standards are to
remain as they were prior to the date of the Distribution.
In addition to the Domestic Distribution Agreements, Baxter and Allegiance
will enter into agreements pursuant to which Baxter will agree to distribute
Allegiance's surgical and other products outside of the United States and to
distribute certain surgical products to the long-term, sub-acute and home care
markets within the United States.
SERVICES AGREEMENTS
Baxter and Allegiance will enter into several services agreements, to be
effective from and after the Distribution Date, pursuant to which Baxter will
provide to Allegiance, and Allegiance will provide to Baxter, certain
administrative services that may be necessary for the conduct of Baxter's and
Allegiance's businesses. Services to be provided to Baxter by Allegiance include
credit, collection and cash application, accounts payable, telecommunications,
and information technology services. Services to be provided to Allegiance by
Baxter include payroll, sales and use tax, human resources (including
international expatriate services), research and development, travel, property
management, and other services. These agreements will be for varying terms and,
subject to certain exceptions, are generally terminable by either party upon 12
months or less notice. Under certain circumstances involving a Change In Control
(see "-- AGENCY, SERVICES AND DISTRIBUTION AGREEMENTS" above) the agreements may
be terminated earlier than normal. The agreements may be renewed upon expiration
upon the mutual agreement of the parties. The prices at which such services will
be provided generally will be equal to or based on the actual cost of rendering
such services.
20
<PAGE>
In addition, Baxter will lease from Allegiance, for a term of ten years, a
217,000 square foot office building at Allegiance's McGaw Park, Illinois
headquarters site. The leased building will continue to be occupied by Baxter's
Renal Division. Allegiance will sublease from Baxter all or a substantial part
of an 85,000 square foot office building located in Deerfield, Illinois. This
building is part of a three building complex leased by Baxter, and Allegiance's
sublease will be for the remainder of the current term of Baxter's lease. Baxter
and Allegiance may also lease or sublease to each other miscellaneous office or
other space for use in connection with various services performed for one
another pursuant to the agreements described above.
ALLEGIANCE FINANCING
Prior to the Distribution Date, Allegiance will incur indebtedness of
approximately $1,200 million from unsecured credit facilities with banks,
short-term debt and new term debt issuances. Approximately $1,160 million of
this indebtedness will be used to repay intercompany debt to Baxter and fund
distributions from Allegiance's foreign operations to Baxter. The remaining $40
million will be used for initial working capital requirements. Working capital
of $40 million represents the best estimate of the level of working capital
required related to negotiated agreements with Baxter. As of the Distribution
Date, a final working capital amount will be determined pursuant to various
operational factors. Allegiance anticipates that it will convert a significant
portion of its initial debt to longer term fixed rate debt, contingent upon
acceptable market conditions. The debt that is not converted will be managed as
part of a short-term loan portfolio supported by a long-term credit facility.
Management expects that Allegiance's senior debt will be investment grade.
21
<PAGE>
ALLEGIANCE BUSINESS
OVERVIEW
Allegiance Corporation is America's largest provider of health-care products
and cost-management services for hospitals and other health-care providers.
Allegiance was formed in June 1996 as a wholly owned subsidiary of Baxter
consisting of Baxter's U.S. distribution, surgical and respiratory-therapy
products, and health-care cost-management services operations. These integrated
businesses recorded total sales of approximately $4.5 billion in 1995.
The economics of health care are undergoing rapid and fundamental change,
particularly in the United States, which is Allegiance's largest current market.
In the past, doctors and nurses were paid for their services with few cost
constraints. Today, large employers, insurance companies and HMOs are
negotiating set fees for the care of patients. For U.S. hospitals and health
systems, Allegiance's main customers, the pressure to reduce costs has never
been greater. At the same time, demand for health services is continuing to
climb with the dramatic growth of elderly populations in the United States and
abroad. This environment offers opportunities for Allegiance, which has invested
in integrated product and service programs that help medical professionals cope
with health care's new economics and demographic trends. Management believes
Allegiance, with its size, breadth of product line, customer relationships,
growing array of cost-management services, and financial strength, is
well-positioned competitively for the increasingly cost-conscious health-care
marketplace.
The health-care distribution market in the United States has experienced
intense competition and a resultant erosion in its margins in recent years in
response to the growth of managed care and increased consolidation among
health-care providers. Allegiance has responded by integrating its
market-leading distribution capabilities with a broad product offering, high
levels of customer service and innovative cost-management services. Within a
larger Baxter organization, Allegiance's cost structure was higher than industry
standards. As an independent public company, Allegiance intends to realign its
cost structure, and improve its distribution returns.
STRATEGIC PROFILE
Allegiance's mission is to align its objectives with those of its customers
- - - -- to help hospitals and others throughout the health-care field fulfill their
mission of serving patients. Allegiance intends to achieve this goal by
providing high-quality products, excellent service and new ways of managing
costs.
Allegiance's leading competitive position within the health-care marketplace
is a function of several key advantages, including its size and breadth of
products; an intense customer-service orientation; a growing portfolio of
cost-management services and financial strength. Allegiance is the only
health-care company that fully integrates distribution, products and services to
bring greater efficiency to health care. In 1995, Allegiance generated more than
$200 million of documented savings for its customers, which include hospitals,
health systems and other providers. Management believes its key competitive
advantages and integrated product and service offerings provide a solid platform
for growth.
SIZE AND BREADTH
Allegiance is the largest provider of health-care products and
cost-management services in the United States. Total net sales in 1995 were
approximately $4.5 billion. Allegiance offers more than 200,000 products -- the
broadest range of medical and laboratory products in the industry. Allegiance's
offering includes its own products as well as products manufactured by more than
2,000 independent suppliers. Allegiance can furnish up to 80 percent of a
hospital's total supply needs, excluding pharmaceuticals. Allegiance operates
more than 60 distribution centers across the country, delivering products to
more than 6,000 locations, often on a just-in-time basis. Management believes
the size and scope of the company are key competitive advantages in the evolving
health-care environment.
22
<PAGE>
CUSTOMER SERVICE
Allegiance is recognized throughout the industry for its service to
customers. Allegiance develops relationships based on collaboration, quality
management processes and common goals. Its sales and service personnel are
rewarded for achieving goals that are established jointly with customers.
Allegiance sets service standards in an industry where the time from customer
order to delivery can be critical. Management believes its focus on customer
service and satisfaction will continue to distinguish Allegiance from
competitors.
COST-MANAGEMENT SERVICES
Allegiance has pioneered a broad range of cost-management services, such as
shared-risk/shared-savings agreements that align Allegiance's goals with those
of its customers. In these accounts, Allegiance and its customers work together
to reduce costs and improve the quality of care. Allegiance assigns clinician
consultants to these cost-management customers. Allegiance's consultants use a
proprietary "best demonstrated practices" database of more than 500 procedures
to help health-care professionals use fewer supplies and improve outcomes. In
addition to clinical consulting, Allegiance offers a range of cost-management
services, including just-in-time delivery, procedure-based product packaging and
outsourcing of certain non-clinical functions. Management believes this
portfolio of cost-management services is a key competitive advantage in the
increasingly cost-conscious health-care market.
FINANCIAL STRENGTH
As America's leading provider of health-care products and cost-management
services, Allegiance has unparalleled opportunity to provide its services to
health-care providers. In 1995, on a pro forma basis, Allegiance achieved
approximately $4.5 billion of net sales, $950 million of gross profit and $410
million of earnings before interest, taxes, depreciation and amortization, or
EBITDA. Allegiance has arranged $1.5 billion of unsecured credit and expects to
receive investment-grade ratings on its senior debt. Management believes that
Allegiance's size and flexibility are important competitive advantages in the
rapidly changing health-care industry. In addition, Allegiance has established
an incentive compensation program for senior managers that is linked to
achieving certain cash-flow and earnings objectives.
STRATEGIC PRIORITIES
Allegiance's strategy is designed to continue to improve efficiency and
returns in its distribution operations, to increase market penetration for its
self-manufactured and "best value" preferred distributed products, and to expand
its ability to help health-care professionals manage costs.
DISTRIBUTION SERVICES
Distribution services are the basis for Allegiance's relationships with
hospitals and laboratories and the starting point for strategic relationships
that align Allegiance's objectives with those of its customers. Strategic
priorities include improving the total economics of distribution; segmenting
customers based on their service needs; and increasing sales of "best value"
products, which result in better service for customers and higher returns for
Allegiance.
PRODUCT OFFERING
Allegiance's products -- from latex gloves to customized surgical-procedure
kits -- hold leadership positions in sales to U.S. hospitals. Allegiance's
strategic priorities include: (i) increasing sales through cost-management
agreements; (ii) increasing sales to non-hospital (alternate-site) health-care
providers in the United States and to customers in selected international
marketplaces; (iii) developing new integrated offerings of products and
cost-management services; (iv) selectively expanding its product portfolio; and
(v) maintaining manufacturing operations at the highest levels of quality and
efficiency.
COST-MANAGEMENT SERVICES
Allegiance can bring to its customers more resources to control costs than
are offered by any competitor. Allegiance's strategy is to work in partnership
with hospitals and others in health care to
23
<PAGE>
help them become more efficient, decrease costs and eliminate many of the
logistical burdens that detract from their primary business -- providing health
care. Strategic priorities include signing more shared-risk/shared-savings
agreements and investing in new cost-management services -- beyond supplies and
logistics -- that help customers reduce costs across a greater portion of their
total operating budget.
DISTRIBUTION SERVICES
Allegiance is the leading distributor of medical and laboratory products in
the United States. Allegiance can supply any of more than 200,000 different
products to its customers. Most items are available for shipment the same day
the customer requests them. Allegiance has more than 60 U.S. distribution
centers that deliver more than 880,000 boxes of products to more than 6,000
locations across the United States every day. Each order can be tracked
electronically. Allegiance has made substantial investments in information
systems to enhance its operations and improve service to customers. In addition
to its own surgical and respiratory-therapy products, Allegiance distributes the
industry's broadest array of products from more than 2,000 manufacturers to a
wide variety of health-care settings. Products range from full lines of
laboratory equipment and operating-room supplies to children's gift packs with
coloring books and crayons.
Allegiance divides its distributed products into two categories:
medical/surgical products ("med/ surg") and laboratory products. It is the
industry leader in both product categories. Allegiance's med/ surg portfolio
comprises a broad array of products, including sutures, endoscopy instruments,
needles and syringes, wound-care products, electrodes, face masks, bed pans,
wash basins, blood-pressure cuffs, stethoscopes, waste-disposal bags and others.
Increasingly, these products are being delivered just-in-time in ready-to-use
quantities. In some cases, Allegiance delivers the products directly to patient
floors. Allegiance distributes products not only to hospitals, but increasingly
to surgery centers, physician clinics, long-term and sub-acute care facilities,
home-care companies and other health-care providers. Laboratory products -- used
primarily to perform diagnostic tests -- are sold primarily to hospitals and
reference labs. These products include supplies such as test tubes, pipettes and
slides; equipment such as microscopes, centrifuges and scales; and machines such
as large-volume automated analyzers.
THE VALUELINK-REGISTERED TRADEMARK- SERVICE
Allegiance's ValueLink-Registered Trademark- "stockless" inventory service
provides just-in-time deliveries of products in small, ready-to-use quantities
to hospitals and health-care networks primarily in metropolitan areas.
Allegiance was the first to bring just-in-time distribution to the health-care
industry and it remains the leader.
The ValueLink-Registered Trademark- service helps hospitals reduce inventory
levels and operating expenses. Allegiance has helped hospitals save an average
of $500,000 in one-time inventory reductions and another $450,000 in annual
operating expenses. Orders from hospitals are transmitted electronically and
products are delivered several times a day, sometimes directly to patient
floors. In some ValueLink-Registered Trademark- accounts, Allegiance personnel
work at the hospital 24 hours a day, stocking shelves as needed. Demand for this
service has been strong. Allegiance ended 1995 with 133
ValueLink-Registered Trademark- accounts, compared with 108 in 1994 and 53 at
the end of 1993. In 1995, sales in ValueLink-Registered Trademark- accounts
increased 28 percent to more than $650 million.
The ValueLink-Registered Trademark- service also serves as a channel through
which Allegiance delivers labor-saving, made-to-order packages containing
virtually every sterile and non-sterile product needed to perform dozens of
medical procedures, from open-heart bypass surgery to a hernia repair.
STRATEGIC SUPPLIER RELATIONSHIPS
In 1995, Allegiance began a process of consolidating its distribution
service around a carefully selected group of preferred suppliers, not
relinquishing product breadth, but seeking to reduce the number of suppliers
that furnish redundant items. This "best value" products strategy is designed to
24
<PAGE>
strengthen Allegiance's relationships with fewer preferred suppliers, resulting
in savings to Allegiance and better service to its customers. At the same time,
Allegiance is continuing to streamline its distribution network to reduce costs,
improve service and strengthen the growing number of cost-management
relationships it is establishing with health-care providers and systems.
SUPPLY CHAIN MANAGEMENT
Supply-chain management requires precise knowledge and planning of customer
demand. Given Allegiance's size and scope, advanced information systems, and
balance of internally manufactured and externally supplied products, Allegiance
is well-positioned to maximize service to customers and minimize inventory
levels and variability. To accelerate this process, Allegiance has made major
investments in information technology that uses EDI, or electronic data
interchange, to exchange purchasing and inventory data with many of its
suppliers and largest customers. Management believes this integrated
distribution and product offering strengthens Allegiance's financial and
competitive position. In 1995, Allegiance opened a National Drop Ship Center in
McGaw Park, Illinois, from which it distributes less-frequently ordered items.
By aggregating such products in one facility, the amount of regional inventory
variability has decreased and Allegiance has achieved lower system-wide
inventory levels.
SERVING HEALTH CARE OUTSIDE HOSPITALS
Health care increasingly is being delivered outside hospitals as health-care
providers re-evaluate their cost position and integrate into regional networks.
Many procedures previously performed in hospital operating rooms are now
performed in surgery centers, and some procedures that had been performed in
surgery centers are now taking place in physician clinics. To reach these
alternate-site customers -- surgery centers, physician clinics, subacute and
long-term care facilities, and home-care providers -- Allegiance has developed a
capability to make more frequent deliveries of smaller orders. Allegiance also
is entering into relationships with dealers that specialize in serving these
fast-growing markets. For some very small, or geographically remote customers,
Allegiance provides service through its Network Sales organization. This sales
and customer-service unit conducts business via the telephone, distributing in
some cases by commercial carrier.
PRODUCT OFFERING
Allegiance has differentiated itself by integrating its product offering
with its distribution and cost-management services. Allegiance offers the
industry's broadest range of medical and laboratory products, representing more
than 2,000 suppliers in addition to its own line of surgical and
respiratory-therapy products. In total, Allegiance can furnish up to 80 percent
of a hospital's supply needs, excluding pharmaceuticals.
Increasingly, Allegiance is working with health professionals to reduce the
variety and number of products they buy under agreements that provide incentives
for Allegiance to help customers save money. In return, customers purchase a
greater portion of their supplies from Allegiance. Allegiance's manufacturing
units custom-assemble purchased products into procedure-based modules.
Allegiance's distribution system -- the largest and most technologically
advanced of the industry -- delivers the customized packages as they are needed.
No other single company provides such a comprehensive offering.
Allegiance operates 28 manufacturing plants, producing products used in
surgery and other medical procedures. All Allegiance plants are ISO 9000
certified. Most of Allegiance's self-manufactured products hold leading sales
positions, and investing further in these product lines is a strategic priority.
Allegiance has several major product lines, most of which enjoy leading
sales positions:
CUSTOM-STERILE-TM- PRODUCTS AND THE PBDS-TM- SERVICE
Allegiance's leading Custom-Sterile-TM- products and Procedure Based
Delivery System-TM- (PBDS-TM-) service help health-care providers save time and
money by assembling customer-designated supplies
25
<PAGE>
into single packages for specific procedures. Custom-Sterile-TM- packs contain
sterile, disposable supplies made by Allegiance and other manufacturers. They
are used to perform dozens of procedures, from open-heart surgery and childbirth
to treating cuts and bruises. Customers also can select items for these packs
from a data base of approximately 30,000 products from nearly 800 manufacturers.
PBDS-TM- modules contain Custom-Sterile-TM- packs along with non-sterile
supplies. PBDS-TM- is one of Allegiance's fastest-growing product-based
cost-management services. Introduced in 1993, the service was in place in 175
hospitals by the end of 1995 and is expected to be in place in 400 hospitals by
the end of 1996. PBDS-TM- modules often are delivered to operating rooms and
other hospital departments on a just-in-time basis through Allegiance's
ValueLink-Registered Trademark- distribution service.
CONVERTORS-REGISTERED TRADEMARK- PRODUCTS
The Convertors-Registered Trademark- product line is a leading brand of
single-use surgical drapes, gowns and apparel. These products provide barrier
protection for patients, doctors and clinical staff during surgery, childbirth
and other procedures. Many of Allegiance's Convertors-Registered Trademark-
products are included in Custom Sterile-TM- packs.
Convertors-Registered Trademark- also provides clean-room apparel and equipment
covers for industrial manufacturers.
GLOVES
Allegiance is the world's largest manufacturer and marketer of medical
gloves. Allegiance produces latex surgical and exam gloves in Malaysia, the
world's biggest source of natural latex, as well as in the United States.
Allegiance also manufactures vinyl exam gloves in the United States.
MEDI-VAC-REGISTERED TRADEMARK- PRODUCTS
Allegiance is the world's leading producer of fluid suction and collection
systems. The Medi-Vac-Registered Trademark- line consists of disposable suction
canisters and liners, suction tubing, and supporting hardware and accessories.
These products are used in the operating room to remove fluids and debris from
the body during surgery. Outside the operating room, the products are used when
fluid must be removed from a patient. The Medi-Vac-Registered Trademark- product
line also includes wound-drainage tubing and reservoirs used to remove fluid
from closed wounds, preventing infection and promoting healing.
Medi-Vac-Registered Trademark- autotransfusion systems collect blood for
reinfusion to the patient after filtration, allowing patients to receive their
own blood instead of transfusions from donors.
RESPIRATORY THERAPY PRODUCTS
Allegiance is a leading manufacturer of respiratory-therapy products, which
are used primarily to deliver oxygen to patients suffering from respiratory
distress. This product line includes ventilator circuits (tubing used to connect
patients to ventilator machines), oxygen masks, cannulae, and suction catheters
used to clear the trachea.
V. MUELLER
Allegiance's V. Mueller product line consists of a broad range of
stainless-steel surgical instruments and related products and services. The
business was established in 1895 and is known worldwide for the quality of its
instruments. V. Mueller manufactures about a third of its product line; other
products are sourced from contract manufacturers. V. Mueller products include
clamps, needle-holders, retractors, specialty scissors and forceps. The business
unit also manufactures and markets the cost-saving Genesis-TM- container system
- - - -- complete instrument sets, assembled to order, sterilized and ready for use in
reusable metal containers.
SPECIAL PROCEDURE PRODUCTS
Allegiance provides specialty biopsy needles for extracting samples of bone
marrow and soft tissue, and a variety of specialty procedure trays. These
include lumbar puncture trays, for measuring pressure and taking samples of
cerebrospinal fluid; thoracentesis trays, for withdrawing fluid from chest or
abdominal cavities, or from joints or cysts; amniocentesis trays, for obtaining
amniotic fluid to assess the condition of fetuses; and other diagnostic trays
and products used by obstetricians and gynecologists.
26
<PAGE>
OTHER PRODUCTS
Allegiance is a manufacturer and a marketer of a range of other leading
products. It is the world's largest producer of latex urinary drainage
catheters, and it manufactures endotracheal tubes for respiration, anesthesia
and other therapies. Allegiance produces a broad line of hot and cold packs used
to provide localized temperature therapy for orthopedic injuries and for
patients recovering from childbirth and surgical procedures. It also
manufactures and markets a broad line of patient-preparation, hair-removal and
skin-care products such as clippers, razors, and basins, as well as special
soaps, sponges and scrub brushes for surgeons and other operating-room
personnel.
COST-MANAGEMENT SERVICES
Reducing costs while improving quality of care is the most significant
challenge facing health-care providers today. Allegiance offers the broadest
range of cost-management services in the health-care industry and is investing
significantly to expand its offering further.
Through its shared-risk/shared-savings programs, Allegiance aligns its goals
with those of its customers. Under these agreements, which Allegiance introduced
to the health-care industry in late 1994, the company and its customers agree to
share the savings if supply and related costs fall below an agreed-upon target,
or share the overage if these costs exceed the target. As of June 1, 1996,
Allegiance had shared-risk/shared-savings agreements covering 34 hospitals, or
approximately 1.5 per cent of all "adjusted beds in operation", a measure of
U.S. hospital inpatient and outpatient activity. In shared-risk/shared-savings
accounts, Allegiance assigns a clinical project manager to work with a
hospital's clinical staff to identify patterns of supply usage, reduce variation
by standardizing procedures and products, and eliminate unnecessary supplies.
Product standardization involves the selection and use of one preferred brand
from many options. Savings are realized from selecting the best-value product,
cost efficiencies from increased volume for the selected brand and dealing with
fewer vendors. Procedure standardization involves helping clinical staff reach
consensus on what supplies should be used in a given procedure, then packaging
and distributing the products. A typical assignment for a clinical project
manager lasts 24 months. Hospitals ultimately buy fewer supplies, but a greater
total portion of their supplies from Allegiance. Sales of Allegiance's surgical
products, for example, have grown more than 40 percent in these accounts, while
the hospitals' total supply costs have decreased.
Much of the savings generated in these cost-management accounts come from
the implementation of PBDS-TM- modules, which contain Allegiance's
self-manufactured products, "best value" products from preferred suppliers, and
other third-party distributed products. These modules reduce hospital labor,
purchasing and other product and product-management costs. Rather than ordering
products separately for a procedure, customers can order a single catalog
number. Rather than nurses having to locate and assemble individual products for
a procedure, the products arrive in one package. Additional savings are achieved
when PBDS-TM- modules are delivered just-in-time, direct to the point of use
through Allegiance's ValueLink-Registered Trademark- service. Only Allegiance
can offer such a unique combination of products and cost management services.
In addition, Allegiance offers customers professional consulting services,
including modules derived from Allegiance's proprietary database of
"best-demonstrated practices," to help hospitals improve their clinical
operations, reduce lengths of stay and improve clinical outcomes. Allegiance
also offers, through its ACCESS-TM- program, the expertise and services of
leaders in other industries such as waste management, food service and property
management.
Each of Allegiance's manufacturing units also offers programs to help
customers control costs. There are programs to help health-care providers
standardize and select the most cost-effective drapes, gowns, gloves and other
products for various procedures; identify the most cost-effective mix of
products to include in custom procedure kits; sterilize, repair and refurbish
surgical instruments; and process reusable laundry, linen and textiles. The
Right Choice-TM- glove-management program, for example, helps health-care
providers select the most cost-effective glove for various procedures while
ensuring appropriate patient care and worker safety.
27
<PAGE>
CONTRACTUAL ARRANGEMENTS; BUYING GROUPS
A substantial portion of Allegiance's products are sold through contracts
with purchasers. Some of these contracts are for terms of more than one year and
include limits on price increases. In the case of hospitals, clinical
laboratories and other facilities, these contracts may provide the customer
incentives to purchase particular products or categories of products. Some of
these contracts are entered into with hospital buying groups which seek to
achieve economies of scale in aggregating multiple hospitals' purchases from
Allegiance.
For the last three years, as a percentage of Allegiance's total revenue,
sales to customers which are members of two of the largest hospital buying
groups, Premier Purchasing Partners, LP ("Premier," which is an affiliate of
Premier, Inc.) and VHA, Inc. ("VHA"), comprised 27 per cent and 16 per cent
respectively in 1995, 23 per cent and 13 per cent respectively in 1994, and 23
per cent and 13 per cent respectively in 1993. Some member hospitals in each
group are free to purchase from the vendors of their choice. The loss of the
relationship with either group would not necessarily mean the loss of sales
attributable to all members of such group. In addition, management of Allegiance
believes that its relationships with its larger customers are excellent. No
other buying group or single customer currently accounts for more than five per
cent of Allegiance's revenue.
SALES AND MARKETING
Allegiance conducts its selling efforts through its subsidiaries. These
subsidiaries have their own sales forces and direct their own sales efforts. In
the United States, Allegiance's subsidiary has implemented a "team selling"
approach with many of its hospitals, health systems and multi-hospital group
customers. This approach relies on an account manager to coordinate the various
Allegiance businesses' sales efforts. The account manager assumes responsibility
for all sales and service contacts with a given customer, acting as a focal
point, and assembles cross-functional teams as needed to meet that customer's
requirements. Allegiance manages its field sales and service organization on a
regional basis. The regional sales organization is designed to develop strong
strategic relationships with customers. In addition, sales are made to
independent distributors, dealers and sales agents. Outside of the United
States, Allegiance products are distributed through Baxter. See "ARRANGEMENTS
BETWEEN BAXTER AND ALLEGIANCE".
RAW MATERIALS SUPPLIERS
Raw materials essential to Allegiance's business are purchased worldwide in
the ordinary course of business from numerous suppliers. The vast majority of
these materials are generally available, and no serious shortages or delays have
been encountered. Certain raw materials used in producing some of Allegiance's
products, including its latex products, are available only from a small number
of suppliers.
In some of these situations, Allegiance has long-term supply contracts with
its suppliers, although it does not consider its obligations under such
contracts to be material. Allegiance does not always recover cost increases
through customer pricing due to contractual limits and market pressure on such
price increases. See "-- CONTRACTUAL ARRANGEMENTS; BUYING GROUPS." See
"ARRANGEMENTS BETWEEN BAXTER AND ALLEGIANCE" for a description of certain
continuing supply arrangements between Baxter and Allegiance.
PATENTS AND TRADEMARKS
Allegiance does not consider any one or more of the patents and trademarks
it holds, or the licenses granted to or by it with respect to any patent or
trademark to be essential to its businesses.
COMPETITION
Allegiance is faced with substantial competition in all of its markets. The
changing health-care environment in recent years has led to increasingly intense
competition among health-care suppliers. Competition is focused on price,
service and product performance. Pressure in these areas is expected to
continue. See "RISK FACTORS -- UNITED STATES COMPETITION."
28
<PAGE>
The future financial success of health-care product and service companies,
such as Allegiance, will depend on their ability to work with health-care
customers to help them enhance their competitiveness through cost management
initiatives. Allegiance management believes it can help its customers achieve
savings in the total health-care system by automating supply-ordering
procedures, optimizing distribution networks, improving utilization and
materials management and achieving economies through product and procedure
standardization, and performing certain non-clinical services on an outsourced
basis. Allegiance management further believes that its strategy of providing
high levels of service to its health-care customers and achieving the best
overall cost in its delivery of health-care products and services is compatible
with any anticipated realignment of the United States health-care system that
may ultimately occur.
QUALITY CONTROL
Allegiance places great emphasis on providing quality products and services
to its customers. An integrated network of quality systems, including control
procedures that are developed and implemented by technically trained
professionals, result in rigid specifications for raw materials, packaging
materials, labels, sterilization procedures and overall process control. The
quality systems integrate the efforts of raw material and finished goods
suppliers to provide the highest value to customers. On a statistical sampling
basis, a quality assurance organization tests components and finished goods at
different stages in the manufacturing process to assure that exacting standards
are met.
GOVERNMENT REGULATION
Most of the products manufactured or sold by Allegiance in the United States
are subject to regulation by the Food and Drug Administration ("FDA"), as well
as by other federal and state agencies. The FDA regulates the introduction and
advertising of new drugs and devices as well as manufacturing procedures,
labeling and record keeping with respect to drugs and devices. The FDA has the
power to seize adulterated or misbranded drugs and devices or to require the
manufacturer to remove them from the market and the power to publicize relevant
facts. From time to time, Baxter has removed products from the market that were
found not to meet acceptable standards. This may occur with respect to
Allegiance in the future. Product regulatory laws exist in most other countries
where Allegiance will do business.
Environmental policies of Allegiance mandate compliance with all applicable
regulatory requirements concerning environmental quality and contemplate, among
other things, appropriate capital expenditures for environmental protection.
Various non-material capital expenditures for environmental protection were made
by Baxter related to the Allegiance Business during 1995 and similar
expenditures are planned for 1996. See "LEGAL PROCEEDINGS."
EMPLOYEES
As of June 1, 1996, Allegiance employed approximately 22,000 people.
LEGAL PROCEEDINGS
Upon the Distribution, Allegiance will assume the defense of litigation
involving claims related to the Allegiance Business, including certain claims of
alleged personal injuries as a result of exposure to natural rubber latex gloves
described below. Allegiance has not been named as a defendant in this litigation
but will be defending and indemnifying Baxter Healthcare Corporation ("BHC"), as
contemplated by the Reorganization Agreement, for all expenses and potential
liabilities associated with claims pertaining to this litigation. It is expected
that Allegiance will be named as a defendant in future litigation, and may be
added as a defendant in existing litigation.
BHC was one of ten defendants named in a purported class action filed in
August 1993, on behalf of all medical and dental personnel in the state of
California who allegedly suffered allergic reactions to natural rubber latex
gloves and other protective equipment or who allegedly have been exposed to
natural rubber latex products. (KENNEDY, ET AL., V. BAXTER HEALTHCARE
CORPORATION, ET AL., Sup. Ct., Sacramento Co., Cal., #535632). The case alleges
that users of various natural rubber latex products,
29
<PAGE>
including medical gloves made and sold by BHC and other manufacturers, suffered
allergic reactions to the products ranging from skin irritation to systemic
anaphylaxis. The Court granted defendants' demurrer to the class action
allegations. On February 29, 1996, the California Appellate Court upheld the
trial court's ruling. In April 1994, a similar purported class action, GREEN, ET
AL. V. BAXTER HEALTHCARE CORPORATION, ET AL., (Cir. Ct., Milwaukee Co., WI,
94CV004977) was filed against Baxter and three other defendants. The class
action allegations have been withdrawn, but additional plaintiffs added
individual claims. As of March 31, 1996, 24 additional lawsuits have been served
on BHC containing similar allegations of sensitization to natural rubber latex
products. Allegiance intends to vigorously defend against these actions.
Allegiance believes that a substantial portion of the liability and defense
costs related to natural rubber latex gloves cases and claims will be covered by
insurance, subject to self-insurance retentions, exclusions, conditions,
coverage gaps, policy limits and insurer solvency. BHC has notified its
insurance companies that it believes that these cases and claims are covered by
BHC's insurance. Most of BHC's insurers have reserved their rights (i.e.,
neither admitted nor denied coverage), and may attempt to reserve in the future,
the right to deny coverage, in whole or in part, due to differing theories
regarding, among other things, the applicability of coverage and when coverage
may attach. It is not expected that the outcome of these matters will have a
material adverse effect on Allegiance's business, results of operations or
financial condition.
Under the United States Superfund statute and many state laws, generators of
hazardous waste which is sent to a disposal or recycling site are liable for
cleanup of the site if contaminants from that property later leak into the
environment. The law provides that potentially responsible parties may be held
jointly and severally liable for the costs of investigating and remediating a
site. This liability applies to the generator even if the waste was handled by a
contractor in full compliance with the law.
As of March 31, 1996, BHC has been named as a potentially responsible party
for cleanup costs at ten hazardous waste sites for which Allegiance has assumed
responsibility. Allegiance's largest exposure is at the Thermo-Chem site in
Muskegon, Michigan. Allegiance expects that the total cleanup costs for this
site will be between $44 million and $65 million, of which Allegiance's share
will be approximately $5 million. This amount, net of payments of approximately
$1 million, has been accrued and is reflected in Allegiance's combined financial
statements. The estimated exposure for the remaining nine sites is approximately
$4 million, which has been accrued and reflected in Allegiance's combined
financial statements.
BHC is a defendant in a number of other claims, investigations and lawsuits
for which Allegiance has assumed responsibility. Based on the advice of counsel,
management does not believe that the other claims, investigations and lawsuits
individually or in the aggregate, will have a material adverse effect on
Allegiance's business, results of operations or financial condition.
PROPERTIES
Allegiance owns or has long-term leases on substantially all of its major
manufacturing facilities. Allegiance maintains 28 manufacturing facilities in
the United States, and also operates manufacturing facilities in France,
Malaysia, Malta and Mexico. Allegiance owns or leases 60 distribution centers in
the United States.
Allegiance maintains a continuing program for improving its properties,
including the retirement or improvement of older facilities and the construction
of new facilities. This program includes improvement of manufacturing facilities
to enable production and quality control programs to conform with the current
state of technology and government regulations. Capital expenditures by Baxter
related to the Allegiance Business were $112 million in 1995, $122 million in
1994 and $273 million in 1993.
30
<PAGE>
ALLEGIANCE PRO FORMA FINANCIAL INFORMATION
INTRODUCTION TO UNAUDITED PRO FORMA COMBINED STATEMENTS OF INCOME
AND CONDENSED BALANCE SHEET
The following unaudited pro forma combined statements of income and
unaudited combined condensed balance sheet present the combined results of
Allegiance and its financial position assuming that the transactions
contemplated by the Distribution and certain significant divestitures described
below had been completed as of the beginning of each period presented for the
statements of income and as of March 31, 1996 for the balance sheet.
The unaudited pro forma information has been prepared utilizing the
historical combined financial statements of Allegiance. This information should
be read in conjunction with the historical combined financial statements and
notes thereto, included elsewhere in this Information Statement. The unaudited
pro forma financial data has been included as required by the rules and
regulations of the Commission and is provided for comparative purposes only. The
unaudited pro forma financial data does not purport to be indicative of the
results of Allegiance in the future or what the financial position and results
of operations would have been had Allegiance been a separate, stand-alone entity
during the periods shown.
UNAUDITED PRO FORMA COMBINED STATEMENT OF INCOME
<TABLE>
<CAPTION>
THREE MONTHS ENDED MARCH 31, 1996
-------------------------------------------------------------------
ADJUSTMENTS
FOR DIVESTED ADJUSTED PRO FORMA
HISTORICAL BUSINESSES (A) HISTORICAL ADJUSTMENTS PRO FORMA
----------- ------------- ----------- ----------- -------------
(IN MILLIONS, EXCEPT SHARES AND PER SHARE INFORMATION)
<S> <C> <C> <C> <C> <C>
Net sales...................................... $ 1,115 -- $ 1,115 $ (3)(b) $1,112
Costs and expenses
Cost of goods sold........................... 889 -- 889 (2)(b) 887
Selling, general and administrative
expenses.................................... 168 -- 168 2(b) 170
Interest, net................................ -- -- -- 23(d) 23
Goodwill amortization........................ 9 -- 9 -- 9
Other income (expense)....................... (1) -- (1) -- (1)
----------- ------------- ----------- ----------- -------------
Total costs and expenses................... 1,065 -- 1,065 23 1,088
----------- ------------- ----------- ----------- -------------
Income before income taxes..................... 50 -- 50 (26) 24
Income tax expense (benefit)................... 19 -- 19 (10)(f) 9
----------- ------------- ----------- ----------- -------------
Net income................................. $ 31 -- $ 31 $ (16) $ 15
----------- ------------- ----------- ----------- -------------
----------- ------------- ----------- ----------- -------------
Share information
Shares to be issued (g)...................... 45,348,527
-------------
-------------
Net income per share (g)..................... $ 0.33
-------------
-------------
</TABLE>
31
<PAGE>
UNAUDITED PRO FORMA COMBINED STATEMENT OF INCOME
<TABLE>
<CAPTION>
THREE MONTHS ENDED MARCH 31, 1995
----------------------------------------------------------------------
ADJUSTMENTS
FOR DIVESTED ADJUSTED PRO FORMA
HISTORICAL BUSINESSES (A) HISTORICAL ADJUSTMENTS PRO FORMA
----------- ------------- ----------- -------------- -------------
(IN MILLIONS, EXCEPT SHARES AND PER SHARE)
<S> <C> <C> <C> <C> <C>
Net sales...................................... $ 1,226 $(118) $ 1,108 $ (4)(b) $1,104
Costs and expenses
Cost of good sold............................ 947 (81) 866 (3)(b) 863
Selling, general and administrative
expenses.................................... 198 (20) 178 1(b) 182
3(c)
Interest, net................................ -- -- -- 23(d) 23
Goodwill amortization........................ 9 -- 9 -- 9
Other (income) expense....................... 3 -- 3 -- 3
----------- ------------- ----------- --- -------------
Total costs and expenses................... 1,157 (101) 1,056 24 1,080
----------- ------------- ----------- --- -------------
Income (loss) before income taxes.............. 69 (17) 52 (28) 24
Income tax expense (benefit)................... 27 (8) 19 (10) 9
----------- ------------- ----------- --- -------------
Net income................................. $ 42 $ (9) $ 33 $ (18) $ 15
----------- ------------- ----------- --- -------------
----------- ------------- ----------- --- -------------
Share information
Shares to be issued (g)...................... 45,348,527
-------------
-------------
Net income per share (g)..................... $ 0.33
-------------
-------------
</TABLE>
32
<PAGE>
UNAUDITED PRO FORMA COMBINED STATEMENT OF INCOME
<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31, 1995
-------------------------------------------------------------------
ADJUSTMENTS
FOR DIVESTED ADJUSTED PRO FORMA
HISTORICAL BUSINESSES (A) HISTORICAL ADJUSTMENTS PRO FORMA
----------- ------------- ----------- ----------- -------------
(IN MILLIONS, EXCEPT SHARES AND PER SHARE INFORMATION)
<S> <C> <C> <C> <C> <C>
Net sales...................................... $ 4,922 $(347) $ 4,575 $ (4)(b) $4,571
Costs and expenses
Cost of goods sold........................... 3,878 (253) 3,625 3,625
Selling, general and administrative
expenses.................................... 756 (55) 701 3 (b) 714
10 (c)
Interest, net................................ -- -- -- 90 (d) 90
Restructuring................................ 76 (76) -- -- --
Goodwill amortization........................ 38 (1) 37 -- 37
Other (income) expense....................... (302) 269 (33) 37 (e) 4
----------- ------------- ----------- ----------- -------------
Total costs and expenses................... 4,446 (116) 4,330 140 4,470
----------- ------------- ----------- ----------- -------------
Income before income taxes..................... 476 (231) 245 (144) 101
Income tax expense (benefit)................... 203 (109) 94 (56)(f) 38
----------- ------------- ----------- ----------- -------------
Net income................................. $ 273 $(122) $ 151 $(88) $ 63
----------- ------------- ----------- ----------- -------------
----------- ------------- ----------- ----------- -------------
Share information
Shares to be issued (g)...................... 45,348,527
-------------
-------------
Net income per share (g)..................... $ 1.39
-------------
-------------
</TABLE>
PRO FORMA ADJUSTMENTS
(a) To adjust the historical financial statements for the impact of the
divestitures of the diagnostics manufacturing business and the Industrial
and Life Sciences division for the periods presented, to reflect only those
ongoing business operations to be included in the Distribution. See Notes 1
and 3 to "Notes to the Combined Financial Statements" for additional
information related to these divestitures.
(b) To reflect the impact of various business arrangements between Allegiance
and Baxter effective on the Distribution Date. For more information
describing business arrangements between companies, see "ARRANGEMENTS
BETWEEN BAXTER AND ALLEGIANCE" elsewhere in the Information Statement.
(c) To reflect (i) the estimated incremental costs associated with being an
independent, public company, including costs associated with corporate
administrative services such as tax, treasury, risk management and
insurance, legal, stockholder relations and human resources and (ii) the
estimated reduction in expenses related to changes in Allegiance's benefit
plans.
(d) To record the estimated interest expense which would have been incurred by
Allegiance based on the incurrence of an estimated $1.2 billion of debt at a
weighted average interest rate of 7.5 percent.
(e) To adjust the historical financial statements for a non-recurring payment
related to the transfer of rights under various service agreements with
Alliant Foodservices, Inc., to reflect only those ongoing business
operations to be included in the Distribution.
(f) To reflect the estimated tax impact, at statutory rates, for pro forma
adjustments (b) through (e).
(g) Pro forma net income per share is computed as if the 45,348,527 common
shares of Allegiance Stock, estimated to be issuable in the Distribution,
based on an assumed exchange ratio of one for six, had been outstanding for
the periods presented.
33
<PAGE>
PRO FORMA COMBINED CONDENSED BALANCE SHEET
<TABLE>
<CAPTION>
MARCH 31, 1996
---------------------------------------------------------------------
ADJUSTMENTS
FOR DIVESTED ADJUSTED PRO FORMA
HISTORICAL BUSINESSES (A) HISTORICAL ADJUSTMENTS PRO FORMA
----------- --------------- ----------- ------------ ------------
(IN MILLIONS)
<S> <C> <C> <C> <C> <C>
Current assets
Cash and equivalents........................... $ 4 -- $ 4 $ 40 (a) $ 44
Accounts receivable, net....................... 489 -- 489 489
Notes and other current receivables............ 42 -- 42 -- 42
Inventories.................................... 712 -- 712 712
Short-term deferred income taxes............... 119 -- 119 -- 119
Prepaid expenses............................... 17 -- 17 -- 17
----------- ------ ----------- ------------ ------------
Total current assets......................... 1,383 -- 1,383 40 1,423
----------- ------ ----------- ------------ ------------
Property, plant and equipment
Property, plant and equipment.................. 1,317 -- 1,317 -- 1,317
Accumulated depreciation and amortization...... 440 -- 440 -- 440
----------- ------ ----------- ------------ ------------
Net property, plant and equipment............ 877 -- 877 -- 877
----------- ------ ----------- ------------ ------------
Other assets
Goodwill and other intangibles................. 1,108 -- 1,108 -- 1,108
Other.......................................... 69 -- 69 -- 69
----------- ------ ----------- ------------ ------------
Total other assets........................... 1,177 -- 1,177 -- 1,177
----------- ------ ----------- ------------ ------------
Total assets............................... $ 3,437 -- $ 3,437 $ 40 $ 3,477
----------- ------ ----------- ------------ ------------
----------- ------ ----------- ------------ ------------
Current liabilities
Accounts payable and accrued liabilities....... $ 662 -- $ 662 $ 662
----------- ------ ----------- ------------ ------------
Long-term debt................................... -- -- -- 1,200 (a) 1,200
----------- ------ ----------- ------------ ------------
Long-term deferred income taxes.................. 113 -- 113 -- 113
----------- ------ ----------- ------------ ------------
Other non-current liabilities.................... 65 -- 65 -- 65
----------- ------ ----------- ------------ ------------
Stockholders' Equity
Investment by and advances from Baxter
International Inc............................. 2,597 -- 2,597 (1,437)(b) --
(1,000)(a)
(160)(a)
Common stock, $1 par value, authorized
200,000,000 shares, outstanding 45,348,527
shares........................................ -- -- -- 45 (b) 45
Retained earnings.............................. -- -- -- 1,392 (b) 1,392
----------- ------ ----------- ------------ ------------
Total liabilities and stockholders'
equity.................................... $ 3,437 -- $ 3,437 $ 40 $ 3,477
----------- ------ ----------- ------------ ------------
----------- ------ ----------- ------------ ------------
</TABLE>
PRO FORMA ADJUSTMENTS
(a) To record the planned incurrence of an estimated $1.2 billion of debt to
fund (i) the repayment of approximately $1,000 million of intercompany
notes, (ii) distributions to Baxter of approximately $160 million from
Allegiance's foreign operations and (iii) approximately $40 million of
Allegiance's initial working capital requirements. Working capital of $40
million represents the best estimate of the level of working capital
required related to negotiated agreements with Baxter. As of the
Distribution Date, a final working capital amount will be determined
pursuant to various operational factors.
(b) To reflect the anticipated distribution of approximately 45,348,527 million
shares of common stock at $1.00 par value per share (at an assumed
distribution ratio of one share of Allegiance Stock for every six shares of
Baxter Stock held on the Record Date) and the elimination of Baxter's equity
investment effected by the anticipated distribution of all outstanding
shares of Allegiance Stock to Baxter stockholders.
34
<PAGE>
ALLEGIANCE PRO FORMA CAPITALIZATION
The following table sets forth, as of March 31, 1996, the capitalization of
Allegiance and the pro forma capitalization after giving effect to the
Distribution as described in the Notes below. This information should be read in
conjunction with the historical pro forma Combined Financial Statements and the
related notes thereto of Allegiance included elsewhere herein. The pro forma
information set forth below may not reflect the capitalization of Allegiance in
the future or as it would have been had Allegiance been a separate, independent
company at March 31, 1996.
<TABLE>
<CAPTION>
MARCH 31, 1996
---------------------------------------
PRO FORMA
HISTORICAL ADJUSTMENTS PRO FORMA
----------- ------------- -----------
(IN MILLIONS, EXCEPT SHARES)
<S> <C> <C> <C>
Long-term debt
Long-term debt........................................................... $ -- $ 1,200(a) $ 1,200
Equity
Investment by and advances from Baxter International Inc................. 2,597 (1,437)(b) --
(1,000)(a)
(160)(a)
Stockholders' equity
Common stock, par value $1.00, authorized 200,000,000 shares, outstanding
45,348,527 shares....................................................... -- 45(b) 45
Retained earnings........................................................ -- 1,392(b) 1,392
----------- ------------- -----------
Total capitalization................................................... $ 2,597 $ 40 $ 2,637
----------- ------------- -----------
----------- ------------- -----------
</TABLE>
PRO FORMA ADJUSTMENTS
(a) To record the planned incurrence of an estimated $1.2 billion of debt to
fund (i) the repayment of approximately $1,000 million of intercompany
notes, (ii) distributions to Baxter of approximately $160 million from
Allegiance's foreign operations and (iii) approximately $40 million of
Allegiance's initial working capital requirements. Working capital of $40
million represents the best estimate of the level of working capital
required related to negotiated agreements with Baxter. As of the
Distribution Date, a final working capital amount will be determined
pursuant to various operational factors.
(b) To reflect the anticipated distribution of approximately 45,348,527 shares
of common stock at $1.00 par value per share (at an assumed distribution
ratio of one share of Allegiance Stock for every six shares of Baxter Stock
held on the Record Date) and the elimination of Baxter's equity investment
effected by the anticipated distribution of all outstanding shares of
Allegiance Stock to Baxter stockholders.
35
<PAGE>
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
The following discussion and analysis presents the factors that had a
material effect on the results of operations of Allegiance during the three
years ended December 31, 1995, and for the three-month periods ended March 31,
1996 and 1995. Also discussed is Allegiance's financial position as of December
31, 1995 and 1994, and March 31, 1996. This discussion should be read in
conjunction with the historical and pro forma combined financial statements and
related notes thereto included elsewhere in this Information Statement.
OVERVIEW
Allegiance operates in a single industry segment as a leading provider of
health-care products and services that help its health-care customers manage and
reduce the total cost of providing patient care. Through its nationwide
distribution network, Allegiance distributes a broad offering of medical,
surgical and laboratory supplies, including its own self-manufactured surgical
and respiratory-therapy products, to hospital and alternate-care customers.
Allegiance also provides cost management services to its health-care customers,
including inventory management programs, customized packaging, and procedure and
process consulting. The delivery of such a broad array of product and service
offerings requires focused investments in cost management services, information
systems and manufacturing efficiencies.
Accelerating cost pressures on United States hospitals are resulting in
increased out-patient and alternate-site health-care service delivery and a
focus on cost-effectiveness and quality. At the same time, the elderly segment
of the population in the U.S. and abroad is growing. These forces increasingly
shape the demand for, and supply of, medical care. Many private health-care
payors are providing incentives for consumers to seek lower cost care outside
the hospital. Many corporations' employee health plans have been restructured to
provide financial incentives for patients to utilize the most cost-effective
forms of treatment (managed care programs, such as health maintenance
organizations, have become more common), and physicians have been encouraged to
provide more cost-effective treatments. In response to these pressures, the U.S.
health-care system has undergone fundamental changes over the past several
years, and such changes and cost-containment efforts are expected to continue
throughout the foreseeable future.
While the high cost of health care is forcing hospitals and other providers
to increase their efficiency, reduce excess capacity and lower costs, Allegiance
management believes that it is well-positioned to work with health-care
providers to help them enhance their competitiveness and to distribute products
to alternate sites as treatment moves outside the hospital. Management believes
that it can help its customers achieve savings in the total health-care system
by automating supply-ordering procedures, optimizing distribution networks,
improving utilization and materials management and achieving economies through
product and procedure standardization, and performing certain non-clinical
services on an outsourced basis. Allegiance management further believes that its
strategy of providing unmatched service to its health-care customers and
achieving the best overall cost in its delivery of health-care products and
services is compatible with any anticipated realignment of the U.S. health-care
system that may ultimately occur.
RESULTS OF OPERATIONS
Allegiance's historical results of operations in 1995, 1994 and 1993 include
revenues and expenses related to certain divested businesses. The Industrial and
Life Sciences division was sold in September 1995 and the diagnostics
manufacturing businesses were sold in December 1994. See Notes 1 and
36
<PAGE>
3 to "Notes to Combined Financial Statements" for additional information related
to these divestitures. The following table presents selected financial data for
Allegiance excluding the revenue and expenses associated with these divested
businesses:
<TABLE>
<CAPTION>
THREE MONTHS ENDED
MARCH 31, YEARS ENDED DECEMBER 31,
-------------------- -------------------------------
1996 1995 1995 1994 1993
--------- --------- --------- --------- ---------
(UNAUDITED) (IN MILLIONS)
<S> <C> <C> <C> <C> <C>
Net sales........................................... $ 1,115 $ 1,108 $ 4,575 $ 4,314 $ 4,249
Costs and expenses
Cost of goods sold................................ 889 866 3,625 3,311 3,245
Selling, general and administrative expenses...... 168 178 701 711 746
Restructuring charge.............................. -- -- -- -- 304
Goodwill amortization............................. 9 9 37 37 37
Other (income) expense............................ (1) 3 (33) (3) (44)
--------- --------- --------- --------- ---------
Total costs and expenses........................ 1,065 1,056 4,330 4,056 4,288
--------- --------- --------- --------- ---------
Pretax income (loss)................................ 50 52 245 258 (39)
Income tax expense (benefit)........................ 19 19 94 101 (13)
--------- --------- --------- --------- ---------
Income (loss)....................................... $ 31 $ 33 $ 151 $ 157 $ (26)
--------- --------- --------- --------- ---------
--------- --------- --------- --------- ---------
</TABLE>
SALES
The following table summarizes net sales, excluding the divested businesses
discussed previously, by major geographic region:
<TABLE>
<CAPTION>
THREE MONTHS ENDED
MARCH 31, YEARS ENDED DECEMBER 31,
---------------------- -----------------------------------
1996 1995 1995 1994 1993
----------- --------- ----------- ----------- ---------
(UNAUDITED) (IN MILLIONS)
<S> <C> <C> <C> <C> <C>
Geographic region
United States............................... $ 1,045 $ 1,042 $ 4,284 $ 4,043 $ 4,001
% increase................................ -- 6% 1%
International............................... 70 66 291 271 248
% increase................................ 6% 7% 9%
----------- --------- ----------- ----------- ---------
Total net sales............................... $ 1,115 $ 1,108 $ 4,575 $ 4,314 $ 4,249
% increase................................ 1% 6% 2%
----------- --------- ----------- ----------- ---------
----------- --------- ----------- ----------- ---------
</TABLE>
Allegiance's total net sales growth of 1% for the three months ended March
31, 1996 as compared to the same period in the prior year, is the result of
planned attempts to reduce sales growth and improve profitability in lower
margin, distributed products in the U.S. Additionally, domestic sales of
self-manufactured surgical products continue to be unfavorably impacted by the
loss of a contract with Columbia/HCA in February 1994. Columbia began
transitioning its surgical supply purchases for certain product lines in early
1994 and continued to transition other product lines throughout 1995 and 1996.
International sales increased by 6% in the first quarter of 1995 as a result of
continued focus on the penetration of surgical products into international
markets.
Domestic net sales growth of 6% in 1995 is primarily due to increased sales
volume in lower margin, distributed products, resulting from an increase in
Valuelink-Registered Trademark- distribution agreements and the large supply and
service contract signed with the VHA in 1994. Domestic net sales in 1994 were
adversely affected by pricing pressures experienced in the domestic market place
and the loss of the Columbia/HCA surgical supply contract.
37
<PAGE>
Allegiance currently has international sales of self-manufactured surgical
products primarily in Canada, France and Germany. International sales growth of
7% in 1995 and 9% in 1994 was the result of continued focus on the penetration
of surgical products into these international markets. International sales
growth in local currency was approximately 5% in 1995 and 13% in 1994.
Allegiance expects to increase its sales efforts internationally.
COSTS AND EXPENSES
The following table summarizes Allegiance's gross margin and expense ratios,
excluding the divested businesses discussed previously:
<TABLE>
<CAPTION>
THREE MONTHS ENDED MARCH
31, YEARS ENDED DECEMBER 31,
------------------------ -------------------------------------
1996 1995 1995 1994 1993
----------- ----------- ----------- ----------- -----------
(UNAUDITED) (IN MILLIONS)
<S> <C> <C> <C> <C> <C>
Gross margin........................................... 20.3% 21.8% 20.8% 23.2% 23.6%
Selling, general and administrative expenses........... 15.1% 16.1% 15.3% 16.5% 17.6%
</TABLE>
The gross margin declined for the three-month period ended March 31, 1996 as
compared with the same period in 1995, due to pricing pressure in the U.S.
combined with lower sales in Allegiance's higher margin surgical products as a
result of the loss of the Columbia/HCA contract. Allegiance's gross margin
decline of 2.8 percentage points between 1993 and 1995 resulted from general
market conditions, growth in lower margin sales of third party products and the
loss of the Columbia/HCA surgical supply contract. Allegiance plans to stabilize
its gross margins by offsetting pricing pressures with manufacturing cost
efficiencies, managing its product mix more effectively, and instituting price
increases.
Selling, general and administrative expenses as a percent of sales for the
quarter ended March 31, 1996 declined 1.0 percentage point from the comparable
period in 1995. Excluding the effect of a non-recurring reversal of excess
reserves related to a downsizing program initiated in early 1993, selling,
general and administrative expenses as a percent of sales declined by
approximately 0.5 percentage point. This decline is the result of initiatives
taken in connection with Allegiance's 1993 restructuring program. Selling,
general and administrative expenses in 1993 were adversely affected by a
downsizing program. Excluding the impact of the downsizing program, selling,
general and administrative expenses as a percent of sales in 1993 would have
been approximately 16.7%. The remaining 1.4 percentage point decline in selling,
general and administrative expenses that occurred between 1993 and 1995 was the
result of initiatives taken in connection with the 1993 restructuring program
and leverage on the growth in distributed products that occurred in 1994.
Management plans to continue to leverage this ratio.
RESTRUCTURING PROGRAM
In November 1993, Baxter initiated a restructuring program to improve
shareholder value and reduce costs. The strategic actions of the program were
designed in part to make the Allegiance Business more efficient and responsive
in addressing the changes occurring in the U.S. health-care system. See Note 4
to "Notes to the Combined Financial Statements" for discussions related to the
initial charge for the program, components of the charge, any resulting changes
in estimates, and cash and non-cash utilization of the related reserves.
Since the announcement of the 1993 restructuring program, Allegiance
management has implemented, or is in the process of implementing, all of the
major strategic actions associated therewith and is satisfied that the program
is progressing on schedule and will meet established financial targets. During
the first quarter of 1996, Allegiance utilized $38 million of restructuring
reserves, including $22 million in cash payments. In 1995, Allegiance utilized
$171 million of restructuring reserves, including $105 million in cash payments.
Cash outflows pertain primarily to employee-related costs for severance,
outplacement assistance, relocation, implementation teams and facility
consolidation. As of March 31, 1996, Allegiance had eliminated approximately
1,890 positions of the
38
<PAGE>
approximately 2,860 positions that were originally expected to be affected by
the program. As process changes were implemented in connection with the
restructuring program, it became apparent that, as certain management level
positions were eliminated, other lower cost positions were added. While this has
generated savings levels consistent with expectations, management has revised
its targeted head count reduction to 2,230 net positions. The majority of the
remaining reductions will occur in 1996 and 1997, as facility closures and
consolidations are completed as planned. In addition to improvements in the
effectiveness of its sales force and the management of customer relations,
Allegiance realized direct savings in manufacturing and administrative costs
from this program of approximately $95 million in 1995 and $40 million in 1994.
These savings have mitigated the effect of declines in gross margin and have
been invested in cost management initiatives. Management is targeting direct
savings of approximately $125 million in 1996, $155 million in 1997 and
exceeding $155 million in 1998. Management anticipates that these savings will
continue to offset potential future gross margin erosion and investments into
cost-management initiatives. Management further believes that its remaining
restructuring reserves are adequate to complete the actions contemplated by the
restructuring program and that future cash expenditures related to the program
will be funded from cash generated from operations.
OTHER INCOME AND EXPENSE
Other income and expense, excluding the divested businesses discussed
previously, is principally comprised of net gains associated with the disposal
or discontinuance of minor, non-strategic businesses.
PRETAX INCOME
The following table compares pretax income, excluding divested businesses
and restructuring charges discussed previously:
<TABLE>
<CAPTION>
THREE MONTHS ENDED
MARCH 31, YEARS ENDED DECEMBER 31,
---------------------- -----------------------------------
1996 1995 1995 1994 1993
----------- --------- ----------- ----------- ---------
(UNAUDITED) (IN MILLIONS)
<S> <C> <C> <C> <C> <C>
Pretax income excluding divested businesses and
restructuring charges................................. $ 50 $ 52 $ 245 $ 258 $ 265
% decrease........................................... (4)% (5)% (3)%
</TABLE>
Pretax income in the first quarter of 1996 decreased primarily due to the
decline in margins, partially offset by the non-recurring reversal of excess
reserves discussed above. Pretax income decreased in 1995 primarily as a result
of gross margin declines, partially offset by a higher level of net gains
associated with the disposal or discontinuance of minor, non-strategic
businesses. Excluding net gains associated with the disposal or discontinuance
of minor, non-strategic businesses, 1995 pretax income would have declined 16%.
The decrease in 1994 is primarily the result of gross margin declines, partially
offset by net gains associated with the disposal or discontinuance of minor,
non-strategic businesses. Excluding these net gains, 1994 pretax income would
have declined 7%.
INCOME TAXES
Allegiance's effective tax rate, excluding divested businesses discussed
previously, was 38% and 37% for the three months ended March 31, 1996 and 1995,
respectively. The increase in the effective tax rate for the quarter is the
result of a larger proportion of earnings generated in higher tax jurisdictions.
Allegiance's effective tax rate, excluding divested businesses discussed
previously, was 38% in 1995, 39% in 1994 and 33% in 1993. The decline in the
effective tax rate in 1995 was a result of a larger proportion of earnings
generated in lower tax jurisdictions. The effective tax rate in 1993 was
impacted by the restructuring charge. Excluding this charge, the effective tax
rate in 1993 would have been 41%; the decrease in the 1994 effective tax rate
was the result of a larger proportion of earnings generated in lower tax
jurisdictions.
39
<PAGE>
NET INCOME
Net income, excluding divested businesses discussed previously, decreased 6%
for the three months ended March 31, 1996 as compared to the same period in
1995. This decrease is consistent with the decrease in pretax income and
increase in the effective interest rate discussed above. Net income for 1995,
excluding divested businesses and net gains associated with the disposal or
discontinuance of minor, non-strategic businesses, decreased 14% as a result of
gross margin declines, partially offset by a decline in the effective tax rate.
After adjusting for the restructuring charge recorded in 1993 and net gains
associated with the disposal or discontinuance of minor, non-strategic
businesses, net income excluding divested businesses decreased by approximately
4% in 1994 as a result of gross margin declines, partially offset by the decline
in Allegiance's effective income tax rate discussed above.
ADOPTION OF NEW ACCOUNTING STANDARDS
In March 1995, the Financial Accounting Standards Board ("FASB") issued
Statement No. 121, "Accounting for the Impairment of Long-Lived Assets and for
Long-Lived Assets to be Disposed Of," which is effective for fiscal years
beginning after December 31, 1995. Adoption of FASB No. 121 in fiscal year 1996
did not have a material impact on Allegiance.
In October 1995, the FASB issued Statement No. 123, "Accounting for
Stock-Based Compensation," which is effective for fiscal years beginning after
December 15, 1995. The statement provides management with a choice of accounting
methods for stock-based transactions with employees. Management has decided to
adopt FASB No. 123 through disclosure only and, accordingly, the required pro
forma information on net income and earnings per share will be included in
Allegiance's fiscal year 1996 financial statements.
IMPACT OF INFLATION
In recent years, Allegiance has experienced increases in its labor and
material cost base influenced, in part, by general inflationary trends. While
not directly related to inflationary trends, Allegiance's revenue base over
recent years has been adversely affected by lower average selling prices on
certain products as a result of changes in Medicare reimbursement regulations,
economic pressures in the U.S. hospital marketplace and increased competition in
certain product lines. There is little correlation between general inflation
rates directly affecting costs and expenses and Allegiance's pricing levels for
products sold to health-care customers. Management expects that these trends
will continue.
LIQUIDITY AND CAPITAL RESOURCES
Management assesses Allegiance's liquidity in terms of its overall ability
to mobilize cash to support ongoing business levels and to fund its growth.
Allegiance's current assets exceeded current liabilities by $721 million at
March 31, 1996 versus an excess of $680 million and $1,055 million at December
31, 1995 and 1994, respectively. Current assets at March 31, 1996 included
accounts and notes receivable of $531 million and inventories of $712 million.
These sources of liquidity are convertible into cash over a relatively short
period of time and thus, will help Allegiance satisfy normal operating cash
requirements.
DEBT AND FINANCIAL INSTRUMENTS
Prior to the Distribution Date, Allegiance will incur indebtedness of
approximately $1,200 million from unsecured credit facilities with banks,
short-term debt and new term debt issuances. Approximately $1,160 million of
this indebtedness will be used to repay intercompany debt to Baxter and fund
distributions from Allegiance's foreign operations to Baxter. The remaining $40
million will be used for initial working capital requirements. Working capital
of $40 million represents the best estimate of the level of working capital
required related to negotiated agreements with Baxter. As of the Distribution
Date, a final working capital amount will be determined pursuant to various
operational factors. Allegiance anticipates that it will convert a significant
portion of its initial debt to longer term fixed
40
<PAGE>
rate debt, contingent upon acceptable market conditions. The debt that is not
converted will be managed as part of a short-term loan portfolio supported by a
long-term credit facility. Management expects that Allegiance's senior debt will
be investment grade.
Assuming a debt level of $1.2 billion, Allegiance's long-term debt as a
percent of total capital would have been approximately 44.5% at March 31, 1996.
Allegiance expects to maintain a debt to capital ratio between 40% and 45% over
the next several years.
Allegiance intends to fund its short-term and long-term obligations as they
mature through cash flow from operations or by issuing additional debt.
Allegiance believes it will have lines of credit adequate to support ongoing
operational and restructuring requirements.
CASH FLOW FROM OPERATIONS
Cash flow provided by operations (which includes working capital components)
was $44 million and $103 million for the three months ended March 31, 1996 and
1995, respectively. Cash flow provided by operations for 1995, 1994 and 1993,
was $253 million, $422 million and $336 million, respectively. To facilitate an
emphasis on cash flow from operations, management monitors an internal
performance measure called "operational cash flow." This measure evaluates each
operating unit on all aspects of cash flow under its direct control. In
addition, the incentive compensation programs for Allegiance's senior management
in each operating unit include significant emphasis on the attainment of both
"operational cash flow" as well as earnings objectives.
The following table reconciles cash flow provided by operations, as
determined by generally accepted accounting principles, to Allegiance's internal
measure of "operational cash flow" (brackets denote cash outflows):
<TABLE>
<CAPTION>
THREE MONTHS ENDED
MARCH 31, YEARS ENDED DECEMBER 31,
-------------------- -------------------------------
1996 1995 1995 1994 1993
--------- --------- --------- --------- ---------
(UNAUDITED) (IN MILLIONS)
<S> <C> <C> <C> <C> <C>
Cash flow provided by operations per Allegiance's combined
statements of cash flows................................... $ 44 $ 103 $ 253 $ 422 $ 336
Capital expenditures........................................ (15) (18) (112) (122) (273)
Other....................................................... -- (1) 41 3 15
--- --------- --------- --------- ---------
Total "operational cash flow"........................... $ 29 $ 84 $ 182 $ 303 $ 78
--- --------- --------- --------- ---------
--- --------- --------- --------- ---------
</TABLE>
The decrease in "operational cash flow" for the first quarter of 1996 was
the result of a decline in earnings (resulting principally from the divestiture
of the Industrial and Life Sciences division) and changes in working capital
components. The decline in "operational cash flow" in 1995 was primarily the
result of a decline in earnings, resulting principally from the divestitures of
the Industrial and Life Sciences division and the diagnostics manufacturing
businesses. The increase in 1994 was the result of lower "operational cash flow"
in 1993. The lower "operational cash flow" in 1993 was the result of changes in
working capital components (principally inventory and accrued liabilities) and
higher capital expenditures resulting from the diagnostics manufacturing
businesses.
41
<PAGE>
INVESTMENT TRANSACTIONS
Net investment transactions for Allegiance are comprised of the following:
<TABLE>
<CAPTION>
THREE MONTHS ENDED
MARCH 31, YEARS ENDED DECEMBER 31,
-------------------- -------------------------------
1996 1995 1995 1994 1993
--------- --------- --------- --------- ---------
(UNAUDITED) (IN MILLIONS)
<S> <C> <C> <C> <C> <C>
Capital expenditures........................................ $ (15) $ (18) $ (112) $ (122) $ (273)
Acquisitions................................................ (9) -- (5) (2) (14)
Proceeds from asset dispositions............................ (5) 184 626 107 68
--- --------- --------- --------- ---------
Total investment transactions, net...................... $ (29) $ 166 $ 509 $ (17) $ (219)
--- --------- --------- --------- ---------
--- --------- --------- --------- ---------
</TABLE>
The reductions in capital expenditures in 1995 and 1994 are primarily the
result of Allegiance's divestitures of the Industrial and Life Sciences division
and the diagnostics manufacturing businesses.
The acquisitions summarized in the above table involved no significant
change to Allegiance's strategic direction, and were made for the purpose of
acquiring technologies, broadening product lines and service offerings, or
expanding market coverage.
Proceeds from asset dispositions in the first quarter of 1995 primarily
related to cash received from the collection of notes receivable related to
Allegiance's divestiture of the diagnostics manufacturing businesses in December
1994. The proceeds received from asset dispositions for the year ended December
31, 1995, primarily related to cash received in connection with Allegiance's
divestiture of its Industrial and Life Sciences division in September 1995 and
the collection of notes receivable related to the divestiture of Allegiance's
diagnostics manufacturing businesses. See Notes 1 and 3 to "Notes to Combined
Financial Statements" for additional information related to these divestitures.
LITIGATION
See Note 12 to "Notes to Combined Financial Statements" for a detailed
description of the status of Allegiance's litigation.
Under the U.S. Superfund statute and many state laws, generators of
hazardous waste which is sent to a disposal or recycling site are liable for
cleanup of the site if contaminants from that property later leak into the
environment. The law provides that potentially responsible parties may be held
jointly and severally liable for the costs of investigating and remediating a
site. This liability applies to the generator even if the waste was handled by a
contractor in full compliance with the law.
As of March 31, 1996, Baxter has been named as a potentially responsible
party for cleanup costs at ten hazardous waste sites, for which Allegiance has
assumed responsibility. The largest assumed exposure is at the Thermo-Chem site
in Muskegon, Michigan. Allegiance expects that the total cleanup costs for this
site will be between $44 million and $65 million, of which Allegiance's share
will be approximately $5 million. This amount, net of payments of approximately
$1 million, has been accrued and is reflected in Allegiance's combined financial
statements. The estimated exposure for the remaining nine sites is approximately
$4 million, which has been accrued and reflected in Allegiance's combined
financial statements.
Upon resolution of any of the uncertainties described in Note 12 to "Notes
to Combined Financial Statements," Allegiance may incur charges in excess of
available reserves. Management does not believe that such charges will have a
material impact on Allegiance's results of operations, cash flow or financial
position.
42
<PAGE>
ALLEGIANCE MANAGEMENT
BOARD OF DIRECTORS
Immediately after the Distribution Date, the Allegiance Board is expected to
consist of the individuals named in the table below. The Allegiance Board will
be divided into three classes. Each director will serve for a term expiring at
the annual meeting of stockholders in the year indicated below. See "CERTAIN
ANTITAKEOVER EFFECTS OF CERTAIN PROVISIONS OF THE CERTIFICATE OF INCORPORATION,
BY-LAWS AND STATE LAW -- CERTIFICATE OF INCORPORATION AND BY-LAWS."
<TABLE>
<CAPTION>
NAME; AGE TERM AS DIRECTOR BACKGROUND
- - - -------------------------- --------------------- --------------------------------------------------------------
<S> <C> <C>
Lester B. Knight Expires 1999 Mr. Knight will be the chairman of the board and chief
Age 37 executive officer of Allegiance. At Baxter, he has been
executive vice president, responsible for the U.S. Healthcare
business since 1992, and a director of Baxter since 1995. He
was elected a corporate vice president of Baxter in 1990. Mr.
Knight joined Baxter in 1981.
Joseph F. Damico Expires 199 Mr. Damico will be the chief operating officer of Allegiance.
Age 42 At Baxter, he has been group vice president, responsible for
the Field Sales, Health Systems, and Distribution
organizations in the U.S. Healthcare business since 1993. He
was elected a corporate vice president of Baxter in 1992. He
was president of Baxter's Pharmaseal division in 1992, and
prior thereto, was president of the Convertors/Custom Sterile
business since 1989. Mr. Damico joined Baxter in 1979.
Silas S. Cathcart Expires 199 Mr. Cathcart is a director of General Electric Company and The
Age 70 Quaker Oats Company. Mr. Cathcart is also a trustee of
Northern Funds Mutual Fund. From 1985 to 1987, and from 1990
to the present, Mr. Cathcart served as a director of Baxter.
From 1970 to 1985 he served as a director of American Hospital
Supply Corporation. Mr. Cathcart served as chairman of the
board and chief executive officer of Kidder, Peabody Group
Inc., an investment banking firm, from 1988 to 1989, and as
president and chief executive officer from 1987 to 1988. From
1972 to 1986, he was chairman of Illinois Tool Works, Inc.
David W. Grainger Expires 199 Since 1968, Mr. Grainger has been chairman of the board of W.
Age 68 W. Grainger, Inc., a nationwide distributor of equipment,
components and supplies. He joined W. W. Grainger, Inc. in
1952. From 1990 to the present, Mr. Grainger has served as a
director of Baxter.
Arthur F. Golden Expires 199 Since 1978, Mr. Golden has been a partner of Davis, Polk &
Age 50 Wardwell, a general practice law firm. He is a director of
Esco Electronics Corporation and Borg Warner Security
Corporation.
</TABLE>
43
<PAGE>
<TABLE>
<S> <C> <C>
Michael D. O'Halleran Expires 199 Since 1995, Mr. O'Halleran has been president of Aon Group,
Age 46 Inc., an insurance holding company, and since 1988, he has
been the chairman of the board of Aon Risk Services, Inc., a
subsidiary of that company.
Kenneth D. Bloem Expires 199 Since 1994, Mr. Bloem has been the chief executive officer of
Age 50 The Advisory Board Company, a privately held research and
publishing company. From 1989 to 1994, he was the president of
Stanford University Hospital.
Connie Curran, Ed.D. Expires 199 Since 1995, Ms. Curran has been president of CurranCare, Inc.,
Age 49 a nation-wide hospital based home care management company.
From 1990 to 1995, she was the vice chairman/national director
of patient services of APM, Inc.
</TABLE>
Messrs. Knight, Cathcart and Grainger are currently directors of Baxter, and
will resign such positions shortly prior to the Distribution Date.
COMMITTEES OF THE BOARD OF DIRECTORS
Allegiance will be managed under the direction of its Board of Directors.
The Allegiance Board will meet on a regular basis to review Allegiance's
operations, strategic and business plans, acquisitions and dispositions, and
other significant developments affecting Allegiance, and to act on matters
requiring Allegiance Board approval. It will also hold special meetings when
important matters require Allegiance Board action between scheduled meetings.
Members of senior management will be invited to Allegiance Board meetings to
discuss the progress of and future plans relating to their areas of
responsibility.
To facilitate independent director review, and to make the most effective
use of the directors' time and capabilities, the Allegiance By-laws establish
various committees, including those described below. The Allegiance Board is
permitted to establish other committees from time to time as it deems
appropriate.
THE AUDIT AND PUBLIC POLICY COMMITTEE
The Audit and Public Policy Committee will review the scope of the audit by
the independent auditors, inquire into the effectiveness of Allegiance's
accounting and internal control functions, and recommend to the Allegiance Board
any changes in the appointment of independent auditors which the committee may
deem to be in the best interests of the corporation and its stockholders. The
committee will also assist the Allegiance Board in establishing and monitoring
compliance with the ethical standards of Allegiance. The Audit and Public Policy
Committee will also review the policies of Allegiance to assure they are
consistent with its social responsibility to employees, customers and to
society, including policies relating to health and safety and ethics. The
committee shall consist solely of directors who are independent of management.
Members of this committee are expected to be Mr. O'Halleran (Chairman), Mr.
Cathcart, Mr. Grainger, Mr. Golden, Mr. Bloem and Ms. Curran.
THE COMPENSATION AND NOMINATING COMMITTEE
The Compensation and Organization Committee will determine the compensation
of officers, other than the chairman of the board and chief executive officer,
exercise the authority of the Allegiance Board concerning employee benefit
plans, serve as the administration committee of Allegiance's stock option plans,
and advise the Allegiance Board on other compensation and employee benefit
matters. In addition, the committee will make recommendations to the Allegiance
Board regarding candidates for election as directors of Allegiance. The
committee will also advise the Board on board committee structure and
membership. The committee shall consist solely of directors who are independent
of management. Members of this committee are expected to be Mr. Cathcart
(Chairman), Mr. Grainger, Mr. Golden, Mr. O'Halleran, Mr. Bloem and Ms. Curran.
44
<PAGE>
COMPENSATION OF DIRECTORS
Cash compensation of non-employee directors will consist of a $1,000 fee for
each board and each committee meeting attended. Chairpersons of committees will
receive an additional annual retainer of $3,000. Employee directors are not
compensated separately for their board or committee activities.
In addition, to align the directors' interests more closely with the
interest of all of the company's stockholders, each non-employee director will
receive an annual retainer in the form of 10,000 Allegiance Stock Options.
EXECUTIVE OFFICERS
Set forth below is information with respect to those individuals who are
expected to serve as executive officers of Allegiance immediately following the
Distribution. Those individuals named below who are currently officers or
employees of Baxter will resign from all such positions prior to or as of the
Distribution Date.
LESTER B. KNIGHT, 37, will be chairman of the board and chief executive
officer of Allegiance. At Baxter, he has been executive vice president,
responsible for the U.S. Healthcare business since 1992. Mr. Knight joined
Baxter in 1981 and served in several manufacturing, research-and-development and
management positions before being named general manager of the company's Renal
business in 1987. He was named president of the Renal business in 1988, and
president of the I.V. Systems business the following year. He was elected a
corporate vice president of Baxter in 1990, and was named executive vice
president in 1992. Mr. Knight is a member of the Board of Directors of Baxter,
but will resign from that board shortly prior to the Distribution Date.
JOSEPH F. DAMICO, 42, will be chief operating officer of Allegiance. At
Baxter, he has been group vice president, responsible for the Field Sales,
Health Systems, and Distribution organizations in the U.S. Healthcare business
since 1993. Mr. Damico joined Baxter in 1979 as a sales representative and
served in a variety of management positions before being named vice president
and general manager of the company's Custom Sterile division in 1987. He was
named president of the Convertors/Custom Sterile business in 1989, and also
assumed responsibility for Baxter's Pharmaseal division in 1992. He was elected
a corporate vice president the same year, and named group vice president in
1993.
PETER B. MCKEE, 58, will be the chief financial officer of Allegiance. He
joined Baxter in May 1996 from FoxMeyer Health Corporation, a leading
pharmaceutical distributor, where he had been senior vice president and chief
financial officer since 1993. Mr. McKee's career as a financial executive spans
more than 35 years. Before joining Dallas-based FoxMeyer, he worked in financial
consulting and held CFO positions at Metro Airlines and Swift Independent
Packing. He also has held senior financial positions at Ford Motor Company and
Cooper Industries Inc.
KATHY BRITTAIN WHITE, 46, will be the chief information officer of
Allegiance. At Baxter, she has been corporate vice president and chief
information officer since 1995. She came to Baxter from AlliedSignal
Corporation, where she had served as vice president, information systems and
services, since 1993. Prior to that, she was vice president, corporate services,
for Guilford Mills, Inc.
ROBERT B. DEBAUN, 45, will be a vice president of Allegiance, responsible
for human resources. At Baxter, he has been vice president of human resources
for the U.S. Distribution organization since 1991. Mr. DeBaun joined Baxter in
1981 as manager of college relations. In 1986, after a series of increasingly
responsible positions, he was named vice president, human resources, for
Baxter's I.V. Systems group.
MARK J. EHLERT, 42, will be a vice president of Allegiance, responsible for
quality assurance and regulatory affairs. At Baxter, he has been vice president,
quality and regulatory affairs, for the U.S. Sales and Distribution organization
since 1994. Mr. Ehlert joined Baxter in 1975. In 1990, after a series of
increasingly responsible positions, he was promoted to general manager of
Baxter's Singapore manufacturing operations.
45
<PAGE>
GAIL GAUMER, 44, will be a vice president of Allegiance, responsible for
strategy and business development as well as cost management services. At
Baxter, she has been president of marketing, strategy and business development
for the U.S. Healthcare business since 1995. Ms. Gaumer joined Baxter in 1980
and held a number of positions in its subsidiary's Renal business. Most
recently, she was president of Renal-Europe. Before that, she was vice president
of global marketing, planning and new business development, and then vice
president and general manager for the Renal business. Before joining Baxter, she
worked for ALZA Corporation, a drug-delivery company. Ms. Gaumer is a director
of FemRx, Inc.
ROBERT J. ZOLLARS, 39, will be a vice president of Allegiance. He will lead
the regional companies and health systems organizations of Allegiance. At
Baxter, he has been president, U.S. Distribution, responsible for its Hospital
Supply/Scientific Products, Life Sciences, Hospitex, Dietary Products, and
ValueLink distribution businesses since 1994. Mr. Zollars joined Baxter in 1979
as a sales representative for the Scientific Products division and rose to vice
president and general manager of the division in 1983. In 1986, he was named
president of the Dietary Products division, and in 1990, became president of the
I.V. Therapy business. He was named president of the Hospital Supply division in
1992, and assumed additional responsibility for Scientific Products in 1993.
RICHARD C. ADLOFF, 38, will be the controller of Allegiance. He has been
vice president of finance for the U.S. Healthcare business since 1994. Mr.
Adloff joined Baxter in 1980 with the Hospital Supply division. In 1990, after a
series of increasingly responsible positions in distribution and manufacturing,
he was promoted to vice president -- finance of IV Systems.
WILLIAM L. FEATHER, 49, will be the general counsel of Allegiance and will
head its law function. At Baxter, he has been associate general counsel for the
U.S. Healthcare business since January 1996. Mr. Feather joined Baxter in 1986
as corporate counsel. He was promoted to senior counsel in 1990 and assistant
general counsel in January 1994.
LEONARD G. KUHR, 38, will be the treasurer of Allegiance. He will also
supervise its tax function. At Baxter, he has been vice president, capital
markets, in a subsidiary's Treasury group since 1995. From 1992 to 1995, Mr.
Kuhr was vice president, finance, for Baxter's Surgical business. Mr. Kuhr
joined Baxter in 1979 and served in a variety of management positions in the
Corporate Tax department, in both domestic and international functions. He was
named vice president and controller of the Specialty Business group in the
company's U.S. Distribution business in 1992.
1995 COMPENSATION OF EXECUTIVE OFFICERS
The following table shows the 1995 compensation for services rendered by the
chairman of the board and chief executive officer of Allegiance and the
individuals who are expected to be the next four most highly compensated
executive officers of Allegiance (collectively, the "named executive officers")
based on their 1995 Baxter compensation. The compensation shown in this table
was paid by Baxter (or its subsidiaries) for all of their services to Baxter and
its subsidiaries. References to "restricted stock" and "stock options" mean
restricted shares of Baxter Stock and options to purchase Baxter Stock. Amounts
shown are for each individual in their last position with Baxter, and do not
necessarily reflect the compensation which these five individuals will earn in
their new capacities as executive officers of Allegiance.
46
<PAGE>
SUMMARY COMPENSATION TABLE
<TABLE>
<CAPTION>
LONG TERM COMPENSATION
---------------------------------------
AWARDS
ANNUAL COMPENSATION ------------------------
---------------------------------------------- RESTRICTED SECURITIES PAYOUTS
OTHER ANNUAL STOCK UNDERLYING ------------- ALL OTHER
SALARY BONUS COMPENSATION AWARD(S) OPTIONS LTIP PAYOUTS COMPENSATION
NAME AND PRINCIPAL POSITION YEAR ($)(1) ($)(1) ($)(2) ($)(3) (#)(4) ($)(5) ($)(6)
- - - ---------------------------- --------- --------- --------- ------------- ----------- ----------- ------------- -------------
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Lester B. Knight 1995 $ 367,000 $ 350,000 $ 12,134 $ 23,139 44,800 -0- $ 23,241
Chairman of the Board &
Chief Executive Officer
Joseph F. Damico 1995 $ 285,000 $ 170,000 $ 2,432 -0- 22,900 -0- $ 13,866
Chief Operating Officer
Kathy B. White 1995 $ 182,692 $ 142,500 $ 929 $ 319,600 41,000 -0- $ 0
Corporate Vice President
Robert J. Zollars 1995 $ 230,000 $ 43,200 -- -0- 10,000 -0- $ 9,346
Corporate Vice President
Gail Gaumer 1995 $ 200,000 $ 43,200 -- -0- 8,500 -0- $ 8,446
Corporate Vice President
</TABLE>
- - - ------------------------------
(1) Amounts shown include cash compensation earned by the named executive
officers during the year indicated, including amounts deferred at the
election of those officers. Bonuses are paid in the year following the year
during which they are earned.
(2) As permitted by the Commission's rules regarding disclosure of executive
compensation, this column excludes perquisites and other personal benefits
for the named executive officer if their total cost in 1995 did not exceed
the lesser of $50,000 or 10% of the total of annual salary and bonus
reported for the named executive officer for such year.
(3) Amounts shown represent the market value at the date of grant, without
giving effect to the diminution in value attributable to the restrictions on
such stock. The amounts shown in this column include grants to the specified
named executive officers under Baxter's 1989 Long-Term Incentive Plan. The
restricted shares granted to Mr. Knight and Ms. White under that Plan could
be earned based on 1996 performance and, if so, they would ordinarily vest
on December 31, 1997. As of December 31, 1995, the number and value of the
aggregate Baxter restricted stock holdings of the named executive officers
are as follows: Mr. Knight -- 22,000 shares ($921,250); Mr. Damico -- 11,508
shares ($481,898); Ms. White -- 9,400 shares ($393,625); Mr. Zollars --
6,931 shares ($290,236); Ms. Gaumer -- 4,408 shares ($184,585). Dividends
are payable on all outstanding shares of Baxter restricted stock held by all
executives at the same rate and time and in the same form in which dividends
are payable on all outstanding shares of Baxter Stock, as required by
Baxter's 1987 Incentive Compensation Program.
(4) No Stock Appreciation Rights ("SARs") were granted by Baxter in 1995, and
there are no outstanding SARs held by any employee or director of
Allegiance. The number shown represents the number of shares of Baxter Stock
for which Baxter options were granted to the named executive officer.
(5) The Commission's rules regarding disclosure of executive compensation allow
awards of restricted stock that are subject to performance-based conditions
on vesting, in addition to lapse of time and/or continued service with
Baxter, to be reported as awards under a long-term incentive plan ("LTIP"),
instead of as restricted stock awards. The rules define an LTIP as a plan
providing compensation intended to serve as incentive for performance to
occur over a period longer than one fiscal year. Restricted stock awards
which are earned based on annual financial performance cannot be reported as
LTIP awards, even if, as in the case of the restricted stock awards
identified in the "Restricted Stock Awards" column, the stock may not be
earned and vested until the end of at least two years.
(6) Amounts shown represent Baxter matching contributions in Baxter's Incentive
Investment Plan, a qualified section 401(k) profit sharing plan, additional
matching contributions in Baxter's deferred compensation plan and the dollar
value of Baxter split-dollar life insurance benefits. Those three amounts
for 1995, expressed in the same order as identified above, for the named
executive officers are as follows: Mr. Knight -- $4,500, $18,510, and $231;
Mr. Damico -- $4,500, $9,300, and $66; Ms. White -- (none); Mr. Zollars --
$4,500, $4,762, and $84; Ms. Gaumer -- $4,500, $3,852, and $94.
Of the named executive officers, Mr. Zollars and Ms. Gaumer are eligible to
receive a special incentive payment. Per the terms of the special incentive, Mr.
Zollars and Ms. Gaumer are eligible to receive a payment equal to one times
annual base salary. The payment will be made three months after the Distribution
Date as long as they have not voluntarily resigned, been terminated for cause,
or have accepted a position outside of the Allegiance organization.
47
<PAGE>
STOCK OPTION GRANTS
The following table contains information relating to the Baxter stock option
grants made in 1995 under Baxter's 1994 Incentive Compensation Program to the
named executive officers.
OPTION GRANTS TABLE
OPTION GRANTS IN LAST FISCAL YEAR (1)(6)(7)
<TABLE>
<CAPTION>
INDIVIDUAL GRANTS
---------------------------------------
PERCENT OF
NUMBER OF TOTAL OPTIONS POTENTIAL REALIZABLE VALUE AT ASSUMED
SECURITIES GRANTED TO ANNUAL RATES OF STOCK
UNDERLYING EMPLOYEES IN EXERCISE OR PRICE APPRECIATION FOR OPTION TERM
OPTIONS FISCAL BASE PRICE EXPIRATION ------------------------------------------
NAME GRANTED (#) YEAR (2) ($/SH)(3) DATE 0% ($) 5% ($)(4) 10% ($)(4)
- - - ----------------------------- ----------- ------------- ----------- ----------- --------- -------------- ---------------
<S> <C> <C> <C> <C> <C> <C> <C>
Mr. Knight................... 44,800 0.9% $ 37.25 7/29/05 $ -0- $ 1,049,498 $ 2,659,637
Mr. Damico................... 22,900 0.4% $ 37.25 7/29/05 $ -0- $ 536,462 $ 1,359,502
21,000 0.4% $ 37.25 7/29/05 $ -0- $ 491,952 $ 1,246,705
Ms. White (5)................ 20,000 0.4% $ 34.00 4/24/05 $ -0- $ 427,648 $ 1,083,744
Mr. Zollars.................. 10,000 0.2% $ 37.25 7/29/05 $ -0- $ 234,263 $ 593,669
Ms. Gaumer................... 8,500 0.2% $ 37.25 7/29/05 $ -0- $ 199,124 $ 504,619
All Stockholders............. N/A N/A N/A N/A $ -0- $6,369,603,169 $16,141,840,341
All Optionees................ 5,200,000 100.0 % $ 37.25 7/29/05 $ -0- $ 121,816,760 $ 308,707,880
Optionee Gain as % of All
Stockholders Gain........... N/A N/A N/A N/A N/A 1.9% 1.9%
</TABLE>
- - - ------------------------------
(1) No SARs were granted by Baxter in 1995.
(2) In 1995, Baxter granted options on approximately 5.2 million shares of
Baxter Stock to approximately 6,400 employees.
(3) The exercise price shown is the closing price of Baxter Stock on the date of
grant, which was July 31, 1995 for all options except the option granted to
Ms. White for 20,000 shares. The exercise price shown for the 20,000 shares
granted to Ms. White is the closing price of Baxter Stock on the date of
grant which was April 24, 1995.
(4) The amounts shown in these two columns represent the potential realizable
values using the options granted and the exercise price. The assumed rates
of stock price appreciation are set by the Commission's executive
compensation disclosure rules and are not intended to forecast the future
appreciation of Baxter Stock.
(5) The 20,000 share grant to Ms. White was an element of the compensation
package provided to her upon joining Baxter in her current role. The 21,000
share grant she received was part of Baxter's normal option grant process.
(6) All options shown in this table except for the 20,000 share grant to Ms.
White, become exercisable five years from the date of grant, subject to
accelerated vesting as follows. One hundred percent of the option will
become exercisable on the first business day after the ninetieth consecutive
calendar day during which the average fair market value of Baxter Stock
equals or exceeds $50 per share. Ms. White's 20,000 share grant becomes
exercisable five years from the date of grant, subject to accelerated
vesting as follows. Fifty percent of the option became exercisable on
December 27, 1995; fifty percent of the option will become exercisable on
the first business day after the ninetieth consecutive calendar day during
which the average fair market value of Baxter Stock equals or exceeds $50
per share. The exercise price may be paid in cash or shares of Baxter Stock.
Baxter's 1994 Program provides that if specified corporate control changes
occur, all outstanding options will become exercisable immediately.
(7) It is expected that the Compensation Committee of the Board of Directors of
Baxter will adopt an equitable adjustment formula applicable to all options
to purchase Baxter Stock which are outstanding as of the Distribution Date.
The formula, which is prescribed by tax and accounting rules, is intended to
preserve the value of the options after the Distribution Date.
48
<PAGE>
STOCK OPTION EXERCISES
The following table contains information relating to the exercise of Baxter
stock options by the named executive officers in 1995 as well as the number and
value of their unexercised Baxter options as of December 31, 1995.
AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR
AND FISCAL YEAR-END OPTION VALUES (1)
<TABLE>
<CAPTION>
NUMBER OF SECURITIES
UNDERLYING UNEXERCISED VALUE OF UNEXERCISED
OPTIONS AT IN-THE-MONEY OPTIONS
SHARES FISCAL YEAR-END (#)(2) AT FISCAL YEAR END ($)(3)
ACQUIRED ON VALUE -------------------------- --------------------------
NAME EXERCISE (#) REALIZED ($) EXERCISABLE UNEXERCISABLE EXERCISABLE UNEXERCISABLE
- - - ------------------------------- ----------- ----------- ----------- ------------- ----------- -------------
<S> <C> <C> <C> <C> <C> <C>
Mr. Knight..................... -0- N/A 46,757 53,800 $ 619,426 $ 350,075
Mr. Damico..................... -0- N/A 32,140 27,733 $ 486,278 $ 182,652
Ms. White...................... -0- N/A 10,000 31,000 $ 78,750 $ 175,875
Mr. Zollars.................... -0- N/A 27,784 12,534 $ 429,462 $ 82,722
Ms. Gaumer..................... -0- N/A 20,320 9,867 $ 310,449 $ 61,014
</TABLE>
- - - ------------------------
(1) No Baxter SARs were exercised by any Allegiance employee in 1995, and there
are no outstanding Baxter SARs held by any employee or director of
Allegiance.
(2) The sum of the numbers under the Exercisable and Unexercisable columns of
this heading represents each named executive officer's total outstanding
Baxter options.
(3) The dollar amounts shown under the Exercisable and Unexercisable columns of
this heading represent the number of exercisable and unexercisable Baxter
options, respectively, which were "In-the-Money" on December 31, 1995,
multiplied by the difference between the closing price of Baxter Stock on
December 31, 1995, which was $41.875 per share, and the exercise price of
the Baxter options. For purposes of these calculations, In-the-Money options
are those with an exercise price below $41.875 per share.
BAXTER PENSION PLAN
The Baxter International Inc. and Subsidiaries Pension Plan's (the "Baxter
Pension Plan") normal retirement benefit equals 1.75% of the average of an
employee's five highest consecutive calendar years of earnings out of his or her
last ten calendar years of earnings ("Final Average Pay"), multiplied by the
employee's years of benefit service, as determined by the Baxter Pension Plan.
In general, the earnings covered by the Baxter Pension Plan include salary,
annual cash bonuses and other regular pay. The figures shown include benefits
payable under the Baxter Pension Plan and Baxter's related defined benefit
excess pension plan. The estimates assume that benefit payments begin at age 65
under a single life annuity form. The figures are net of the Social Security
offset specified by the Baxter Pension Plan's benefit formula and therefore do
not include Social Security benefits payable from the federal government. The
primary Social Security amount used in the calculations is that payable for an
individual attaining age 65 in 1995.
49
<PAGE>
PENSION PLAN TABLE
Estimated Annual Retirement Benefits
Years of Pension Plan Participation (1)
<TABLE>
<CAPTION>
FINAL
AVERAGE
PAY (1) 15 20 25 30 35
- - - ------------ ----------- ----------- ----------- ----------- -----------
<S> <C> <C> <C> <C> <C>
$ 100,000 $ 22,300 $ 29,800 $ 37,200 $ 44,700 $ 52,300
200,000 48,600 64,800 81,000 97,200 113,500
300,000 74,800 99,800 124,700 149,700 174,800
400,000 101,100 134,800 168,500 202,200 236,000
500,000 127,300 169,800 212,200 254,700 297,300
600,000 153,600 204,800 256,000 307,200 358,500
700,000 179,800 239,800 299,700 359,700 419,800
</TABLE>
- - - ------------------------
(1) As of January 1, 1996, the named executive officers' years of Baxter Pension
Plan participation and Final Average Pay for purposes of calculating annual
retirement benefits payable under the Baxter Pension Plan are as follows:
Mr. Knight -- 13 years and $538,702; Mr. Damico -- 16 years and $370,048;
Ms. White -- 0 years and $0; Mr. Zollars -- 16 years and $254,798; Ms.
Gaumer -- 16 years and $216,743.
Although age 65 is the normal retirement age under the Baxter Pension Plan,
the Baxter Pension Plan has early retirement provisions based on a "point"
system. Under the point system, each participant is awarded one point for each
year of benefit service as determined by the Baxter Pension Plan and one point
for each year of age. Participants who terminate employment after accumulating
65 points, and who wait to begin receiving their Baxter Pension Plan benefits
until they have 85 points, receive the same Baxter Pension Plan benefits they
would otherwise receive at age 65, regardless of their actual age when they
begin receiving their Baxter Pension Plan benefits.
BAXTER STOCK HELD BY ALLEGIANCE EMPLOYEES
Baxter restricted stock held by Allegiance employees will continue to be
earned, based upon performance through December 31, 1996, and vested, in
accordance with the terms and conditions of those grants, as if the employee's
service with Allegiance were service with Baxter. Allegiance employees holding
Baxter Stock Options will, as of the Distribution Date, be considered terminated
and, as such, vesting and exercise will be in accordance with the terms and
conditions of the outstanding grants.
COMPENSATION OF EXECUTIVE OFFICERS
The compensation of Allegiance's executive officers for periods beginning on
and after the Distribution Date will be determined by the Allegiance Board of
Directors or its Compensation Committee.
COMPENSATION PHILOSOPHY FOR EXECUTIVE OFFICERS
Allegiance's philosophy will be to provide compensation opportunities
supporting Allegiance's values. Forms and levels of total compensation will be
structured to be competitive when compared to other companies of similar focus
and size. These companies are reported in surveys whose participants include
many companies in the Fortune 500 as well as other companies with which
Allegiance and its subsidiaries compete for executive talent ("comparable
companies"). This philosophy is intended to assist Allegiance in attracting,
retaining and motivating executives with superior leadership and management
abilities. Consistent with this philosophy, a total compensation structure will
be determined for each officer, including Mr. Knight, consisting primarily of
salary, cash bonus, stock options and benefits. The proportions of these
elements of compensation will vary among the officers depending upon their
levels of responsibility. The senior executive officers will receive a larger
portion of their total compensation through performance-based incentive plans,
which place a greater percentage of their compensation at risk while more
closely aligning their interests with the interests of Allegiance's
stockholders.
50
<PAGE>
Allegiance's philosophy with respect to the cap on the tax-deductibility of
executive compensation will be to maximize the benefit of tax laws for
Allegiance's stockholders by seeking performance-based exemptions where
consistent with Allegiance's compensation policies and practices. Allegiance
will adopt performance goals for the officer cash bonus plan which are expected
to satisfy the deductibility requirements with respect to any payments under
those plans.
COMPENSATION ELEMENTS
Salaries will be established each year at a level primarily intended to be
competitive at the 50th percentile with salaries of executive officers in
comparable companies. In addition, officer salaries will be based on the
officer's individual performance. Bonuses are intended to provide executive
officers with an opportunity to receive additional cash compensation but only if
they earn it through Allegiance's achievement of strong performance results as
measured by key financial indicators. Each year, a bonus target will be
established for each executive officer at the 50th percentile of the market data
of comparable companies. After year-end results are calculated, each officer's
bonus will be determined based on Allegiance's performance against the key
financial indicators established for the year. Achievement of the performance
objective will determine an officer's opportunity to earn bonus compensation
either significantly above or below the 50th percentile of opportunity within
comparable companies.
Stock options will be granted under Allegiance's 1996 Incentive Compensation
Program ("1996 Program"). They represent a vehicle for more closely aligning
management's and stockholders' interests, specifically motivating executives to
remain focused on the market value of Allegiance Stock. Options will be granted
with an exercise price equal to the fair-market value of Allegiance Stock on the
day of the grant.
The number of stock options granted to executive officers is expected to be
formula-driven. The formula is designed to provide an opportunity to earn
stock-based compensation at a third-quartile level compared to executives in
comparable companies.
1996 INCENTIVE COMPENSATION PROGRAM
Allegiance expects to adopt the Allegiance Corporation 1996 Incentive
Compensation Program ("Program"). The 1996 Program will be approved by Baxter as
sole stockholder of Allegiance prior to the Distribution.
GENERAL
The 1996 Program is designed to promote success and enhance the value of
Allegiance by linking participants' interests more closely to those of
Allegiance stockholders and by providing participants with an incentive for
excellence.
The Program will be administered by the Compensation Committee of Allegiance
("Committee"). The Committee must consist of two or more directors who qualify
as non-employee directors under Rule 16b-3 of the Securities Exchange Act of
1934 and as outside directors under Section 162(m) of the Code. Incentives may
consist of the following: (a) stock options; (b) restricted stock; (c) stock
awards; (d) performance shares; and (e) other incentives, including cash.
Incentives may be granted to any employee of Allegiance (including directors of
Allegiance who are also employees of Allegiance) selected from time to time by
the Committee.
The number of shares of Allegiance Stock authorized for issuance under the
Program will not exceed 17.8% of the outstanding shares of Allegiance Stock as
of the Distribution Date.
STOCK OPTIONS
Under the Program, the Committee may grant non-qualified and incentive stock
options to eligible employees to purchase shares of Allegiance Stock from
Allegiance. The Program gives the Committee discretion, with respect to any such
stock option, to determine the number and purchase price of the shares subject
to the option, the term of each option and the time or times during its term
when the option becomes exercisable, subject to the following limitations. No
stock option may be
51
<PAGE>
granted with a purchase price less than the fair market value of the shares
subject to the option on the date of grant and the term may not exceed 10 years
and one day from the date of grant, except with respect to options granted
during the first ten days after the Distribution Date which may be granted at a
per share exercise price determined based upon the market price of Allegiance
Stock during a period of ten trading days following the Distribution Date. No
person may receive, in any calendar year, stock options which, in the aggregate,
represent more than 1,000,000 shares of Allegiance Stock. The initial option
grant to the named executive officers will be as follows: Mr. Knight,
shares; Mr. Damico, shares; Ms. White, shares; Mr. Zollars,
shares; and Ms. Gaumer, shares.
STOCK APPRECIATION RIGHTS
SARs may be granted by the Committee pursuant to the Program in such number
and on such terms as the Committee may decide, provided that the term of an SAR
may not exceed 10 years and one day from the date of grant. SARs may be granted
together with or independently of any stock option. SARs may be paid in
Allegiance Stock or cash, as determined by the Committee. No person may receive,
in any calendar year, SARs which, in the aggregate, represent more than
1,000,000 shares of Allegiance Stock.
RESTRICTED STOCK
Restricted stock consists of the sale or transfer by Allegiance to an
eligible employee of one or more shares of Allegiance Stock which are subject to
restrictions on their sale or other transfer by the employee. The price, if any,
at which restricted stock will be sold will be determined by the Committee, and
it may vary from time to time and among employees and may require no payment or
be less than the fair market value of the shares at the date of sale. All shares
of restricted stock may be subject to the attainment of performance goals under
Section 162(m) of the Code and other restrictions as the Committee may
determine. Subject to these restrictions and the other requirements of the
Program, a participant receiving restricted stock will have the rights of a
stockholder (including voting and dividend rights) as to those shares only to
the extent the Committee designates such rights at the time of the grant. No
person may receive in any calendar year restricted stock which, in the
aggregate, represents more than 100,000 shares of Allegiance Stock.
STOCK AWARDS
Stock awards consist of the transfer by Allegiance to an eligible employee
of shares of Allegiance Stock, without payment, as additional compensation for
his or her services to Allegiance or a subsidiary of Allegiance. Stock awards
are subject to the following limitations: No person subject to Section 16(a) of
the Exchange Act (executive officers of Allegiance) may receive a Stock Award,
and no person eligible to receive a Stock Award may receive a Stock Award
representing more than 2,500 shares of Allegiance Stock in any calendar year.
PERFORMANCE SHARES
Performance shares consist of the grant by Allegiance to an eligible
employee of a contingent right to receive payment of shares of Allegiance Stock.
The performance shares will be paid in shares of Allegiance Stock to the extent
performance goals set forth in the grant are achieved. All grants of performance
shares will be subject to the attainment of performance goals under Section
162(m) of the Code. The number of shares granted and the performance goals will
be determined by the Committee.
OTHER INCENTIVES
Other incentives may consist of a payment in cash or stock by Allegiance to
an eligible employee as additional compensation for his or her services to
Allegiance or a subsidiary of Allegiance. The form, amount and the terms and
conditions of other incentives will be determined by the Committee.
SECTION 162(M) PERFORMANCE GOALS
Under the Program, grants of restricted stock, performance shares, and other
incentives (as defined in the Program) may be subject to the attainment of
performance goals under Section 162(m)
52
<PAGE>
of the Code. The regulations under Section 162(m) require the performance goals
related to grants under the Program to be approved separately by Allegiance's
stockholders. Performance goals for performance based grants may include, but
are not limited to stock price, sales, return on equity, cash flow, market
share, earnings per share and/or costs.
NON-TRANSFERABILITY OF INCENTIVES
Unless otherwise determined by the Committee, no stock option, SAR,
restricted stock, performance share or other incentive granted under the Program
will be transferable by its holder, except in the event of the holder's death,
by will or the laws of descent and distribution. During an employee's lifetime,
an incentive may be exercised only by the employee or the employee's guardian or
legal representative. The Committee may allow the limited transfer of an
incentive to the immediate family of an employee to facilitate estate planning.
AMENDMENT OF THE PROGRAM
The Board of Directors may amend or discontinue the Program at any time.
However, no amendment or discontinuance may (a) alter or impair, without the
consent of the recipient, an incentive previously granted, (b) increase the
maximum number of shares of Allegiance Stock which may be issued to all
employees under the Program, or (c) result in a change which would disqualify
the Program from the exemption provided by Rule 16b-3 of the Securities Exchange
Act of 1934. In addition, the Board of Directors may not amend the Program
without approval of Allegiance's stockholders to the extent such approval is
required by law, agreement or any exchange on which Allegiance Stock is traded.
ACCELERATION OF INCENTIVES
In the event of a change in control of Allegiance (as specified in the
Program), the restrictions on all outstanding shares of restricted stock will
lapse immediately, all outstanding stock options and SARs will become
exercisable immediately and all performance goals will be deemed to be met and
payment made immediately.
CHANGE OF CONTROL PLAN
Allegiance expects to adopt the Allegiance Change of Control Plan ("Change
of Control Plan"). Pursuant to agreements entered into under this Plan, several
executive officers are entitled to separation pay and benefits following a
change of control in Allegiance and the employees subsequent termination of
employment unless such termination is voluntary and unprovoked or results from
death, disability, retirement or cause. The eligible termination must occur
within 24 months of the change of control or the agreement is void. The Plan
will continue for three years from the distribution date and automatically renew
every three years from that date unless the participants receive written notice
of termination of the plan at least ninety days prior to the renewal date.
Under this Plan, the separation pay will equal three years' anualized base
salary and target cash bonus plus the value of all deferred or unvested awards
under all incentive compensation plans per the terms of the 1996 Incentive
Compensation Program.
In the event that any payments would be subject to an excise tax under the
Code, the Company will pay an additional gross-up amount for any excise tax and
federal, state and local income taxes, such that the net amount of the payments
would be equal to the net payments after income taxes had the excise tax and
resulting gross-up not been imposed.
ALLEGIANCE RETIREMENT PLAN
Allegiance will adopt a qualified defined contribution retirement plan (the
"Allegiance Retirement Plan") for its United States employees effective on the
Distribution date. This plan will include a section 401(k) deferred compensation
account ("401(k) account"), a company matching contribution account, a
performance account, and a transition account for each eligible employee as
described below.
53
<PAGE>
The defined contribution accounts for transferring employees under the
Baxter International Inc. and Subsidiaries Incentive Investment Plan (the
"Baxter Incentive Investment Plan"), Baxter's qualified section 401(k) profit
sharing plan, will be transferred to the Allegiance Retirement Plan. The
Allegiance Retirement Plan will establish a fund to hold the Baxter stock
currently held on behalf of Allegiance employees in the Baxter Incentive
Investment Plan. The Allegiance Retirement Plan will allow participants to
redirect the balances of their Allegiance Retirement Plan accounts that are
invested in the Baxter stock fund but will not allow participants to direct that
their plan accounts make new investments in Baxter stock within the Allegiance
Retirement Plan.
401(k) ACCOUNT AND COMPANY MATCHING CONTRIBUTION ACCOUNT
Employees of Allegiance will be eligible to contribute to the Allegiance
401(k) account on or after the Distribution Date. Participants may elect to
contribute, on a before-tax basis, up to twelve percent of their annual base
compensation into their 401(k) accounts. Allegiance will match the first three
percent of the participant's annual base compensation contributed to the plan on
a dollar for dollar basis.
PERFORMANCE ACCOUNT
Subject to the terms of the Allegiance Retirement Plan, employees of
Allegiance will be eligible to receive contributions to their performance
accounts under such plan. Allegiance will make annual contributions to each
performance account equal to three percent of a participant's annual base
compensation.
In addition, Allegiance may make additional performance account
contributions on a discretionary basis as certain performance measures are
achieved. The additional contributions will be allocated to each eligible
participant's account in proportion to each participant's annual base
compensation. These additional discretionary contributions may be made more
frequently or less frequently than the annual three percent contribution.
TRANSITION ACCOUNT
Allegiance recognizes that certain longer service employees need additional
benefits to assist in transitioning from Baxter's United States Pension Plan to
Allegiance's Retirement Plan. Contributions to a transition account within
Allegiance's Retirement Plan will be provided to two groups of Allegiance
employees.
Employees with at least 55 "points" and 10 years of "benefit service" (as
determined under the terms of the Baxter Pension Plan explained on page 49) as
of the Distribution Date will have transition profit sharing contributions made
annually over an eight year period, and each of these contributions will be
equal to not less than 3% and not more than 8% of the participant's annual base
compensation, depending on the participant's points under the Baxter Pension
Plan as of the Distribution Date. The named executive officers eligible to
receive contributions to the transition account are as follows: Mr. Knight --
0%; Mr. Damico -- 3%; Ms. White -- 0%; Mr. Zollars -- 3%; and Ms. Gaumer -- 3%.
Allegiance employees who have at least 15 years of "benefit service" but
less than 55 "points" (as determined under the terms of the Baxter Pension Plan
explained on page 49) as of the Distribution Date will receive transition profit
sharing contributions made annually over an eight year period, and each of these
contributions will be equal to 2% of the participant's annual base compensation.
ALLEGIANCE EXCESS PLAN
Federal income tax laws limit the amount Allegiance may contribute to the
accounts of certain highly compensated participants under the Allegiance
Retirement Plan. Federal income tax laws also limit the amount participants may
contribute to their accounts under the Allegiance Retirement Plan. Allegiance
will adopt an unfunded non-qualified excess plan (the "Allegiance Excess Plan")
that will credit participants affected by the limits with the amount of
contributions that the participants would have contributed or that Allegiance
would have contributed on their behalf to the Allegiance Retirement Plan but for
such limits.
54
<PAGE>
BAXTER PENSION PLAN
Eligible Allegiance employees (transferring employees) will continue to
participate for purposes of benefit accruals in the Baxter Pension Plan through
the Distribution Date. All benefit accruals for Allegiance employees in the
Baxter Pension Plan cease as of the Distribution Date and all Allegiance
employees will be fully vested in their accrued benefits under the Baxter
Pension Plan as of such date. The terms of the Baxter Pension Plan will be
amended with respect to Allegiance employees to impute certain compensation paid
by Allegiance during 1996 in order to provide for a full year's earnings for
1996 to be included in determining the Final Average Pay of transferring
employees. Allegiance employees with vested accrued benefits in the Baxter
Pension Plan will have those benefits maintained by the Baxter Pension Plan
until they are eligible or required to receive them.
EMPLOYEE STOCK PURCHASE PLAN
Allegiance will adopt an employee stock purchase plan for its United States
employees, as described in Section 423 of the Code. All active employees of
Allegiance and its United States subsidiaries will be eligible to participate in
the Plan. The employee stock purchase plan makes available shares of Allegiance
Stock for purchase by eligible employees through payroll deductions at a maximum
rate to be determined by the Committee. The purchase price per share will be
equal to 85% of the fair market value of Allegiance Stock on the effective date
of subscription. 2,000,000 shares will be reserved for issuance under this plan.
COMPENSATION COMMITTEE INTERLOCKS DISCLOSURE AND INSIDER PARTICIPATION
There are no compensation committee interlocks.
55
<PAGE>
OWNERSHIP OF ALLEGIANCE COMMON STOCK BY CERTAIN BENEFICIAL OWNERS
Until the Distribution Date, Baxter will own all of the outstanding shares
of Allegiance Stock. No person or group is anticipated to be the beneficial
owner of more than five per cent of Allegiance Stock outstanding as of the
Distribution Date based upon the number of outstanding shares of Baxter Stock on
June 1, 1996. The following table sets forth information, as of June 1, 1996,
with respect to the expected beneficial ownership of Allegiance Stock by each
director and named executive officer of Allegiance and by all directors and
executive officers of Allegiance as a group. The information relating to
directors and named executive officers is furnished by the respective directors
and officers. No director or named executive officer of Allegiance beneficially
owned more than one per cent of the outstanding Baxter Stock. All Allegiance
directors and executive officers as a group own less than one per cent of the
outstanding Baxter Stock. It is not expected that any director or executive
officer of Allegiance will own more than one per cent of the outstanding
Allegiance Stock.
<TABLE>
<CAPTION>
BAXTER STOCK
BENEFICIALLY RIGHT TO
NAME OF BENEFICIAL OWNER OR GROUP OWNED ACQUIRE
- - - ------------------------------------------------------------------------------ ---------------- ---------------
<S> <C> <C>
Lester B. Knight.............................................................. 281,742(1) 46,757
Joseph F. Damico.............................................................. 195,416(1) 32,140
Silas S. Cathcart............................................................. 7,334(1) --
David W. Grainger............................................................. 32,500(1) --
Arthur F. Golden.............................................................. -- --
Michael D. O'Halleran......................................................... -- --
Kenneth D. Bloem.............................................................. -- --
Connie Curran, Ed.D........................................................... -- --
Peter B. McKee................................................................ -- --
Kathy Brittain White.......................................................... 19,400 (1) 10,000
Gail Gaumer................................................................... 86,832 (1) 20,320
Robert J. Zollars............................................................. 90,711 (1) 28,451
All Directors and Executive Officers.......................................... 941,260 (1) 22,203
</TABLE>
- - - ------------------------
(1) Amounts to less than one per cent; total includes all shares listed under
right to acquire.
CERTAIN TRANSACTIONS
Allegiance has in the past engaged in numerous transactions with Baxter.
Such transactions have included, among other things, the extension of
inter-company loans, the provision of various other types of financial support
by or to Baxter, and the sharing of services and administration and the costs
thereof. See "ARRANGEMENTS BETWEEN BAXTER AND ALLEGIANCE -- REORGANIZATION
AGREEMENT."
HART-SCOTT-RODINO FILING REQUIREMENT
Any person receiving shares of Allegiance Stock pursuant to the Distribution
and meeting the criteria set forth below may be required to file a Pre-merger
Notification and Report pursuant to the Hart-Scott-Rodino Antitrust Improvements
Act of 1976, as amended (the "HSR Act"). In general, if (i) a person receiving
shares of Allegiance Stock pursuant to the Distribution would own, upon
consummation of the Distribution, Allegiance Stock that exceeds $15 million in
value, (ii) certain jurisdictional requirements are met and (iii) no exemption
applies, then the HSR Act would require that such person file a Pre-merger
Notification and Report Form and observe the applicable waiting periods under
the HSR Act prior to acquiring Allegiance Stock pursuant to the Distribution.
If such waiting periods have not expired or been terminated at the
Distribution Date with respect to such recipient, Baxter may be required to
deliver such recipient's shares of Allegiance Stock into an escrow facility
pending the expiration or termination of such waiting period. Holders of Baxter
Stock are urged to consult their legal counsel to determine whether the
requirements of the HSR Act will apply to the receipt by them of shares of
Allegiance Stock in the Distribution.
56
<PAGE>
DESCRIPTION OF ALLEGIANCE CAPITAL STOCK
AUTHORIZED CAPITAL STOCK
The authorized capital stock of Allegiance will consist of 200,000,000
shares of Allegiance Stock and 20,000,000 shares of preferred stock, par value
$.01 per share (the "Allegiance Preferred Stock"). No shares of Allegiance
Preferred Stock will be issued in connection with the Distribution. Based on the
number of shares of Baxter Stock outstanding as of June 1, 1996, up to
approximately [45] million shares of Allegiance Stock will be issued to
stockholders of Baxter in the Distribution. All of the shares of Allegiance
Stock issued in the Distribution will be validly issued, fully paid and
non-assessable. The following summary description of the capital stock of
Allegiance is qualified in its entirety by reference to the proposed forms of
the Certificate of Incorporation and By-laws of Allegiance, forms of which are
attached hereto as Annexes A and B, respectively.
ALLEGIANCE STOCK
Holders of Allegiance Stock are entitled to one vote for each share held on
all matters submitted to a vote of stockholders and, except with respect to the
election of directors which requires a plurality of the votes cast, and except
as described under "CERTAIN ANTI-TAKEOVER EFFECTS OF CERTAIN PROVISIONS OF THE
CERTIFICATE OF INCORPORATION, BY-LAWS AND STATE LAW -- CERTIFICATE OF
INCORPORATION, BY-LAWS AND STATE LAW -- AMENDMENT OF CERTAIN PROVISIONS OF THE
CERTIFICATE OF INCORPORATION AND BY-LAWS", a majority of the votes cast is
required for all action to be taken by stockholders. Holders of Allegiance Stock
do not have cumulative voting rights in the election of directors and have no
preemptive, subscription, redemption, sinking fund or conversion rights. Subject
to preferences that may be applicable to holders of any outstanding shares of
any Allegiance Preferred Stock, holders of Allegiance Stock are entitled to such
dividends as may be declared by the Allegiance Board out of funds legally
available therefor. Upon any liquidation, dissolution or winding-up of
Allegiance, the assets legally available for distribution to stockholders are
distributable ratably among the holders of Allegiance Stock at that time
outstanding, subject to prior distribution rights of creditors of Allegiance and
to the preferential rights of any outstanding shares of Allegiance Preferred
Stock.
ALLEGIANCE PREFERRED STOCK
Under the Certificate of Incorporation the Allegiance Board is authorized to
provide for the issuance of Allegiance Preferred Stock, in one or more series,
and to determine, with respect to any such series, the designations, voting
powers, preferences and rights of such series, and such qualifications,
limitations or restrictions thereof, as the Allegiance Board shall determine.
See "CERTAIN ANTI-TAKEOVER EFFECTS OF CERTAIN PROVISIONS OF THE CERTIFICATE OF
INCORPORATION, BY-LAWS AND STATE LAW -- CERTIFICATE OF INCORPORATION AND
BY-LAWS." In connection with the Rights Agreement to be adopted by Allegiance,
the Allegiance Board will designate a series of Preferred Stock (the "Preferred
Shares"). See "-- Allegiance Rights Agreement."
ALLEGIANCE RIGHTS AGREEMENT
Prior to the Distribution, it is expected that the Allegiance Board will
adopt a Rights Agreement (the "Rights Agreement") between Allegiance and
, N.A. (the "Rights Agent") and cause to be
issued one preferred share purchase right (a "Right") with each share of
Allegiance Stock issued to holders of Baxter Stock at the close of business on
the Record Date.
Each Right will entitle the registered holder to purchase from Allegiance
one one-hundredth of a share of the Series A Junior Participating Preferred
Stock (a "Preferred Share") at a price of $ per one one-hundredth of a
Preferred Share (the "Purchase Price") subject to adjustment. The terms of the
Rights will be set forth in the Rights Agreement. The description set forth
below is intended as a summary only and is qualified in its entirety by
reference to the Rights Agreement, which is attached hereto as Annex C.
57
<PAGE>
Until the earlier to occur of (i) 10 days following a public announcement
that a person or group of affiliated or associated persons has acquired
beneficial ownership of 15% or more of the outstanding shares of Allegiance
Stock (an "Acquiring Person") or (ii) 10 business days (or such later date as
may be determined by action of the Allegiance Board prior to such time as any
person or group of affiliated persons becomes an Acquiring Person) following the
commencement of a tender offer or exchange offer the consummation of which would
result in the beneficial ownership by a person or group of 15% or more of the
outstanding shares of Allegiance Stock (the earlier of (i) and (ii) being the
"Rights Distribution Date"), the Rights will be evidenced, with respect to any
shares of Allegiance Stock outstanding as of the Record Date, by such Allegiance
Stock certificates with a copy of a summary of rights attached thereto.
The Rights Agreement provides that, until the Rights Distribution Date (or
earlier redemption or expiration of the Rights), the Rights will be transferred
with and only with the shares of Allegiance Stock. Until the Rights Distribution
Date (or earlier redemption or expiration of the Rights), new Allegiance Stock
certificates issued after the Record Date upon transfer or new issuance of
Allegiance Stock will contain a notation incorporating the Rights Agreement by
reference. Until the Rights Distribution Date (or earlier redemption or
expiration of the Rights), the surrender for transfer of any certificates for
Allegiance Stock outstanding, even without such notation or a copy of the
summary of rights being attached thereto, will also constitute the transfer of
the Rights associated with the Allegiance Stock represented by such certificate.
As soon as practicable following the Rights Distribution Date, separate
certificates evidencing the Rights ("Rights Certificates") will be mailed to
holders of record of Allegiance Stock as of the close of business on the Rights
Distribution Date and such separate Right Certificates alone will evidence the
Rights.
The Rights are not exercisable until the Rights Distribution Date. The
Rights will expire on , 2006 (the "Final Expiration Date"), unless
the Final Expiration Date is extended or unless the Rights are earlier redeemed
or exchanged by Allegiance, in each case, as described below.
The Purchase Price payable, and the number of Preferred Shares or other
securities or property issuable, upon exercise of the Rights are subject to
adjustment from time to time to prevent dilution (i) in the event of a stock
dividend on, or a subdivision, combination or reclassification of, the Preferred
Shares, (ii) upon the grant to holders of the Preferred Shares of certain rights
or warrants to subscribe for or purchase Preferred Shares at a price, or
securities convertible into Preferred Shares with a conversion price, less than
the then-current market price of the Preferred Shares, or (iii) upon the
distribution to holders of the Preferred Shares of evidences of indebtedness,
cash (other than a regular quarterly cash dividend out of the earnings or
retained earnings of Allegiance), assets (other than a dividend payable in
Preferred Shares) or of subscription rights or warrants (other than those
referred to above).
The number of outstanding Rights and the number of one one-hundredths of a
Preferred Share issuable upon exercise of each Right are also subject to
adjustment in the event of a stock split of Allegiance Stock or a stock dividend
on Allegiance Stock payable in Allegiance Stock or subdivisions, consolidations
or combinations of Allegiance Stock occurring, in any such case, prior to the
Rights Distribution Date.
Preferred Shares purchasable upon exercise of the Rights will not be
redeemable. Each Preferred Share will be entitled to a minimum preferential
quarterly dividend payment of $1 per share but will be entitled to an aggregate
dividend of 100 times the dividend declared per share of Allegiance Stock. In
the event of liquidation, the holders of the Preferred Shares will be entitled
to a minimum preferential liquidation payment of $100 per share. Each Preferred
Share will have 100 votes, voting together with the Allegiance Stock. Finally,
in the event of any merger, consolidation or other transaction in which shares
of Allegiance Stock are exchanged, each Preferred Share will be entitled to
receive 100 times the amount received per share of Allegiance Stock. The Rights
are protected by customary anti-dilution provisions.
58
<PAGE>
Because of the nature of the dividend, liquidation and voting rights, the
value of the one one-hundredth interest in a Preferred Share purchasable upon
exercise of each Right should approximate the value of one share of Allegiance
Stock.
In the event that any person or group of affiliated or associated persons
becomes an Acquiring Person, proper provision shall be made so that each holder
of a Right, other than Rights beneficially owned by the Acquiring Person (which
will thereafter be void), will thereafter have the right to receive upon
exercise that number of shares of Allegiance Stock having a market value of two
times the exercise price of the Right. In the event that Allegiance is acquired
in a merger or other business combination transaction or 50% or more of its
consolidated assets or earning power are sold after a person or group of
affiliated or associated persons has become an Acquiring Person, proper
provision will be made so that each holder of a Right will thereafter have the
right to receive, upon the exercise thereof at the then current exercise price
of the Right, that number of shares of common stock of the acquiring company
which at the time of such transaction will have a market value of two times the
exercise price of the Right.
At any time after any person or group of affiliates or associated persons
becomes an Acquiring Person and prior to the acquisition by such person or group
of 50% or more of the outstanding shares of Allegiance Stock, the Allegiance
Board may exchange the Rights (other than Rights owned by such person or group
which will have become void), in whole or in part, at an exchange ratio of one
share of Allegiance Stock, or one one-hundredth of a Preferred Share (or of a
share of a class or series of Allegiance Preferred Stock having equivalent
rights, preferences and privileges), per Right (subject to adjustment).
With certain exceptions, no adjustment in the Purchase Price will be
required until cumulative adjustments amount to at least 1% in such Purchase
Price. No fractional Preferred Shares will be issued (other than fractions which
are integral multiples of one one-hundredth of a Preferred Share, which may, at
the election of Allegiance, be evidenced by depositary receipts) and, in lieu
thereof, an adjustment in cash will be made based on the market price of the
Preferred Shares on the last trading day prior to the date of exercise.
In general, Allegiance may redeem the Rights in whole, but not in part, at a
price of $.01 per Right (payable in cash, Allegiance Stock or other
consideration deemed appropriate by the Allegiance Board) at any time until ten
days following the first public announcement that a person or group of
affiliated or associated persons has become an Acquiring Person. Immediately
upon the action of the Allegiance Board authorizing any redemption, the Rights
will terminate and the only right of the holders of Rights will be to receive
the redemption price.
The terms of the Rights may be amended by the Allegiance Board without the
consent of the holders of the Rights, including an amendment to lower certain
thresholds described above to not less than 10%, except that from and after such
time as any person or group of affiliated or associated persons becomes an
Acquiring Person no such amendment may adversely affect the interests of the
holders of the Rights.
Until a Right is exercised, the holder thereof, as such, will have no rights
as a stockholder of Allegiance, including, without limitation, the right to vote
or to receive dividends.
The Rights will have certain anti-takeover effects. The Rights will cause
substantial dilution to a person or group that attempts to acquire Allegiance on
terms not approved by the Allegiance Board. The Rights should not interfere with
any merger or other business combination approved by the Allegiance Board
because the Rights may be redeemed by Allegiance until the tenth day following
the first public announcement that a person or group has become an Acquiring
Person.
59
<PAGE>
CERTAIN ANTITAKEOVER EFFECTS OF CERTAIN PROVISIONS OF THE
CERTIFICATE OF INCORPORATION, BY-LAWS AND STATE LAW
CERTIFICATE OF INCORPORATION AND BY-LAWS
The Certificate of Incorporation and the By-laws of Allegiance contain
certain provisions that could make more difficult the acquisition of Allegiance
by means of a tender offer, proxy contest or otherwise. The description set
forth below is intended as a summary only and is qualified in its entirety by
reference to the Certificate of Incorporation and the By-laws, forms of which
are attached hereto as Annex A and Annex B, respectively.
CLASSIFIED BOARD OF DIRECTORS.
The Certificate of Incorporation of Allegiance provides that the Allegiance
directors (other than those who may be elected by the holders of any series of
Preferred Shares under specified circumstances), will be divided into three
classes of directors, with the classes to be as nearly equal in number as
possible. Immediately after the Distribution, the Allegiance Board will consist
of the persons referred to in "ALLEGIANCE MANAGEMENT -- DIRECTORS." The
Certificate of Incorporation provides that the term of office of the first class
will expire at the 1997 annual meeting of stockholders, the term of office of
the second class will expire at the 1998 annual meeting of stockholders and the
term of office of the third class will expire at the 1999 annual meeting of
stockholders.
The classification of directors will have the effect of making it more
difficult for stockholders to change the composition of the Allegiance Board. At
least two annual meetings of stockholders, instead of one, will generally be
required to effect a change in a majority of the Allegiance Board. Such a delay
may help ensure that Allegiance's directors, if confronted by a holder
attempting to force a proxy contest, a tender or exchange offer or an
extraordinary corporate transaction, would have sufficient time to review the
proposal as well as any available alternatives to the proposal and to act in
what they believe to be the best interest of the stockholders. The
classification provisions will apply to every election of directors, however,
regardless of whether a change in the composition of the Allegiance Board would
be beneficial to Allegiance and its stockholders and whether or not a majority
of Allegiance's stockholders believe that such a change would be desirable.
The classification provisions could also have the effect of discouraging a
third party from initiating a proxy contest, making a tender offer or otherwise
attempting to obtain control of Allegiance, even though such an attempt might be
beneficial to Allegiance and its stockholders. The classification of the
Allegiance Board could thus increase the likelihood that incumbent directors
will retain their position. In addition, because the classification provisions
may discourage accumulations of large blocks of Allegiance's stock by purchasers
whose objective is to take control of Allegiance and remove a majority of the
Allegiance Board, the classification of the Allegiance Board could tend to
reduce the likelihood of fluctuations in the market price of Allegiance Stock
that might result from accumulations of large blocks. Accordingly, stockholders
could be deprived of certain opportunities to sell their shares of Allegiance
Stock at a higher market price than might otherwise be obtainable.
NUMBER OF DIRECTORS; FILLING VACANCIES; REMOVAL.
The Allegiance Certificate of Incorporation provides that, subject to any
rights of holders of Allegiance Preferred Stock to elect additional directors
under specific circumstances, the number of directors will be the number from
time to time fixed by the Allegiance Board. In addition, the Certificate of
Incorporation provides that, subject to any rights of holders of Allegiance
Preferred Shares, any vacancy that results from an increase in the number of
directors or for any other reason, may be filled by a majority of directors then
in office. Accordingly, absent an amendment to the Allegiance Certificate of
Incorporation, the Allegiance Board could prevent any stockholder from enlarging
the Allegiance Board and filling the new directorships created thereby with such
stockholder's own nominees. Under the Delaware Law, unless otherwise provided in
the Certificate of Incorporation, directors serving on a classified board may
only be removed by the stockholders for cause.
60
<PAGE>
NO STOCKHOLDER ACTION BY WRITTEN CONSENT; SPECIAL MEETINGS.
The Allegiance Certificate of Incorporation prohibits stockholder action by
written consent in lieu of a meeting. The By-laws provide that special meetings
of the stockholders may be called only (a) by the chairman of the board or the
secretary, and shall be called upon a request signed by a majority of the
directors or (b) by resolution of the directors.
The provisions of the Certificate of Incorporation of Allegiance prohibiting
stockholder action by written consent may have the effect of delaying
consideration of a stockholder proposal until the next annual meeting unless a
special meeting is called at the request of a majority of the Board. These
provisions would also prevent the holders of a majority of the voting power of
the Voting Stock from unilaterally using the written consent procedure to take
stockholder action. Moreover, a stockholder could not force stockholder
consideration of a proposal over the opposition of the Allegiance Board by
calling a special meeting of stockholders prior to the time a majority of the
Board believes such consideration to be appropriate.
ADVANCE NOTICE OF STOCKHOLDER NOMINATIONS AND STOCKHOLDER
PROPOSALS REQUIRED.
The Allegiance By-laws establish an advance notice procedure for
stockholders to make nominations of candidates for election as directors, or
bring other business before an annual meeting of stockholders of Allegiance (the
"Stockholder Notice Procedure").
The Stockholder Notice Procedure provides that only persons who are
nominated by, or at the direction of, the Allegiance Board, or by a stockholder
who has given timely written notice to the Secretary of Allegiance prior to the
meeting at which directors are to be elected, will be eligible for election as
directors of Allegiance. The Stockholder Notice Procedure provides that at an
annual meeting only such business may be conducted as has been brought before
the meeting by, or at the direction of, the Allegiance Board or by a stockholder
who has given timely written notice to the Secretary of Allegiance of such
stockholder's intention to bring such business before such meeting. Under the
Stockholder Notice Procedure, for notice of stockholder nominations to be made
at an annual meeting to be timely, such notice must be received by Allegiance
not less than 60 days nor more than 90 days prior to the first anniversary of
the previous year's annual meeting (if the date of any other annual meeting is
advanced by more than 30 days from such anniversary date, not later than the
10th day after the notice of the date of the annual meeting was mailed or public
announcement of the date of such meeting was made). Under the Stockholder Notice
Procedure, for notice of a stockholder nomination to be made at a special
meeting at which directors are to be elected to be timely, such notice must be
received by Allegiance not earlier than the 90th day before such meeting and not
later than the 10th day after the notice of the date of the special meeting was
mailed or public announcement of the date of such meeting was made. For the
purpose of determining whether a stockholder's notice is timely delivered in
connection with the 1997 annual meeting, the first anniversary of the previous
year's annual meeting is deemed to be , 1997.
Under the Stockholder Notice Procedure, a stockholder's notice to Allegiance
proposing to nominate a person for election as a director must contain certain
information including, without limitation, the name and address of the
nominating stockholder, the class and number of shares of stock of Allegiance
which are owned by such stockholder, and all information regarding the proposed
nominee that would be required to be included in a proxy statement soliciting
proxies for the proposed nominee. Under the Stockholder Notice Procedure, a
stockholder's notice relating to the conduct of business other than the
nomination of directors must contain certain information about such business and
about the proposing stockholders, including, without limitation, a brief
description of the business the stockholder proposes to bring before the
meeting, the reasons for conducting such business at such meeting, the name and
address of such stockholder, the class and number of shares of stock of
Allegiance beneficially owned by such stockholder, and any material interest of
such stockholder in the business so proposed. If the Chairman of the Board or
other officer presiding at a meeting
61
<PAGE>
determines that a person was not nominated, or other business was not brought
before the meeting, in accordance with the Stockholder Notice Procedure, such
person will not be eligible for election as a director, or such business will
not be conducted at such meeting, as the case may be.
By requiring advance notice of nominations by stockholders, the Stockholder
Notice Procedure will afford the Allegiance Board an opportunity to consider the
qualifications of the proposed nominees and, to the extent deemed necessary or
desirable by the Allegiance Board, to inform Stockholders about such
qualifications. By requiring advance notice of other proposed business, the
Stockholder Notice Procedure will also provide a more orderly procedure for
conducting annual meetings of stockholders and, to the extent deemed necessary
or desirable by the Allegiance Board, will provide the Allegiance Board with an
opportunity to inform stockholders, prior to such meetings, of any business
proposed to be conducted at such meetings, together with any recommendations as
to the Board's position regarding action to be taken with respect to such
business, so that stockholders can better decide whether to attend such a
meeting or to grant a proxy regarding the disposition of any such business.
Although the By-laws do not give the Allegiance Board any power to approve
or disapprove stockholder nominations for the election of directors or proposals
for action, they may have the effect of precluding a contest for the election of
directors or the consideration of stockholder proposals if the proper procedures
are not followed, and of discouraging or deterring a third party from conducting
a solicitation of proxies to elect its own slate of directors or to approve its
own proposal, without regard to whether consideration of such nominees or
proposals might be harmful or beneficial to Allegiance and its stockholders.
AMENDMENT OF CERTAIN PROVISIONS OF THE CERTIFICATE OF
INCORPORATION AND BY-LAWS
Under Delaware Law, the stockholders have the right to adopt, amend or
repeal the by-laws and, with the approval of the board of directors, the
certificate of incorporation of a corporation. In addition, under Delaware Law,
if the certificate of incorporation so provides, the by-laws may be adopted,
amended or repealed by the board of directors. The Certificate of Incorporation
provides that the affirmative vote of the holders of at least 66 2/3% of the
voting power of the outstanding shares of Voting Stock, voting together as a
single class, is required to amend provisions of the Certificate of
Incorporation relating to the prohibition of stockholder action without a
meeting; the number, election and term of Allegiance's directors; and the
issuance of rights. The By-laws may be amended by the Allegiance Board or by the
affirmative vote of the holders of at least 66 2/3% of the voting power of the
outstanding shares of Voting Stock, voting together as a single class. These
66 2/3% voting requirements will have the effect of making more difficult any
amendment by stockholders of the By-laws or of any of the provisions of the
Certificate of Incorporation described above, even if a majority of Allegiance's
stockholders believe that such amendment would be in their best interests.
STATE LAW
ANTITAKEOVER LEGISLATION
Section 203 of the Delaware Law provides that, subject to certain exceptions
specified therein, a corporation shall not engage in any business combination
with any interested stockholder for a three-year period following the date that
such stockholder becomes an interested stockholder unless (i) prior to such
date, the board of directors of the corporation approved either the business
combination or the transaction which resulted in the stockholder becoming an
interested stockholder; (ii) upon consummation of the transaction which resulted
in the stockholder becoming an interested stockholder, the interested
stockholder owned at least 85% of the voting stock of the corporation
outstanding at the time the transaction commenced (excluding certain shares); or
(iii) on or subsequent to such date, the business combination is approved by the
board of directors of the corporation and by the affirmative vote of at least
66 2/3% of the outstanding voting stock which is not owned by the interested
stockholder. Except as specified in Section 203 of the Delaware Law, an
"interested stockholder" is defined to include (x) any person that is the owner
of 15% or more of the outstanding voting stock of the
62
<PAGE>
corporation, or is an affiliate or associate of the corporation and was the
owner of 15% or more of the outstanding voting stock of the corporation, at any
time within three years immediately prior to the relevant date and (y) the
affiliates and associates of any such person.
Under certain circumstances, Section 203 of the Delaware Law makes it more
difficult for a person who would be an interested stockholder to effect various
business combinations with a corporation for a three-year period, although the
stockholders may elect to exclude a corporation from the restrictions imposed
thereunder. The Certificate of Incorporation does not exclude Allegiance from
the restrictions imposed under Section 203 of the Delaware Law. It is
anticipated that the provisions of Section 203 of the Delaware Law may encourage
companies interested in acquiring Allegiance to negotiate in advance with the
Allegiance Board, since the stockholder approval requirement would be avoided if
a majority of the directors then in office approves either the business
combination or the transaction which results in the stockholder becoming an
interested stockholder.
LIABILITY AND INDEMNIFICATION OF DIRECTORS AND OFFICERS
LIMITATION OF LIABILITY OF DIRECTORS
The Allegiance Certificate of Incorporation provides that a director of
Allegiance will not be personally liable to Allegiance or its stockholders for
monetary damages for breach of fiduciary duty as a director, except for
liability (i) for any breach of the director's duty of loyalty to Allegiance or
its stockholders, (ii) for acts or omissions not in good faith or which involve
intentional misconduct or a knowing violation of law, (iii) under Section 174 of
the Delaware Law, which concerns unlawful payments of dividends, stock purchases
or redemptions, or (iv) for any transaction from which the director derived an
improper personal benefit.
While the Certificate of Incorporation provides directors with protection
from awards for monetary damages for breaches of their duty of care, it does not
eliminate such duty. Accordingly, the Certificate of Incorporation will have no
effect on the availability of equitable remedies such as an injunction or
rescission based on a director's breach of his or her duty of care. The
provisions of the Certificate of Incorporation described above apply to an
officer of Allegiance only if he or she is a director of Allegiance and is
acting in his or her capacity as director, and do not apply to officers of
Allegiance who are not directors.
INDEMNIFICATION OF DIRECTORS AND OFFICERS
The Allegiance Certificate of Incorporation provides that each person who is
or was or had agreed to become a director or officer of Allegiance, and each
person who serves or may have served at the request of Allegiance as a director,
officer, employee or agent of another corporation, partnership, joint venture,
trust or other enterprise, will be indemnified by Allegiance to the fullest
extent permitted from time to time by Delaware law, as the same exists or may
hereafter be amended, except with respect to an action commenced by such
directors or officers against Allegiance or by such directors or officers as a
derivative action.
The Certificate of Incorporation provides that the right to indemnification
and the payment of expenses conferred in the Certificate of Incorporation will
not be exclusive of any other right which any person may have or may in the
future acquire under any agreement, vote of stockholders or disinterested
directors or otherwise. The Certificate of Incorporation permits Allegiance to
maintain insurance on behalf of any person who is or was a director, officer,
employee or agent of Allegiance, or is serving at the request of Allegiance as a
director, officer, employee or agent of another corporation, partnership, joint
venture, trust or other enterprise against any expense, liability or loss,
whether or not Allegiance would have the power to indemnify such person against
such liability under the Certificate of Incorporation or Delaware Law.
Allegiance intends to obtain directors and officers liability insurance
providing coverage to its directors and officers.
63
<PAGE>
ADDITIONAL INFORMATION
There has not been in the past and there is not presently pending any
litigation or proceeding involving a director, officer, employee or agent of
Allegiance in which indemnification would be required or permitted by the
Certificate of Incorporation.
64
<PAGE>
ALLEGIANCE CORPORATION
INDEX TO COMBINED FINANCIAL STATEMENTS
<TABLE>
<CAPTION>
PAGE
---------
<S> <C>
Report of Independent Accountants.......................................................................... F-2
Combined Statements of Income.............................................................................. F-3
Combined Balance Sheets.................................................................................... F-4
Combined Statements of Cash Flows.......................................................................... F-5
Combined Statements of Equity.............................................................................. F-6
Notes to Combined Financial Statements..................................................................... F-7
Schedule II -- Valuation and Qualifying Accounts........................................................... F-19
</TABLE>
F-1
<PAGE>
REPORT OF INDEPENDENT ACCOUNTANTS
To the Board of Directors and Shareholders of
Baxter International Inc.
In our opinion, the accompanying combined balance sheets and the related
combined statements of income, cash flows and equity present fairly, in all
material respects, the financial position of Allegiance Corporation at December
31, 1995 and 1994, and the results of its operations and its cash flows for each
of the three years in the period ended December 31, 1995, in conformity with
generally accepted accounting principles. These financial statements are the
responsibility of Baxter International Inc.'s management; our responsibility is
to express an opinion on these financial statements based on our audits. We
conducted our audits of these statements in accordance with generally accepted
auditing standards which require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements, assessing the
accounting principles used and significant estimates made by management, and
evaluating the overall financial statement presentation. We believe that our
audits provide a reasonable basis for the opinion expressed above.
Our audits of the combined financial statements of Allegiance also included
an audit of Financial Statement Schedule II appearing on page F-19 of this Form
10. In our opinion, this Financial Statement Schedule presents fairly, in all
material respects, the information set forth therein when read in conjunction
with the related combined financial statements.
Price Waterhouse LLP
Chicago, Illinois
June 27, 1996
F-2
<PAGE>
ALLEGIANCE CORPORATION
COMBINED STATEMENTS OF INCOME
(IN MILLIONS)
<TABLE>
<CAPTION>
THREE MONTHS ENDED
MARCH 31, YEARS ENDED DECEMBER 31,
-------------------- -------------------------------
1996 1995 1995 1994 1993
--------- --------- --------- --------- ---------
(UNAUDITED)
<S> <C> <C> <C> <C> <C>
Net sales..................................................... $ 1,115 $ 1,226 $ 4,922 $ 5,109 $ 5,019
Costs and expenses
Cost of goods sold.......................................... 889 947 3,878 3,731 3,613
Selling, general and administrative expenses................ 168 198 756 1,005 1,061
Restructuring charges....................................... -- -- 76 -- 484
Goodwill amortization....................................... 9 9 38 41 41
Other (income) expense...................................... (1) 3 (302) (6) (26)
--------- --------- --------- --------- ---------
Total costs and expenses.................................. 1,065 1,157 4,446 4,771 5,173
--------- --------- --------- --------- ---------
Income (loss) before income taxes............................. 50 69 476 338 (154)
Income tax expense (benefit).................................. 19 27 203 123 (86)
--------- --------- --------- --------- ---------
Income (loss) before cumulative effect of accounting change... 31 42 273 215 (68)
Cumulative effect of change in accounting for other
postemployment benefits, net of income tax benefit of $3..... -- -- -- -- (5)
--------- --------- --------- --------- ---------
Net income (loss)......................................... $ 31 $ 42 $ 273 $ 215 $ (73)
--------- --------- --------- --------- ---------
--------- --------- --------- --------- ---------
</TABLE>
The accompanying notes are an integral part of these combined financial
statements.
F-3
<PAGE>
ALLEGIANCE CORPORATION
COMBINED BALANCE SHEETS
(IN MILLIONS)
<TABLE>
<CAPTION>
DECEMBER 31,
--------------------
1995 1994
MARCH 31, --------- ---------
1996
-----------
(UNAUDITED)
<S> <C> <C> <C>
Current assets
Cash and equivalents.......................................................... $ 4 $ 1 $ 3
Accounts receivable, net of allowance for doubtful accounts of $19 at March
31, 1996, and $18 and $17 at December 31, 1995 and 1994, respectively........ 489 487 635
Notes and other current receivables........................................... 42 59 246
Inventories................................................................... 712 684 721
Short-term deferred income taxes.............................................. 119 129 145
Prepaid expenses.............................................................. 17 12 25
----------- --------- ---------
Total current assets........................................................ 1,383 1,372 1,775
----------- --------- ---------
Property, plant and equipment
Property, plant and equipment................................................. 1,317 1,307 1,330
Accumulated depreciation and amortization..................................... 440 429 410
----------- --------- ---------
Net property, plant and equipment............................................. 877 878 920
----------- --------- ---------
Other assets
Goodwill and other intangibles................................................ 1,108 1,116 1,214
Other......................................................................... 69 78 122
----------- --------- ---------
Total other assets.......................................................... 1,177 1,194 1,336
----------- --------- ---------
Total assets.............................................................. $ 3,437 $ 3,444 $ 4,031
----------- --------- ---------
----------- --------- ---------
Current liabilities
Accounts payable and accrued liabilities...................................... $ 662 $ 692 $ 720
Long-term deferred income taxes............................................... 113 110 54
Other noncurrent liabilities.................................................. 65 64 188
Equity
Investment by and advances from Baxter International Inc...................... 2,597 2,578 3,069
----------- --------- ---------
Total liabilities and equity.............................................. $ 3,437 $ 3,444 $ 4,031
----------- --------- ---------
----------- --------- ---------
</TABLE>
The accompanying notes are an integral part of these combined financial
statements.
F-4
<PAGE>
ALLEGIANCE CORPORATION
COMBINED STATEMENTS OF CASH FLOWS
(IN MILLIONS)
<TABLE>
<CAPTION>
THREE MONTHS ENDED MARCH
31, YEARS ENDED DECEMBER 31,
------------------------ -------------------------------
1996 1995 1995 1994 1993
------------- --------- --------- --------- ---------
(UNAUDITED)
(BRACKETS DENOTE CASH OUTFLOWS)
<S> <C> <C> <C> <C> <C>
Cash flow provided by operations
Income (loss) before cumulative effect of accounting change... $ 31 $ 42 $ 273 $ 215 $ (68)
Adjustments
Depreciation and amortization............................... 37 41 165 223 221
Deferred income taxes....................................... 13 13 50 3 (199)
Gain on asset dispositions, net............................. -- 4 (263) (11) (36)
Restructuring charges....................................... -- -- 76 -- 484
Other....................................................... 1 1 5 2 11
Changes in balance sheet items
Accounts receivable......................................... 13 1 73 8 (6)
Inventories................................................. (29) (20) 29 86 (124)
Accounts payable and other current liabilities.............. (9) 16 (120) (43) 78
Restructuring program payments.............................. (11) (13) (62) (54) (18)
Other....................................................... (2) 18 27 (7) (7)
--- --------- --------- --------- ---------
Cash flow provided by operations.............................. 44 103 253 422 336
--- --------- --------- --------- ---------
Investment transactions
Capital expenditures.......................................... (15) (18) (112) (122) (273)
Acquisitions (net of cash received)........................... (9) -- (5) (2) (14)
Proceeds from asset dispositions.............................. (5) 184 626 107 68
--- --------- --------- --------- ---------
Investment transactions, net.................................. (29) 166 509 (17) (219)
--- --------- --------- --------- ---------
Financing transactions
Advances from (payments to) Baxter International Inc., net.... (12) (269) (764) (402) (119)
--- --------- --------- --------- ---------
Financing transactions, net................................... (12) (269) (764) (402) (119)
--- --------- --------- --------- ---------
Increase (decrease) in cash and equivalents..................... 3 -- (2) 3 (2)
Cash and equivalents at beginning of period..................... 1 3 3 -- 2
--- --------- --------- --------- ---------
Cash and equivalents at end of period........................... $ 4 $ 3 $ 1 $ 3 $ --
--- --------- --------- --------- ---------
--- --------- --------- --------- ---------
</TABLE>
The accompanying notes are an integral part of these combined financial
statements.
F-5
<PAGE>
ALLEGIANCE CORPORATION
COMBINED STATEMENTS OF EQUITY
(IN MILLIONS)
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31,
-------------------------------
1995 1994 1993
THREE MONTHS --------- --------- ---------
ENDED MARCH 31,
1996
---------------
(UNAUDITED)
<S> <C> <C> <C> <C>
Investment by and advances from Baxter International Inc.
Beginning balance............................................... $ 2,578 $ 3,069 $ 3,256 $ 3,443
Net income...................................................... 31 273 215 (68)
Advances from (payments to) Baxter International Inc., net...... (12) (764) (402) (119)
------- --------- --------- ---------
Ending balance.................................................... $ 2,597 $ 2,578 $ 3,069 $ 3,256
------- --------- --------- ---------
------- --------- --------- ---------
</TABLE>
The accompanying notes are an integral part of these combined financial
statements.
F-6
<PAGE>
ALLEGIANCE CORPORATION
NOTES TO COMBINED FINANCIAL STATEMENTS
1. DESCRIPTION OF THE BUSINESS
On November 27, 1995, the board of directors of Baxter International Inc.
("Baxter") approved in principle a plan to distribute to Baxter stockholders all
of the outstanding stock of its health-care cost management business in a
spin-off transaction (the "Distribution") which is expected to be tax-free.
Allegiance Corporation ("Allegiance" or the "company") operates in a single
industry segment as a leading provider of medical products and services that
help its health-care customers manage and reduce the total cost of providing
patient care. Through its nationwide distribution network, Allegiance
distributes a broad offering of medical, surgical and laboratory supplies,
including its own self-manufactured surgical and respiratory-therapy products,
to hospital and alternate-care customers. Allegiance also provides cost
management services to its health-care customers through inventory management
programs, customized packaging, and procedure and process consulting. The
delivery of such a broad array of product and service offerings requires focused
investments in cost management services, information systems and manufacturing
efficiencies.
The Distribution is expected to occur in late 1996 and will result in
Allegiance operating as an independent entity with publicly traded common stock.
Baxter will have no ownership interest in Allegiance after the spin-off but will
continue to conduct business as described in the Reorganization and other
agreements outlined in Note 8 to the Combined Financial Statements. However,
Baxter will, unless released by third parties, remain liable for certain lease,
guarantee and other obligations and liabilities that are transferred to and
assumed by Allegiance. Allegiance will be obligated by the Reorganization
agreement to indemnify Baxter against liabilities related to those transferred
obligations and liabilities.
Allegiance's historical results of operations in 1995, 1994 and 1993 include
revenues and expenses related to certain divested businesses. The Industrial and
Life Sciences division was sold in September 1995 and the diagnostics
manufacturing businesses were sold in December 1994. See Note 3 to the Combined
Financial Statements for additional information related to these divestitures.
The following table presents selected financial data for Allegiance
excluding the revenue and expenses associated with these divested businesses:
<TABLE>
<CAPTION>
THREE MONTHS ENDED
MARCH 31, YEARS ENDED DECEMBER 31,
-------------------- -------------------------------
1996 1995 1995 1994 1993
--------- --------- --------- --------- ---------
(UNAUDITED) (IN MILLIONS)
<S> <C> <C> <C> <C> <C>
Net sales..................................................... $ 1,115 $ 1,108 $ 4,575 $ 4,314 $ 4,249
Costs and expenses
Cost of goods sold.......................................... 889 866 3,625 3,311 3,245
Selling, general and administrative expenses................ 168 178 701 711 746
Restructuring charges....................................... -- -- -- -- 304
Goodwill amortization....................................... 9 9 37 37 37
Other (income) expense...................................... (1) 3 (33) (3) (44)
--------- --------- --------- --------- ---------
Total costs and expenses.................................. 1,065 1,056 4,330 4,056 4,288
--------- --------- --------- --------- ---------
Pretax income (loss).......................................... 50 52 245 258 (39)
Income tax expense (benefit).................................. 19 19 94 101 (13)
--------- --------- --------- --------- ---------
Income (loss)............................................. $ 31 $ 33 $ 151 $ 157 $ (26)
--------- --------- --------- --------- ---------
--------- --------- --------- --------- ---------
</TABLE>
F-7
<PAGE>
ALLEGIANCE CORPORATION
NOTES TO COMBINED FINANCIAL STATEMENTS (CONTINUED)
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
This summary of significant accounting policies is presented to assist the
reader in understanding and evaluating the combined financial statements. These
policies are in conformity with generally accepted accounting principles and
have been applied consistently in all material respects. The preparation of
financial statements in conformity with generally accepted accounting principles
requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts of
revenues and expenses during the reporting period. Actual results could differ
from those estimates.
BASIS OF PRESENTATION
The accompanying combined financial statements include those assets,
liabilities, revenues and expenses directly attributable to Allegiance's
operations. These financial statements have been prepared as if Allegiance had
operated as a free-standing entity for all periods presented (excluding certain
incremental corporate expenses that would have been incurred had it operated on
a stand-alone basis). Operations outside the United States and Puerto Rico,
which are not significant, are included in the combined financial statements on
the basis of fiscal years ending November 30.
The financial information included herein does not necessarily reflect what
the financial position and results of operations of Allegiance would have been
had it operated as a stand-alone entity during the periods covered, and may not
be indicative of future operations or financial position.
INTERIM FINANCIAL STATEMENTS
In the opinion of management, the interim combined financial statements
reflect all adjustments necessary for a fair presentation of the interim
periods. All such adjustments are of a normal, recurring nature. The results of
operations for the interim periods are not necessarily indicative of the results
of operations to be expected for the full year.
CASH AND EQUIVALENTS
Cash and equivalents include cash, cash investments and marketable
securities with original maturities of three months or less. Cash payments for
income taxes related to Allegiance's operations were made by Baxter.
INVENTORIES
Inventories are stated at the lower of cost (first-in, first-out method) or
market. Market for raw materials is based on replacement costs and for other
inventory classifications on net realizable value. Appropriate consideration is
given to deterioration, obsolescence and other factors in evaluating net
realizable value.
Inventories consisted of the following:
<TABLE>
<CAPTION>
DECEMBER 31,
--------------------
1995 1994
--------- ---------
MARCH 31,
1996
-------------
(UNAUDITED)
(IN MILLIONS)
<S> <C> <C> <C>
Raw materials................................................... $ 66 $ 54 $ 64
Work in process................................................. 54 49 55
Finished products............................................... 592 581 602
----- --------- ---------
Total inventories........................................... $ 712 $ 684 $ 721
----- --------- ---------
----- --------- ---------
</TABLE>
F-8
<PAGE>
ALLEGIANCE CORPORATION
NOTES TO COMBINED FINANCIAL STATEMENTS (CONTINUED)
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment are stated at cost. Depreciation and
amortization are provided for financial reporting purposes principally on the
straight-line method over the following estimated useful lives: buildings and
leasehold improvements, 20 to 44 years; machinery and other equipment, 3 to 20
years; equipment leased or rented to customers, 1 to 5 years. Leasehold
improvements are depreciated over the life of the related facility leases or the
asset whichever is shorter. Straight-line and accelerated methods of
depreciation are used for income tax purposes.
Property, plant and equipment consisted of the following:
<TABLE>
<CAPTION>
DECEMBER 31,
--------------------
1995 1994
--------- ---------
(IN MILLIONS)
<S> <C> <C>
Land.................................................................. $ 102 $ 104
Buildings and leasehold improvements.................................. 396 386
Machinery and equipment............................................... 724 778
Equipment leased or rented to customers............................... 14 16
Construction in progress.............................................. 71 46
--------- ---------
Total property, plant and equipment, at cost........................ 1,307 1,330
Accumulated depreciation and amortization............................. (429) (410)
--------- ---------
Net property, plant and equipment................................. $ 878 $ 920
--------- ---------
--------- ---------
</TABLE>
Depreciation expense was $106, $154 and $156 million in 1995, 1994 and 1993,
respectively. Repairs and maintenance expense was $36 million in 1995, $30
million in 1994 and $33 million in 1993.
GOODWILL AND OTHER INTANGIBLE ASSETS
Goodwill represents the excess of cost over the fair value of net assets
acquired and is amortized on a straight-line basis over estimated useful lives
not exceeding 40 years. Based upon management's assessment of the future
undiscounted operating cash flows of acquired businesses, the carrying value of
goodwill at December 31, 1995, has not been impaired. As of December 31, 1995
and 1994, goodwill was $1,092 million and $1,170 million, respectively, net of
accumulated amortization of $369 million and $345 million, respectively.
Other intangible assets include purchased patents, trademarks, deferred
charges and other identified rights which are amortized on a straight-line basis
over their legal or estimated useful lives, whichever is shorter (generally not
exceeding 17 years). As of December 31, 1995 and 1994, other intangibles were
$24 million and $44 million, respectively, net of accumulated amortization of
$46 million and $38 million, respectively.
INCOME TAXES
Allegiance's operations were historically included in Baxter's consolidated
U.S. federal and state income tax returns and in the tax returns of certain
Baxter foreign subsidiaries. The provision for income taxes has been determined
as if Allegiance had filed separate tax returns under its existing structure for
the periods presented. Accordingly, the effective tax rate of Allegiance in
future years could vary from its historical effective rates depending on
Allegiance's future legal structure and tax elections. All income taxes are
settled with Baxter on a current basis through the "Investment By and Advances
From Baxter" account.
F-9
<PAGE>
ALLEGIANCE CORPORATION
NOTES TO COMBINED FINANCIAL STATEMENTS (CONTINUED)
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Provision has been made for income taxes in accordance with Financial
Accounting Standards Board ("FASB") Statement No. 109, "Accounting for Income
Taxes."
DERIVATIVES
Gains and losses on hedges of existing assets or liabilities are included in
the carrying amounts of those assets or liabilities and are ultimately
recognized in income as part of those carrying amounts. Gains and losses
relating to qualifying hedges of firm commitments or anticipated transactions
also are deferred and are recognized in income or as adjustments of carrying
amounts when the hedged transaction occurs.
3. ACQUISITIONS, INVESTMENTS IN AFFILIATES AND DIVESTITURES
ACQUISITIONS
Allegiance invested $5 million in 1995, $2 million in 1994 and $14 million
in 1993 for acquisitions accounted for as purchase transactions and investments
in affiliated companies. Had the acquisitions taken place on January 1,
consolidated results in the year of acquisition would not have been materially
different from reported results. These acquisitions involved no significant
change in Allegiance's strategic direction and were made to acquire
technologies, broaden product lines and expand market coverage.
DIVESTITURES
In 1995, Allegiance disposed of several businesses or product lines which
resulted in a net gain of $141 million (net of $122 million in related income
tax expense). The majority of the net gain for 1995 related to the divestiture
of Allegiance's Industrial and Life Sciences Division ("Industrial") to VWR
Corporation for approximately $400 million in cash and $25 million in deferred
payments, resulting in a gain of $268 million. As part of the divestiture,
Allegiance will continue to supply its self-manufactured products and supplies
sold in non-health-care markets to VWR Corporation under a long-term
distribution agreement. Allegiance disposed of or discontinued several minor
non-strategic or unprofitable product lines or investments which resulted in a
net gain of $8 million (net of $3 million in related income tax expense) in 1994
and $22 million (net of $14 million in related income tax expense) in 1993. The
majority of these transactions resulted in the disposition of Allegiance's
entire interest in such product lines and investments.
Proceeds from divestitures were $626 million in 1995, $107 million in 1994
and $68 million in 1993. Proceeds in 1995 included approximately $400 million
for the Industrial divestiture discussed earlier. The divestiture of the
diagnostics manufacturing business discussed in Note 4 to the Combined Financial
Statements included proceeds of approximately $200 million in 1995 and $44
million in 1994.
4. RESTRUCTURING CHARGES
In November 1993, Baxter's board of directors approved a series of strategic
actions to improve shareholder value and reduce costs. The strategic actions of
the program were designed in part to make the Allegiance Business more efficient
and responsive in addressing the changes occurring in the U.S. health-care
system. In November 1993, a $484 million pretax provision was recorded to cover
costs associated with these restructuring initiatives. Since the announcement of
the 1993 restructuring program, Allegiance has implemented, or is in the process
of implementing, all of the major strategic actions associated with the
restructuring program, which is expected to be completed in 1997.
F-10
<PAGE>
ALLEGIANCE CORPORATION
NOTES TO COMBINED FINANCIAL STATEMENTS (CONTINUED)
4. RESTRUCTURING CHARGES (CONTINUED)
Included in the 1993 restructuring plan was the intent to divest the
diagnostics manufacturing businesses and a valuation allowance was established
as a component of the 1993 restructuring charge. In December 1994, subject to
certain settlement provisions, the divestiture of these businesses was completed
and net proceeds were received of approximately $44 million in cash, $200
million in installment notes (which were collected in cash during January 1995)
and $40 million in face value of preferred stock. In addition, accounts
receivable were retained of approximately $85 million, which was collected from
customers in the normal course of business. Allegiance has retained the rights
to distribute all current diagnostics products in the U.S.
Throughout 1995, active discussions took place with the buyer of the
diagnostics businesses related to interpretations of and responsibility relative
to the settlement provisions contained in the purchase and sale and related
agreements. The divestiture was also significantly complicated by a dispute
between the diagnostics manufacturing businesses and one of its major suppliers,
which ultimately led to a lower than expected final valuation of the business.
This dispute has been settled. In the third quarter of 1995, settlement
negotiations were completed with the buyer of the diagnostics businesses and
adjustments to the purchase price were finalized along with a revision of cost
estimates to complete the divestiture. This resulted in an additional
restructuring charge of approximately $76 million.
Employee-related costs include provisions for severance, outplacement
assistance, relocation and retention payments for employees in the affected
operations worldwide. Since the inception of the restructuring program,
approximately 1,890 of the 2,860 positions that were originally expected to be
affected by the program have been eliminated. As process changes were
implemented in connection with the restructuring program, it became apparent
that, as certain management level positions were eliminated, other lower cost
positions were added. While this has generated savings levels consistent with
expectations, management has revised its targeted head count reduction to 2,230
net positions. The majority of the remaining reductions will occur in 1996 and
1997, as facility closures and consolidations are completed as planned.
F-11
<PAGE>
ALLEGIANCE CORPORATION
NOTES TO COMBINED FINANCIAL STATEMENTS (CONTINUED)
4. RESTRUCTURING CHARGES (CONTINUED)
The following table summarizes the 1993 restructuring program for Allegiance
businesses:
<TABLE>
<CAPTION>
DIVESTITURES
EMPLOYEE- AND ASSET OTHER
RELATED COSTS WRITE-DOWNS COSTS TOTAL
------------- ------------- --------- ---------
(IN MILLIONS)
<S> <C> <C> <C> <C>
Initial restructuring charge..................... $ 103 $ 278 $ 103 $ 484
Utilization:
Cash........................................... (31) (22) (23) (76)
Noncash........................................ -- (160) -- (160)
----- ------ --------- ---------
December 31, 1994................................ $ 72 $ 96 $ 80 $ 248
----- ------ --------- ---------
Utilization:
Cash........................................... (29) (43) (33) (105)
Noncash........................................ -- (66) -- (66)
Adjustment to reserve............................ -- 76 -- 76
----- ------ --------- ---------
December 31, 1995................................ $ 43 $ 63 $ 47 $ 153
----- ------ --------- ---------
Utilization:
Cash........................................... (7) (11) (4) (22)
Noncash........................................ -- (16) -- (16)
----- ------ --------- ---------
March 31, 1996................................... $ 36 $ 36 $ 43 $ 115
----- ------ --------- ---------
----- ------ --------- ---------
</TABLE>
The 1995 restructuring reserve balance consisted of $89 million of current
and $64 million noncurrent liabilities. The balance in the 1994 reserves
consisted of $80 million of current and $168 million of non-current liabilities.
5. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
Accounts payable and accrued liabilities consisted of the following:
<TABLE>
<CAPTION>
DECEMBER 31,
1995 1994
--------- ---------------
(IN MILLIONS)
<S> <C> <C>
Accounts payable, principally trade.................................... $ 378 $ 390
Employee compensation and withholdings................................. 88 109
Restructuring.......................................................... 89 80
Property, payroll and other taxes...................................... 40 37
Other.................................................................. 97 104
--------- -----
Accounts payable and accrued liabilities............................... $ 692 $ 720
--------- -----
--------- -----
</TABLE>
6. LEASE OBLIGATIONS
Certain facilities and equipment are leased under operating leases expiring
at various dates. Most of the operating leases contain renewal options. Total
expense for all operating leases was $26 million in 1995, $38 million in 1994
and $38 million in 1993.
F-12
<PAGE>
ALLEGIANCE CORPORATION
NOTES TO COMBINED FINANCIAL STATEMENTS (CONTINUED)
6. LEASE OBLIGATIONS (CONTINUED)
Future minimum lease payments (including interest) under noncancelable
operating leases at December 31, 1995 were as follows:
<TABLE>
<CAPTION>
OPERATING
LEASES
---------------
(IN MILLIONS)
<S> <C>
1996................................................................... $ 20
1997................................................................... 15
1998................................................................... 11
1999................................................................... 6
2000................................................................... 4
Thereafter............................................................. 6
---
Total obligations and commitments...................................... $ 62
---
---
</TABLE>
7. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT
CONCENTRATIONS OF CREDIT RISK
Allegiance provides credit, in the normal course of business, to hospitals,
private and government institutions, health-care agencies, insurance agencies
and doctors' offices. Allegiance performs ongoing credit evaluations of its
customers and maintains reserves for potential credit losses which, when
realized, have been within the range of management's allowance for doubtful
accounts.
FINANCIAL INSTRUMENT USE
For all periods presented, Allegiance has been considered in Baxter's
overall risk management strategy. As part of this strategy, Baxter uses certain
financial instruments to reduce its exposure to adverse movements in foreign
exchange rates. These financial instruments are not used for trading purposes.
FOREIGN EXCHANGE RISK MANAGEMENT
As part of implementing its strategy, Baxter has allocated to Allegiance the
income and expense associated with certain option contracts used to hedge
anticipated cost of production expected to be denominated in foreign currencies.
The terms of these financial instruments were less than one year. Allocated net
expense and the related notional amounts for these options were immaterial in
all years presented. Subsequent to year-end 1995, Baxter entered into options to
reduce its foreign exchange exposures. Baxter allocated to Allegiance options
with a notional value of approximately $40 million to hedge anticipated costs of
production expected to be denominated in foreign currency.
FAIR VALUES OF FINANCIAL INSTRUMENTS
<TABLE>
<CAPTION>
CARRYING AMOUNTS APPROXIMATE FAIR
VALUES
---------------------- ----------------------
AS OF DECEMBER 31 (IN MILLIONS) 1995 1994 1995 1994
- - - ------------------------------------------------------------ --------- ----- --------- -----
<S> <C> <C> <C> <C>
Investment in affiliates.................................... $ 15 $ 9 $ 15 $ 9
</TABLE>
The carrying values of cash and cash equivalents, accounts receivable and
payable, and accrued liabilities, approximate fair value due to the short-term
maturities of these assets and liabilities.
Investments in affiliates are accounted for by both the cost and equity
methods and pertain to several minor equity investments in companies for which
fair values are determined by quoted market prices and others for which fair
values are not readily available, but are believed to exceed carrying amounts.
F-13
<PAGE>
ALLEGIANCE CORPORATION
NOTES TO COMBINED FINANCIAL STATEMENTS (CONTINUED)
8. RELATED PARTY TRANSACTIONS
Baxter has provided to Allegiance certain legal, treasury, insurance and
administrative services. Charges for these services are based on actual costs
incurred by Baxter. In addition, Allegiance is the primary distributor of
Baxter's intravenous solutions, cardiovascular devices and other products in the
United States and also provides other services to Baxter. Negotiated fees for
these distribution services have generally been under the same terms and
conditions granted to independent third parties. Additionally, these fees are
not materially different than the terms of the Distribution Agreement subsequent
to the Distribution. A summary of related party transactions, all of which are
with Baxter or Baxter affiliates, is shown in the table below (in millions):
<TABLE>
<CAPTION>
1995 1994 1993
--------- --------- ---------
<S> <C> <C> <C>
Allegiance provided:
Distribution services to Baxter in the U.S......................... $ 214 $ 206 $ 201
Administrative services to Baxter.................................. $ 25 $ 24 $ 23
Allegiance received:
Administrative services from Baxter................................ $ 48 $ 46 $ 44
International distribution services from Baxter.................... $ 26 $ 25 $ 23
</TABLE>
Management believes that the basis used for allocating corporate services is
reasonable. However, the terms of these transactions may differ from those that
would result from transactions among unrelated parties.
Allegiance participates in a centralized cash management program
administered by Baxter. Short-term advances from Baxter or excess cash sent to
Baxter has been treated as an adjustment to the "Investment By and Advances From
Baxter" account through the Balance Sheet date. No interest is charged on this
balance.
Effective on the Distribution Date, Baxter and Allegiance will enter into a
series of administrative services agreements pursuant to which Baxter and
Allegiance will continue to provide, for a specified period of time, certain
administrative services which each entity historically has provided to the
other. These agreements require both parties to pay to each other a fee which
approximates the actual costs of these services. Additionally, subsequent to the
spin-off, Allegiance will have continuing significant relationships with Baxter
as a distributor, customer and supplier for a wide array of health-care products
and services, and for specified transitional administrative support services.
See "Arrangements Between Baxter and Allegiance" included elsewhere in this
Information Statement, for detailed descriptions of the related agreements.
9. RETIREMENT AND OTHER BENEFIT PROGRAMS
Allegiance participated in Baxter-sponsored non-contributory, defined
benefit pension plans covering substantially all employees in the U.S. and
Puerto Rico. The benefits were based on years of service and the employee's
compensation during 5 of the last 10 years of employment as defined by the
plans. Plan assets, which are maintained in a trust administered by Baxter,
consist primarily of equity and fixed income securities. Baxter and Allegiance
have announced their intent to freeze benefits under these plans at the date of
the spin-off for Allegiance employees. The pension liability related to
Allegiance employees' service prior to the spin-off date will remain with
Baxter.
Pension expense associated with the Baxter-sponsored plans prior to its
being frozen was $17 million, $22 million and $28 million for 1995, 1994 and
1993, respectively. The assumed discount rate applied to benefit obligations to
determine 1995 pension expense was 9% and the assumed long-term rate of return
on assets was 9.5% for the U.S. and Puerto Rico plans.
F-14
<PAGE>
ALLEGIANCE CORPORATION
NOTES TO COMBINED FINANCIAL STATEMENTS (CONTINUED)
9. RETIREMENT AND OTHER BENEFIT PROGRAMS (CONTINUED)
In addition to pension benefits, Allegiance participated in Baxter-sponsored
contributory health-care and life insurance benefits for substantially all
domestic retired employees. Baxter and Allegiance have announced that they will
freeze benefits under these plans at the date of the spin-off for Allegiance
employees. Expense associated with these benefits prior to the date of the
spin-off were $9 million in 1995, $9 million in 1994 and $11 million in 1993.
Effective, January 1, 1993, Allegiance adopted FASB Statement No. 112,
"Employers' Accounting for Postemployment Benefits" which requires accrual
accounting for postemployment benefits such as disability related and
workers-compensation payments. The company recorded the obligation as a
cumulative effect of an accounting change for $5 million (net of $3 million in
related income tax benefits). The effect of this change on 1993 operating income
versus the prior method of accounting for these benefits was not material. The
liability associated with these benefits was $14 million for 1995 and 1994.
Most U.S. employees are eligible to participate in a qualified 401(k) plan.
Participants may contribute up to 12% of their annual compensation (limited in
1995 to $9,240 per individual) to the plan and Allegiance matches participants'
contributions, up to 3% of compensation. Matching contributions made by
Allegiance were $11 million in 1995, $14 million in 1994 and $14 million 1993.
10. OTHER (INCOME) EXPENSE
Components of other (income) expense are as follows:
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31,
-------------------------------
1995 1994 1993
--------- --------- ---------
(IN MILLIONS)
<S> <C> <C> <C>
Asset dispositions, net.............................................. $ (263) $ (11) $ (36)
Foreign exchange..................................................... -- 5 --
Other................................................................ (39) -- 10
--------- --- ---
Total other income................................................... $ (302) $ (6) $ (26)
--------- --- ---
--------- --- ---
</TABLE>
11. INCOME TAXES
Income (loss) before tax expense by category is as follows:
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31,
-------------------------------
1995 1994 1993
--------- --------- ---------
(IN MILLIONS)
<S> <C> <C> <C>
U.S................................................................. $ 434 $ 292 $ (191)
International....................................................... 42 46 37
--------- --------- ---------
Income (loss) before income tax expense............................. $ 476 $ 338 $ (154)
--------- --------- ---------
--------- --------- ---------
</TABLE>
F-15
<PAGE>
ALLEGIANCE CORPORATION
NOTES TO COMBINED FINANCIAL STATEMENTS (CONTINUED)
11. INCOME TAXES (CONTINUED)
Income tax expense before cumulative effect of accounting change by category
and by income statement classification is as follows:
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31,
-------------------------------
1995 1994 1993
--------- --------- ---------
(IN MILLIONS)
<S> <C> <C> <C>
Current
U.S.
Federal......................................................... $ 124 $ 91 $ 79
State and local, including Puerto Rico.......................... 34 26 29
International..................................................... (5) 3 5
--------- --------- ---------
Current income tax expense........................................ 153 120 113
--------- --------- ---------
Deferred
U.S.
Federal......................................................... 38 (5) (164)
State and local, including Puerto Rico.......................... 8 4 (34)
International..................................................... 4 4 (1)
--------- --------- ---------
Deferred income tax expense (benefit)............................. 50 3 (199)
--------- --------- ---------
Income tax expense (benefit)........................................ $ 203 $ 123 $ (86)
--------- --------- ---------
--------- --------- ---------
</TABLE>
The income tax expense shown above was calculated as if Allegiance were a
stand-alone entity.
The components of deferred tax assets and liabilities are as follows:
<TABLE>
<CAPTION>
DECEMBER 31,
-------------------------------
1995 1994 1993
--------- --------- ---------
(IN MILLIONS)
<S> <C> <C> <C>
Deferred tax assets
Accrued expenses................................................... $ 70 $ 60 $ 60
Restructuring costs................................................ 57 77 111
Other.............................................................. -- -- 1
--------- --------- ---------
Total deferred tax assets........................................ 127 137 172
--------- --------- ---------
Deferred tax liabilities
Asset basis differences............................................ 107 46 70
Other.............................................................. 1 -- 8
--------- --------- ---------
Total deferred tax liabilities................................... 108 46 78
--------- --------- ---------
Net deferred tax assets.......................................... $ 19 $ 91 $ 94
--------- --------- ---------
--------- --------- ---------
</TABLE>
In 1995, $22 million of deferred tax assets related to the divestiture of
the diagnostics manufacturing business were transferred to Baxter.
F-16
<PAGE>
ALLEGIANCE CORPORATION
NOTES TO COMBINED FINANCIAL STATEMENTS (CONTINUED)
11. INCOME TAXES (CONTINUED)
Income tax expense differs from income tax expense calculated by using the
U.S. federal income tax rate for the following reasons:
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31,
-------------------------------
1995 1994 1993
--------- --------- ---------
(IN MILLIONS)
<S> <C> <C> <C>
Income tax expense (benefit) at statutory rate....................... $ 166 $ 118 $ (54)
Tax-exempt operations................................................ (17) (23) (37)
Non deductible goodwill.............................................. 28 14 14
State and local taxes................................................ 27 15 (12)
Foreign tax (benefit)................................................ (1) (2) (2)
Other................................................................ -- 1 5
--------- --------- ---------
Income tax expense (benefit)....................................... $ 203 $ 123 $ (86)
--------- --------- ---------
--------- --------- ---------
</TABLE>
Allegiance has manufacturing operations outside the U.S. that benefit from
reductions in local tax rates under tax incentives that will continue at least
through 1998. U.S. federal income taxes, net of available foreign tax credits,
on unremitted earnings deemed permanently reinvested would not be material.
12. LEGAL PROCEEDINGS
Upon the Distribution, Allegiance will assume the defense of litigation
involving claims related to Allegiance Business, including certain claims of
alleged personal injuries as a result of exposure to natural rubber latex gloves
described below. Allegiance has not been named as a defendant in this litigation
but will be defending and indemnifying Baxter Healthcare Corporation ("BHC"), as
contemplated by the Reorganization Agreement, for all expenses and potential
liabilities associated with claims pertaining to this litigation. It is expected
that Allegiance will be named as a defendant in future litigation and may be
added as a defendant in existing litigation.
BHC was one of ten defendants named in a purported class action filed in
August 1993, on behalf of all medical and dental personnel in the state of
California who allegedly suffered allergic reactions to natural rubber latex
gloves and other protective equipment or who allegedly have been exposed to
natural rubber latex products. (KENNEDY, ET AL., V. BAXTER HEALTHCARE
CORPORATION, ET AL., Sup. Ct., Sacramento Co., Cal., #535632). The case alleges
that users of various natural rubber latex products, including medical gloves
made and sold by BHC and other manufacturers, suffered allergic reactions to the
products ranging from skin irritation to systemic anaphylaxis. The Court granted
defendants' demurrer to the class action allegations. On February 29, 1996, the
California Appellate Court upheld the trial court's ruling. In April 1994, a
similar purported class action, GREEN, ET AL. V. BAXTER HEALTHCARE CORPORATION,
ET AL., (Cir. Ct., Milwaukee Co., WI, 94CV004977) was filed against Baxter and
three other defendants. The class action allegations have been withdrawn, but
additional plaintiffs added individual claims. As of March 31, 1996, 24
additional lawsuits have been served on BHC containing similar allegations of
sensitization to natural rubber latex products. Allegiance intends to vigorously
defend against these actions.
Allegiance believes that a substantial portion of the liability and defense
costs related to natural rubber latex gloves cases and claims will be covered by
insurance, subject to self-insurance retentions, exclusions, conditions,
coverage gaps, policy limits and insurer solvency. BHC has notified its
insurance companies that it believes that these cases and claims are covered by
BHC's insurance. Most of BHC's insurers have reserved their rights (i.e.,
neither admitted nor denied coverage), and may attempt to reserve in the future,
the right to deny coverage, in whole or in part, due to differing
F-17
<PAGE>
ALLEGIANCE CORPORATION
NOTES TO COMBINED FINANCIAL STATEMENTS (CONTINUED)
12. LEGAL PROCEEDINGS (CONTINUED)
theories regarding, among other things, the applicability of coverage and when
coverage may attach. It is not expected that the outcome of these matters will
have a material adverse effect on Allegiance's business, cash flow, results of
operations or financial condition.
Under the U.S. Superfund statute and many state laws, generators of
hazardous waste which is sent to a disposal or recycling site are liable for
cleanup of the site if contaminants from that property later leak into the
environment. The law provides that potentially responsible parties may be held
jointly and severally liable for the costs of investigating and remediating a
site. This liability applies to the generator even if the waste was handled by a
contractor in full compliance with the law.
As of March 31, 1996, BHC has been named as a potentially responsible party
for cleanup costs at ten hazardous waste sites, for which Allegiance has assumed
responsibility. Allegiance's largest assumed exposure is at the Thermo-Chem site
in Muskegon, Michigan. Allegiance expects that the total cleanup costs for this
site will be between $44 million and $65 million, of which Allegiance's share
will be approximately $5 million. This amount, net of payments of approximately
$1 million, has been accrued and is reflected in Allegiance's combined financial
statements. The estimated exposure for the remaining nine sites is approximately
$4 million, which has been accrued and reflected in Allegiance's combined
financial statements.
BHC is a defendant in a number of other claims, investigations and lawsuits
for which Allegiance has assumed responsibility. Based on the advice of counsel,
management does not believe that the other claims, investigations and lawsuits
individually or in the aggregate, will have a material adverse effect on
Allegiance's business, cash flow, results of operations or financial condition.
13. INDUSTRY INFORMATION
Allegiance operates in a single industry segment as a leading provider of
medical products and services that help its health-care customers manage and
reduce the total cost of providing patient care. Through its nationwide
distribution network, Allegiance distributes a broad offering of hospital
supplies, including its own self-manufactured surgical and respiratory-therapy
products, to hospital and alternate-care customers. Allegiance also provides
cost management services to its health-care customers through inventory
management programs, customized packaging, and procedure and process consulting.
International sales from self-manufactured products are primarily in Canada,
France and Germany. For surgical products, the majority of raw materials used
for the manufacture of latex gloves are located in Malaysia. None of these
geographic locations represent 10% or more of net sales or identifiable assets
of Allegiance.
For the last three years, sales to customers which are members of two large
hospital buying groups, Premier and VHA, Inc. ("VHA"), as a percentage of total
sales were 27% and 16%, respectively in 1995, 23% and 13%, respectively in 1994,
and 23% and 13%, respectively in 1993. Premier and VHA each are comprised of a
group of health-care organizations which benefit from the pricing and other
benefits available to members of the group. However, some members are free to
purchase from the vendors of their choice. The loss of the relationship with
either group would not necessarily mean the loss of sales attributable to all
members of such group.
F-18
<PAGE>
SCHEDULE II
VALUATION AND QUALIFYING ACCOUNTS
(IN MILLIONS OF DOLLARS)
<TABLE>
<CAPTION>
ADDITIONS
-----------------------------------------------------------------------------
BALANCE AT CHARGED TO CHARGED TO DEDUCTIONS BALANCE
BEGINNING COSTS AND OTHER FROM AT END OF
DESCRIPTION OF PERIOD EXPENSES ACCOUNTS (A) RESERVES PERIOD
- - - ---------------------------------------------------- ------------- --------------- --------------- --------------- -----------
<S> <C> <C> <C> <C> <C>
Year ended December 31, 1995:
Accounts receivable............................... $ 17 $ 3 $ -- $ (2) $ 18
-- --
-- --
--- --- ---
--- --- ---
Year ended December 31, 1994:
Accounts receivable............................... $ 13 $ 7 $ 1 $ (4) $ 17
-- --
-- --
--- --- ---
--- --- ---
Year ended December 31, 1993:
Accounts receivable............................... $ 12 $ 3 $ -- $ (2) $ 13
-- --
-- --
--- --- ---
--- --- ---
</TABLE>
- - - ------------------------
(A) Valuation accounts of acquired or divested companies and foreign currency
translation adjustments. Reserves are deducted from assets to which they
apply.
F-19
<PAGE>
INFORMATION STATEMENT
TABLE OF CONTENTS
<TABLE>
<CAPTION>
DESCRIPTION PAGE
- - - ----------------------------------------------- -----
<S> <C>
AVAILABLE INFORMATION.......................... 2
SUMMARY........................................ 3
SELECTED HISTORICAL FINANCIAL DATA............. 7
SUPPLEMENTARY FINANCIAL DATA................... 8
RISK FACTORS................................... 9
UNITED STATES HEALTH-CARE ENVIRONMENT 9
UNITED STATES COMPETITION.................... 9
REVENUES FROM CUSTOMERS PURCHASING THROUGH
BUYING GROUPS............................... 10
POTENTIAL TAXABILITY......................... 10
FINANCIAL LEVERAGE........................... 10
MUTUAL DISTRIBUTION ARRANGEMENTS............. 10
DEPENDENCE ON ADMINISTRATIVE SERVICES........ 10
NO OPERATING HISTORY AS AN INDEPENDENT
COMPANY..................................... 11
NO PRIOR MARKET FOR ALLEGIANCE COMMON
STOCK....................................... 11
ALLEGIANCE DIVIDEND POLICY................... 11
EFFECTS ON STOCK............................. 11
CERTAIN ANTI-TAKEOVER EFFECTS................ 11
GOVERNMENT REGULATION........................ 11
BACKGROUND 12
ALLEGIANCE..................................... 12
THE DISTRIBUTION............................... 13
REASONS FOR THE DISTRIBUTION................. 13
MANNER OF EFFECTING THE DISTRIBUTION......... 13
CERTAIN FEDERAL INCOME TAX CONSEQUENCES OF
THE DISTRIBUTION............................ 14
LISTING AND TRADING OF ALLEGIANCE COMMON
STOCK....................................... 15
FUTURE MANAGEMENT OF ALLEGIANCE.............. 15
OPINIONS OF FINANCIAL ADVISOR................ 15
ARRANGEMENTS BETWEEN BAXTER AND ALLEGIANCE..... 17
REORGANIZATION AGREEMENT..................... 17
TAX SHARING AGREEMENT........................ 19
AGENCY, SERVICES AND DISTRIBUTION
AGREEMENTS.................................. 19
SERVICES AGREEMENTS.......................... 20
ALLEGIANCE FINANCING........................... 21
ALLEGIANCE BUSINESS............................ 22
OVERVIEW..................................... 22
STRATEGIC PROFILE............................ 22
STRATEGIC PRIORITIES......................... 23
DISTRIBUTION SERVICES........................ 24
PRODUCT OFFERING............................. 25
COST-MANAGEMENT SERVICES..................... 27
CONTRACTUAL ARRANGEMENTS; BUYING GROUPS...... 28
SALES AND MARKETING.......................... 28
RAW MATERIALS SUPPLIERS...................... 28
PATENTS AND TRADEMARKS....................... 28
COMPETITION.................................. 28
QUALITY CONTROL.............................. 29
GOVERNMENT REGULATION........................ 29
EMPLOYEES.................................... 29
<CAPTION>
DESCRIPTION PAGE
- - - ----------------------------------------------- -----
<S> <C>
LEGAL PROCEEDINGS.............................. 29
PROPERTIES..................................... 30
ALLEGIANCE PRO FORMA FINANCIAL INFORMATION..... 31
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF
OPERATIONS.................................... 36
OVERVIEW..................................... 36
RESULTS OF OPERATIONS........................ 36
LIQUIDITY AND CAPITAL RESOURCES.............. 40
ALLEGIANCE MANAGEMENT.......................... 43
BOARD OF DIRECTORS........................... 43
COMMITTEES OF THE BOARD OF DIRECTORS......... 44
THE AUDIT AND PUBLIC POLICY COMMITTEE........ 44
THE COMPENSATION AND NOMINATING COMMITTEE.... 44
COMPENSATION OF DIRECTORS.................... 45
EXECUTIVE OFFICERS........................... 45
1995 COMPENSATION OF EXECUTIVE OFFICERS...... 46
STOCK OPTION GRANTS.......................... 48
STOCK OPTION EXERCISES....................... 49
BAXTER PENSION PLAN.......................... 49
BAXTER STOCK HELD BY ALLEGIANCE EMPLOYEES.... 50
COMPENSATION OF EXECUTIVE OFFICERS........... 50
COMPENSATION PHILOSOPHY FOR EXECUTIVE
OFFICERS ................................... 50
COMPENSATION ELEMENTS........................ 51
1996 INCENTIVE COMPENSATION PROGRAM.......... 51
CHANGE OF CONTROL PLAN....................... 53
ALLEGIANCE RETIREMENT PLAN................... 53
COMPENSATION COMMITTEE INTERLOCKS DISCLOSURE
AND INSIDER PARTICIPATION................... 55
OWNERSHIP OF ALLEGIANCE COMMON STOCK BY CERTAIN
BENEFICIAL OWNERS............................. 56
DISCRIPTION OF ALLEGIANCE CAPITAL STOCK........ 57
AUTHORIZED CAPITAL STOCK..................... 57
ALLEGIANCE STOCK............................. 57
ALLEGIANCE PREFERRED STOCK................... 57
ALLEGIANCE RIGHTS AGREEMENT.................. 57
CERTAIN ANTI-TAKEOVER EFFECTS.................. 60
CERTIFICATE OF INCORPORATION AND BY-LAWS..... 60
STATE LAW.................................... 62
LIABILITY AND INDEMNIFICATION OF DIRECTORS AND
OFFICERS...................................... 63
LIMITATION OF LIABILITY OF DIRECTORS......... 63
INDEMNIFICATION OF DIRECTORS AND OFFICERS.... 63
INDEX TO COMBINED FINANCIAL STATEMENTS......... F-1
ANNEX A -- CERTIFICATE OF INCORPORATION........
ANNEX B -- BY-LAWS.............................
</TABLE>
<PAGE>
PART II
INFORMATION NOT INCLUDED IN INFORMATION STATEMENT
E X H I B I T I N D E X
EXHIBIT NUMBER DESCRIPTION OF DOCUMENT
- - - -------------- -----------------------
** 2 Form of Reorganization Agreement
* 3.1 Form of Amended and Restated Certificate of Incorporation
of Allegiance Corporation (attached to Information
Statement as Annex A and incorporated herein by reference)
* 3.2 Form of Amended and Restated Bylaws of Allegiance Corporation
(attached to Information Statement as Annex B and incorporated
herein by reference)
** 4.1 Certificate of Common Stock of Allegiance Corporation
** 4.2 Form of Rights Agreement, by and between Allegiance
Corporation and the rights agent named therein (attached to
Information Statement as Annex E and incorporated herein by
reference)
** 10.1 Form of Allegiance Corporation 1996 Incentive Plan
** 10.2 Form of Tax Sharing Agreement
** 10.3 Form of Change of Control Plan
** 10.4 Retention Agreement for Mr. Zollars
** 10.5 Retention Agreement for Ms. Gaumer
** 22 Subsidiaries of Allegiance Corporation
** 27 Financial Data Schedule
NOTE:
* Filed herewith
** To be filed by amendment
<PAGE>
PART II-1
S I G N A T U R E
Pursuant to the requirements of Section 12 of the Securities Exchange Act of
1934, as amended, the registrant has duly caused this registration statement
to be signed on its behalf by the undersigned, thereunto duly authorized.
ALLEGIANCE CORPORATION
By: /s/ Lester B. Knight
--------------------------
Lester B. Knight
Chairman of the Board and
Chief Executive Officer
DATE: June 28, 1996
Page 2
<PAGE>
PART II-2
I N D E X T O E X H I B I T S
EXHIBIT NUMBER DESCRIPTION OF DOCUMENT Page
- - - -------------- ----------------------- ----
** 2 Form of Reorganization Agreement
* 3.1 Form of Amended and Restated Certificate
of Incorporation of Allegiance Corporation
(attached to Information Statement as Annex A
and incorporated herein by reference)
* 3.2 Form of Amended and Restated Bylaws of Allegiance
Corporation
(attached to Information Statement as Annex B
and incorporated herein by reference)
** 4.1 Certificate of Common Stock of Allegiance Corporation
** 4.2 Form of Rights Agreement, by and between Allegiance
Corporation and the rights agent named therein
(attached to Information Statement as Annex E
and incorporated herein by reference)
** 10.1 Form of Allegiance Corporation 1996 Incentive Plan
** 10.2 Form of Tax Sharing Agreement
** 10.3 Form of Change of Control Plan
** 10.4 Retention Agreement for Mr. Zollars
** 10.5 Retention Agreement for Ms. Gaumer
** 22 Subsidiaries of Allegiance Corporation
** 27 Financial Data Schedule
Page 3
<PAGE>
EXHIBIT 3.1
AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
OF
ALLEGIANCE CORPORATION
* * * * *
Allegiance Corporation, a Delaware corporation, initially incorporated on June
______, 1996, has duly adopted by action of its Board of Directors and
stockholders the following amended and restated certificate of incorporation in
accordance with the provisions of Sections 242 and 245 of the General
Corporation Law of Delaware.
FIRST: The name of the Corporation is Allegiance Corporation .
SECOND: The registered office of the Corporation in the State of Delaware is
located at 1209 Orange Street in the City of Wilmington, County of New Castle.
The name of the registered agent of the Corporation is The Corporation Trust
Company.
THIRD: The purpose of the Corporation is to engage in any lawful act or
activity for which corporations may be organized under the General Corporation
Law of Delaware.
FOURTH: The total number of shares of stock which the Corporation shall have
authority to issue is Two Hundred Twenty Million (220,000,000) shares, of which
Twenty Million (20,000,000) shares, par value $.01 per share, shall be preferred
stock (the "Preferred Stock") and of which Two Hundred Million (200,000,000)
shares, par value $1.00 per share, shall be common stock (the "Common Stock").
Authority is hereby expressly granted to and vested in the Board of Directors of
the Corporation to issue Preferred Stock in one or more series and in connection
therewith to fix by resolutions providing for the issue of such series the
number of shares to be included in such series and the designations and such
voting powers, full or limited, or no voting powers, and such of the preferences
and relative, participating, optional or other special rights, and the
qualifications, limitations or restrictions thereof, of such series of the
Preferred Stock which are not fixed by the certificate of incorporation, to the
full extent now or hereafter permitted by the laws of the State of Delaware.
Without limiting the generality of the grant of authority contained in the
preceding sentence, the Board of Directors is authorized to determine any or all
of the following, and the shares of each series may vary from the shares of any
other series in any or all of the following respects:
1. The number of shares of such series (which may subsequently be
increased, except as otherwise provided by the resolutions of the Board of
Directors providing for the issue of such series, or decreased to a number not
less than the number of shares then outstanding) and the distinctive designation
thereof;
2. The dividend rights, if any, of such series, the dividend preferences,
if any, as between such series and any other class or series of stock, whether
and the extent to which shares of such series shall be entitled to participate
in dividends with shares of any other series or class of
<PAGE>
stock, whether and the extent to which dividends on such series shall be
cumulative, and any limitations, restrictions or conditions on the payment of
such dividends;
3. The time or times during which, the price or prices at which, and any
other terms or conditions on which the shares of such series may be redeemed, if
redeemable;
4. The rights of such series, and the preferences, if any, as between
such series and any other class or series of stock, in the event of any
voluntary or involuntary liquidation, dissolution or winding up of the
Corporation and whether and the extent to which shares of any such series shall
be entitled to participate in such event with any other class or series of
stock;
5. The voting powers, if any, in addition to the voting powers prescribed
by law of shares of such series and, to the extent not prohibited by applicable
law, voting powers which may exceed one vote per share, and the terms of
exercise of such voting powers;
6. Whether shares of such series shall be convertible into or
exchangeable for shares of any other series or class of stock, or any other
securities, and the terms and conditions, if any, applicable to such rights; and
7. The terms and conditions, if any, of any purchase, retirement or
sinking fund which may be provided for the shares of such series.
FIFTH: Subject to any rights of the holders of the Preferred Stock or any
terms thereof to elect additional directors under specified circumstances, the
number of directors which shall constitute the whole Board of Directors of the
Corporation shall be the number from time to time fixed by the Board of
Directors. A decrease in the number of directors shall not affect the term of
office of any director then in office.
Subject to any rights of the holders of the Preferred Stock or any series
thereof to fill any newly created directorships or vacancies, any vacancy on the
Board of Directors that results from an increase in the number of directors or
for any other reason, may be filled by a majority of the directors then in
office; and any other vacancy on the Board of Directors may be filled by a
majority of the directors then in office, although less than a quorum, or by a
sole remaining director.
Subject to the rights of the holders of any series of Preferred Stock, any
director may be removed from office at any time, but only for cause and only by
the affirmative vote of at least a majority of the then outstanding shares
entitled to vote for the election of such director.
Unless the Corporation's bylaws specify otherwise, the election of directors of
the Corporation need not be by written ballot.
SIXTH: The directors, other than those who may be elected by the holders of
any series of Preferred Stock under specified circumstances, shall be divided,
with respect to the time for which they severally hold office, into three
classes, with the term of office of the first class to expire at the 1997 annual
meeting of stockholders, the term of office of the second class to expire at the
1998 annual meeting of stockholders and the terms of office of the third class
to expire at the
Page 2
<PAGE>
1999 annual meeting of stockholders , with each director to hold office until
his or her successor shall have been duly elected and qualified. The directors
chosen to succeed those whose terms are expiring shall be identified as being of
the same class as the directors whom they succeed and shall be elected for a
term expiring at the third succeeding annual meeting of stockholders or
thereafter in each case until their respective successors are elected and
qualified, subject to death, resignation, retirement or removal from office.
Any new positions created as a result of the increase in the number of directors
shall be allocated to make the classes of directors as nearly equal as possible.
Any director elected to fill a term resulting from an increase in the number of
directors shall have the same term as the other members of his class. A
director elected to fill any other vacancy shall have the same remaining term as
that of his predecessor.
Notwithstanding the foregoing, whenever the holders of any one or more classes
or series of Preferred Stock issued by the Corporation shall have the right,
voting separately by class or series, to elect directors at an annual or special
meeting of stockholders, the election, term of office, filling of vacancies and
other features of such directorships shall be governed by the terms of the
certificate of incorporation applicable thereto, and such directors so elected
shall not be divided into classes pursuant to this Article SIXTH unless
expressly provided by such terms.
SEVENTH: The Board of Directors shall have such powers as are permitted by the
General Corporation Law of Delaware, including, without limitation, without the
assent or vote of the stockholders, to make, alter, amend, change, add to, or
repeal the bylaws of the Corporation; to fix and vary the amount to be reserved
as working capital; to authorize and cause to be executed mortgages and liens
upon all the property of the Corporation, or any part thereof, to determine the
use and disposition of any surplus or net profits over and above the capital
stock paid in, and to fix the times for the declaration and payment of
dividends.
EIGHTH:
The Board of Directors is hereby authorized to create and issue, whether or not
in connection with the issuance and sale of any of its capital stock or other
securities or property, rights entitling the holders thereof to purchase from
the Corporation shares of stock or other securities of the Corporation or any
other corporation. The times at which and the terms upon which such rights are
to be issued will be determined by the Board of Directors and set forth in the
contracts or instruments that evidence such rights. The authority of the Board
of Directors with respect to such rights shall include, but not be limited to,
determination of the following:
(A) the initial purchase price per share or other unit of the capital
stock or other securities or property to be purchased upon exercise of such
rights;
(B) provisions relating to the times at which and the circumstances under
which such rights may be exercised or sold or otherwise transferred, either
together with or separately from, any other capital stock or other securities of
the Corporation;
(C) provisions which adjust the number or exercise price of such rights or
amount or nature of the capital stock or other securities or property receivable
upon exercise of such rights in the event of a combination, split or
recapitalization of any capital stock of the Corporation, a change in ownership
of the Corporation's capital stock or other securities or a reorganization,
Page 3
<PAGE>
merger, consolidation, sale of assets or other occurrence relating to the
Corporation or any capital stock of the Corporation, and provisions restricting
the ability of the Corporation to enter into any such transaction absent an
assumption by the other party or parties thereto of the obligations of the
Corporation under such rights;
(D) provisions which deny the holder of a specified percentage of the
outstanding capital stock or other securities of the Corporation the right to
exercise such rights and/or cause the rights held by such holder to become void;
(E) provisions which permit the Corporation to redeem or exchange such
rights; and
(F) the appointment of a rights agent with respect to such rights.
NINTH: Notwithstanding anything contained in this Certificate of
Incorporation to the contrary, the affirmative vote of at least two-thirds of
the voting power of the then outstanding Voting Stock (as defined below), voting
together as a single class, shall be required to amend or repeal, or adopt any
provisions inconsistent, with the bylaws of the Corporation or Articles FIFTH,
SIXTH and EIGHTH of this Certificate of Incorporation. For the purposes of this
Certificate of Incorporation, "Voting Stock" shall mean the outstanding shares
of capital stock of the Corporation entitled to vote generally in the election
of Directors.
TENTH: No person who is, or was at any time but is no longer serving as, a
director of the Corporation shall be personally liable to the Corporation or its
stockholders for monetary damages for any breach of fiduciary duty by such
person as a director; provided that the provisions of this Article TENTH shall
not eliminate or limit the liability of a director (i) for any breach of the
director's duty of loyalty to the Corporation or its stockholders, (ii) for acts
or omissions not in good faith or which involve intentional misconduct or a
knowing violation of law, (iii) under Section 174 of the General Corporation Law
of the State of Delaware or (iv) for any transaction from which the director
derived an improper personal benefit. If the General Corporation Law of the
State of Delaware is amended to authorize corporate action further eliminating
or limiting the personal liability of directors, then the liability of a
director of the Corporation shall be eliminated or limited to the fullest extent
permitted by the General Corporation Law of the State of Delaware, as so
amended. No amendment to or repeal of this Article TENTH shall have the effect
of increasing the liability or alleged liability of any director of the
Corporation for or with respect to any act or omission of such director
occurring prior to such amendment or repeal.
ELEVENTH: The Corporation shall indemnify and advance expenses to each person
who serves as an officer or director of the Corporation or a subsidiary of the
Corporation and each person who serves or may have served at the request of the
Corporation as a director, officer, employee, or agent of another corporation,
partnership, joint venture, trust or other enterprise from any liability
incurred as a result of such service to the fullest extent permitted by the
General Corporation Law of Delaware as it may from time to time be amended,
except with respect to an action commenced by such director or officer against
the Corporation or by such director or officer as a derivative action by or in
the right of the Corporation. Each person who is or was an employee or agent of
the Corporation and each officer or director who commences any action against
the Corporation or a derivative action by or in the right of the Corporation may
be similarly indemnified and receive an advance of expenses at the discretion of
the Board of Directors.
Page 4
<PAGE>
The indemnification and advancement of expenses provided by, or granted pursuant
to, the certificate of incorporation shall not be deemed exclusive of any other
rights to which those seeking indemnification or advancement of expenses may be
entitled under any agreement, vote of stockholders or disinterested directors or
otherwise, both as to action in their official capacity and as to action in
another capacity while holding such office.
The Corporation may purchase and maintain insurance on behalf of any person who
is or was a director, officer, employee or agent of the Corporation, or is or
was serving at the request of this Corporation as a director, officer, employee
or agent of another corporation, partnership, joint venture, trust or other
enterprise against any liability asserted against him and incurred by him in any
such capacity, or arising out of his status as such, whether or not the
Corporation would have the power to indemnify him against such liability under
this certificate of incorporation or Delaware law.
The indemnification and advancement of expenses provided by, or granted pursuant
to, this certificate of incorporation shall, unless otherwise provided when
authorized or ratified, continue as to a person who has ceased to be a director,
officer, employee or agent and shall inure to the benefit of the heirs,
executors and administrators of such a person.
TWELFTH: The Corporation reserves the right to amend, alter, change or repeal
any provision contained in this certificate of incorporation, in the manner now
or hereafter prescribed by statute, and all rights conferred upon the
stockholders herein are granted subject to this reservation. No amendment to
this certificate of incorporation or repeal of any article of this certificate
of incorporation shall increase the liability or alleged liability or reduce or
limit the right to indemnification of any directors, officers, employees or
agents of the Corporation for acts or omissions of such person occurring prior
to such amendment or repeal.
THIRTEENTH: No action which requires the vote or consent of stockholders of
the Corporation may be taken without a meeting and vote of stockholders and the
power of stockholders to consent in writing without a meeting to the taking of
any action is specifically denied.
IN WITNESS WHEREOF, Allegiance Corporation has caused this Amended and Restated
Certificate of Incorporation to be signed by (NAME) , its (OFFICER
TITLE) , this ______day of ___________________, 1996.
ALLEGIANCE CORPORATION
By
---------------------------
(Name)
ATTEST: (Title)
By
---------------------------
(Name)
(Title)
Page 5
<PAGE>
EXHIBIT 23
- - - --------------------------------------------------------------------------------
CONSENT OF PRICE WATERHOUSE LLP
- - - --------------------------------------------------------------------------------
We hereby consent to the incorporation in the Information Statement constituting
part of the Registration Statement on Form 10 of our report dated June 27, 1996
appearing on page F-2 of (the "Form 10") of Allegiance Corporation the Form 10.
We also consent to the incorporation of our report on the Financial Statement
Schedule, which appears on page F-19 of the Form 10.
PRICE WATERHOUSE LLP
Chicago, Illinois
June 27, 1996
<PAGE>
EXHIBIT 3.2
AMENDED AND RESTATED EFFECTIVE _____________, 1996
ALLEGIANCE CORPORATION
BYLAWS
ARTICLE I
STOCKHOLDERS
SECTION 1. PLACE OF HOLDING MEETINGS. All meetings of the stockholders
shall be held at the principal executive offices of the Corporation, or such
other place as shall be determined by the Board of Directors.
SECTION 2. ELECTION OF DIRECTORS.
(a) The annual meeting of stockholders for the election of directors and
the transaction of other business shall be held at such time and date as shall
be determined by the Board of Directors.
(b) Only persons who are nominated in accordance with the following
procedures shall be eligible for election as directors of the Corporation,
except as may be otherwise provided in the Certificate of Incorporation of the
Corporation with respect to the right of holders of preferred stock of the
Corporation to nominate and elect a specified number of directors in certain
circumstances. Nominations of persons for election to the Board of Directors
may be made at any annual meeting of stockholders, or at any special meeting of
stockholders called for the purpose of electing directors, (i) by or at the
direction of the Board of Directors (or any duly authorized committee thereof)
or (ii) by any stockholder of the Corporation (A) who is a stockholder of record
or beneficial owner on the date of the giving of the notice provided for in this
Section 2 and on the record date for the determination of stockholders entitled
to vote at such meeting and (B) who complies with the notice procedures set
forth in this Section 2.
(c) In addition to any other applicable requirements, for a nomination to
be made by a stockholder, such stockholder must have given timely notice thereof
in proper written form to the secretary of the Corporation.
(d) To be timely, a stockholder's notice to the secretary must be
delivered to or mailed and received at the principal executive offices of the
Corporation (i) in the case of an annual meeting, not less than sixty (60) days
nor more than ninety (90) days prior to the anniversary date of the immediately
preceding annual meeting of stockholders; PROVIDED, HOWEVER, that in the event
that the annual meeting is called for a date that is not within thirty (30) days
before or after such anniversary date, notice by the stockholder in order to be
timely must be so received not later than the close of business on the tenth
(10th) day following the day on which such notice of the date of
<PAGE>
the annual meeting was mailed or such public disclosure of the date of the
annual meeting was made, whichever occurs first, and (ii) in the case of a
special meeting of stockholders called for the purpose of electing directors,
not later than the close of business on the tenth (10th) day following the day
on which notice of the date of the special meeting was mailed or public
disclosure of the date of the special meeting was made, whichever occurs first.
(e) To be in proper written form, a stockholder's notice to the secretary
must set forth (i) as to each person whom the stockholder proposes to nominate
for election as a director (A) the name, age, business address and residence
address of the person, (B) the principal occupation or employment of the person,
(C) the class or series and number of shares of capital stock of the Corporation
which are owned beneficially or of record by the person and (D) any other
information relating to the person that would be required to be disclosed in a
proxy statement or other filings required to be made in connection with
solicitations of proxies for election of directors pursuant to Section 14 of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules
and regulations promulgated thereunder; and (ii) as to the stockholder giving
the notice (A) the name and record address of such stockholder, (B) the class or
series and number of shares of capital stock of the Corporation which are owned
beneficially or of record by such stockholder, (C) a description of all
arrangements or understandings between such stockholder and each proposed
nominee and any other person or persons (including their names) pursuant to
which the nomination(s) are to be made by such stockholder, (D) a representation
that such stockholder intends to appear in person or by proxy at the meeting to
nominate the persons named in its notice and (E) any other information relating
to such stockholder that would be required to be disclosed in a proxy statement
or other filings required to be made in connection with solicitations of proxies
for election of directors pursuant to Section 14 of the Exchange Act and the
rules and regulations promulgated thereunder. Such notice must be accompanied
by a written consent of each proposed nominee to being named as a nominee and to
serve as a director if elected.
(f) No person shall be eligible for election as a director of the
Corporation, at any annual meeting of stockholders or at any special meeting of
stockholders called for the purpose of electing directors, unless nominated in
accordance with the procedures set forth in this Section 2. If the chairman of
the meeting determines that a nomination was not made in accordance with the
foregoing procedures, the chairman shall declare to the meeting that the
nomination was defective and such defective nomination shall be disregarded.
(g) The determination of whether shares of capital stock of the
Corporation are owned beneficially under this Section 2 shall be made in the
same manner applicable to proposals submitted pursuant to Rule 14a-8 of the
Securities Exchange Act of 1934.
SECTION 3. VOTING. Each stockholder entitled to vote in accordance with the
terms of the Certificate of Incorporation, these Bylaws or Delaware law shall,
unless the Certificate of Incorporation or Delaware law otherwise provides, be
entitled to one vote, in person or by proxy, for each share of stock entitled to
vote held by such stockholder, but no proxy shall be voted after three years
from its date unless such proxy provides for a longer period. The vote for
directors, and upon the demand of any stockholder, the vote upon any question
before the meeting, shall be by ballot. Except for the election of directors,
which shall be decided by a plurality of the shares
Page 2
<PAGE>
present in person or represented by proxy at the meeting and entitled to vote
thereat, all matters shall be decided by the affirmative vote of a majority of
shares present in person or represented by proxy at any meeting duly called and
entitled to vote thereat, except as otherwise provided by the Certificate of
Incorporation and/or Delaware law.
A stockholder may authorize another person or persons to act for such
stockholder as proxy (i) by executing a writing authorizing such person or
persons to act as such, which execution may be accomplished by such stockholder
or such stockholder's authorized officer, director, employee or agent signing
such writing or causing his or her signature to be affixed to such writing by
any reasonable means, including, but not limited to, facsimile signature, or
(ii) by transmitting or authorizing the transmission of a telegram, cablegram or
other means of electronic transmission (a "Transmission") to the person who will
be the holder of the proxy or to a proxy solicitation firm, proxy support
service organization or like agent duly authorized by the person who will be the
holder of the proxy to receive such Transmission, which Transmission must either
set forth or be submitted with information from which it can be determined that
such Transmission was authorized by such stockholder. The Secretary or such
other person or persons as shall be appointed from time to time by the Board of
Directors shall examine Transmissions to determine if they are valid. If it is
determined that a Transmission is valid, the person or persons making that
determination shall specify the information upon which such person or persons
relied. Any copy, facsimile telecommunication or other reliable reproduction of
such a writing or such a Transmission that is a complete reproduction of the
entire original writing or Transmission may be substituted or used in lieu of
the original writing or Transmission for any and all purposes for which the
original writing or Transmission could be used.
The secretary shall prepare and make, at least ten days before each meeting of
stockholders, a complete list of the stockholders entitled to vote at the
meeting, arranged in alphabetical order, and showing the address of each
stockholder and the number of shares registered in the name of each stockholder.
Such list shall be open to the examination of any stockholder, for any purpose
germane to the meeting, during ordinary business hours, for a period of at least
ten days prior to the meeting, either at a place within the city where the
meeting is to be held, which place shall be specified in the notice of meeting,
or, if not so specified, at the place where the meeting is to be held. The list
shall also be produced and kept at the time and place of the meeting during the
whole time thereof and may be inspected by any stockholder who is present.
SECTION 4. QUORUM. Except as provided in the next section hereof, any
number of stockholders together holding a majority of the stock issued and
outstanding and entitled to vote thereat, who shall be present in person or
represented by proxy at any meeting duly called, shall constitute a quorum for
the transaction of business.
SECTION 5. ADJOURNMENT OF MEETINGS. If less than a quorum shall be in
attendance at any time for which the meeting shall have been called, the meeting
may, after the lapse of at least half an hour, be adjourned from time to time by
a majority of the stockholders present or represented and entitled to vote
thereat. If notice of such adjourned meeting is sent to the stockholders
entitled by statute to receive the same, and such notice contains a statement of
the
Page 3
<PAGE>
purpose of the meeting, that the previous meeting failed for lack of a quorum,
and that under the provisions of this Section it is proposed to hold the
adjourned meeting with a quorum of those present, then any number of
stockholders, in person or by proxy, shall constitute a quorum at such meeting
unless otherwise provided by statute.
SECTION 6. SPECIAL MEETINGS: HOW CALLED. Special meetings of the
stockholders for any purpose or purposes may be called only (a) by the chairman
of the board and chief executive officer or secretary, and shall be called by
the chairman of the board and chief executive officer or secretary upon a
request in writing therefor, stating the purpose or purposes thereof, delivered
to the chairman of the board and chief executive officer or secretary, signed by
a majority of the directors or (b) by resolution of the directors.
SECTION 7. NOTICE OF STOCKHOLDERS' MEETINGS. Written or printed notice
stating the time and place of regular or special meetings of the stockholders
and the general nature of the business to be considered shall be mailed by the
secretary, or such other officer as the Board of Directors may designate, to
each stockholder entitled to vote thereat at his address as it appears on the
records of the Corporation, at least twenty (20) days but not more than sixty
(60) days before the date of such meeting.
SECTION 8. CONDUCT OF THE MEETINGS.
(a) The chairman of the meeting shall have absolute authority over matters
of procedure and there shall be no appeal from the ruling of the chairman. If
the chairman, in his absolute discretion, deems it advisable to dispense with
the rules of parliamentary procedure as to any one meeting of stockholders or
part thereof, the chairman shall so state and shall clearly state the rules
under which the meeting or appropriate part thereof shall be conducted.
(b) If disorder should arise which prevents continuation of the legitimate
business of the meeting, the chairman may quit the chair and announce the
adjournment of the meeting; and upon his doing so, the meeting is immediately
adjourned.
(c) The chairman may ask or require that anyone not a bona fide
stockholder or proxy leave the meeting.
(d) A resolution or motion shall be considered for vote only if (i)
proposed by a stockholder or duly authorized proxy, and seconded by an
individual, who is a stockholder or a duly authorized proxy, other than the
individual who proposed the resolution and (ii) all other requirements under
law, the Corporation's Certificate of Incorporation, these Bylaws or otherwise,
for consideration of such a resolution or motion have been duly satisfied as
determined by the chairman in his absolute discretion, from which there shall be
no appeal.
Page 4
<PAGE>
SECTION 9. ANNUAL MEETINGS.
(a) No business may be transacted at an annual meeting of stockholders,
other than business that is either (i) specified in the notice of meeting (or
any supplement thereto) given by or at the direction of the Board of Directors
(or any duly authorized committee thereof), (ii) otherwise properly brought
before the annual meeting by or at the direction of the Board of Directors (or
any duly authorized committee thereof) or (iii) otherwise properly brought
before the annual meeting by any stockholder of the Corporation (A) who is a
stockholder of record or beneficial owner on the date of the giving of the
notice provided for in this Section 9 and on the record date for the
determination of stockholders entitled to vote at such annual meeting and (B)
who complies with the notice procedures set forth in this Section 9.
(b) In addition to any other applicable requirements, for business to be
properly brought before an annual meeting by a stockholder, such stockholder
must have given timely notice thereof in proper written form to the secretary of
the Corporation, which notice is not withdrawn by such stockholder at or prior
to such annual meeting.
(c) To be timely, a stockholder's notice to the secretary must be
delivered to or mailed and received at the principal executive offices of the
Corporation not less than sixty (60) days nor more than ninety (90) days prior
to the anniversary date of the immediately preceding annual meeting of
stockholders; PROVIDED, HOWEVER, that in the event that the annual meeting is
called for a date that is not within thirty (30) days before or after such
anniversary date, notice by the stockholder in order to be timely must be so
received not later than the close of business on the tenth (10th) day following
the day on which such notice of the date of the annual meeting was mailed or
such public disclosure of the date of the annual meeting was made, whichever
occurs first.
(d) To be in proper written form, a stockholder's notice to the secretary
must set forth as to each matter such stockholder proposes to bring before the
annual meeting (i) a brief description of the business desired to be brought
before the annual meeting and the reasons for conducting such business at the
annual meeting, (ii) the name and record address of such stockholder, (iii) the
class or series and number of shares of capital stock of the Corporation which
are owned beneficially or of record by such stockholder, (iv) a description of
all arrangements or understandings between such stockholder and any other person
or persons (including their names) in connection with the proposal of such
business by such stockholder and any material interest of such stockholder in
such business and (v) a representation that such stockholder intends to appear
in person or by proxy at the annual meeting to bring such business before the
meeting.
(e) No business shall be conducted at the annual meeting of stockholders
except business brought before the annual meeting in accordance with the
procedures set forth in this Section 9. If the chairman of the annual meeting
determines that business was not properly brought before the annual meeting in
accordance with the foregoing procedures, the chairman shall declare to the
meeting that the business was not properly brought before the meeting and such
business shall not be transacted.
(f) The determination of whether shares of capital stock of the
Corporation are owned beneficially under this Section 9 shall be made in the
same manner applicable to proposals submitted pursuant to Rule 14a-8 of the
Securities Exchange Act of 1934.
Page 5
<PAGE>
ARTICLE II
DIRECTORS
SECTION 1. QUALIFICATION AND QUORUM. One-third of the total number of
directors (rounded upwards, if necessary, to the next whole number) shall
constitute a quorum for the transaction of business at any meeting of the board.
If at any meeting of the board there shall be less than a quorum present, a
majority of those present may adjourn the meeting from time to time until a
quorum is obtained, and no further notice thereof need to be given other than by
announcement at said meeting which shall be so adjourned. The board may also
transact business without a meeting if all members of the board consent thereto
in writing.
The act of the majority of the directors present at any meeting at which a
quorum is present shall be the act of the Board of Directors, unless otherwise
provided by the laws of the State of Delaware, the Certificate of Incorporation
or these Bylaws.
SECTION 2. FIRST MEETING. The newly elected directors may hold their first
meeting for the purpose of organization and the transaction of business, if a
quorum is present, immediately after the annual meeting of the stockholders; or
the time and place of such meeting may be fixed by the written consent of all
the directors.
SECTION 3. REGULAR MEETINGS. A regular annual meeting of the Board of
Directors shall be held, without call or notice, in connection with the annual
meeting of stockholders, for the purpose of organizing the Board of Directors,
electing officers and transacting any other business that may properly come
before such meeting. Additional regular meetings of the Board of Directors may
be held without call or notice at such times as shall be determined by the Board
of Directors.
SECTION 4 ELECTION OF OFFICERS. At the first meeting or at any subsequent
meeting called for the purpose, the directors shall elect a chairman of the
board and chief executive officer as well as a secretary, and may elect a
president, one or more executive vice presidents, one or more senior vice
presidents, one or more group vice presidents, one or more vice presidents, a
treasurer, and one or more assistant secretaries, who need not be directors.
Each such officer shall hold office until the next annual election of officers,
and until his successor is elected and qualified.
SECTION 5. SPECIAL MEETINGS: HOW CALLED: NOTICE. Special meetings of the
board may be called by the chairman of the board and chief executive officer or
the president or the secretary on the written request of any two directors on
twenty-four (24) hours notice to each director. Such notice, which need not
specify the purpose of the meeting or the matters to be considered thereat, may
be given as provided in Article VIII, personally (including by telephone) or by
telegram or other written communication delivered to the residence or office of
the director. Such personal notice or written communication shall be effective
when delivered.
Page 6
<PAGE>
SECTION 6. PLACE OF MEETING. The directors may hold their meetings and have
one or more offices, and keep the books of the Corporation, outside the State of
Delaware, at any office or offices of the Corporation, or at any place as they
may from time to time by resolution determine.
SECTION 7. GENERAL POWERS OF DIRECTORS. The Board of Directors shall have
the management of the business of the Corporation, and subject to the
restrictions imposed by law, by the Certificate of Incorporation, or by these
Bylaws, may exercise all the powers of the Corporation, including any powers
incidental thereto.
SECTION 8. COMPENSATION OF DIRECTORS. Directors shall not receive any
stated salary for their services as directors, but by resolution of the board
compensation may be paid together with expenses of attendance at meetings.
Nothing herein contained shall be construed to preclude any director from
serving the Corporation in any other capacity as an officer, agent or otherwise,
and receiving compensation therefor.
ARTICLE III
COMMITTEES
SECTION 1. The Board of Directors shall create an audit and public policy
committee, and a compensation and nominating committee, and may create such
other committees as the board, from time to time, deems desirable. Each
committee shall consist of three or more of the directors of the Corporation
and, to the extent provided in the resolutions creating the committees or in
these Bylaws, shall have the powers of the Board of Directors in the management
of the business and affairs of the Corporation.
SECTION 2. The audit and public policy committee shall consist solely of
directors who are independent of management and free from any relationships
that, in the opinion of the Board of Directors, would interfere with their
exercise of independent judgment as a committee member. The Policy Statement on
Audit Committees issued by the New York Stock Exchange, as in effect from time
to time, shall be applicable in determining which directors are "independent"
for this purpose.
The audit and public policy committee shall assist the Board of Directors in
fulfilling its responsibilities for the Corporation's accounting and financial
reporting practices and provide a channel of communication between the Board of
Directors and the Corporation's independent auditors. The committee also shall
review the policies and practices of the Corporation to assure that they are
consistent with its social responsibility to employees, to customers and to
society.
Page 7
<PAGE>
To accomplish the above purposes, the audit and public policy committee shall:
(a) Review with the independent auditors the scope of their annual and
interim examinations, placing particular attention where either the committee or
the auditors believe such attention should be directed, and to direct the
auditors to expand (but not to limit) the scope of their audit whenever such
action is, in the opinion of the committee, necessary or desirable. The
independent auditors shall have sole authority to determine the scope of the
audit which they deem necessary for the formation of an opinion on financial
statements;
(b) Consult with the auditors during any annual or interim audit on any
situation which the auditors deem advisable for resolution prior to the
completion of their examination;
(c) Meet with the auditors to appraise the effectiveness of the audit
effort. Such appraisal shall include a discussion of the overall approach to
and the scope of the examination, with particular attention on those areas on
which either the committee or the auditors believe emphasis is necessary or
desirable;
(d) Determine through discussions with the auditors and otherwise, that no
restrictions were placed by management on the scope of the examination or its
implementation;
(e) Inquire into the effectiveness of the Corporation's accounting and
internal control functions through discussions with the auditors and appropriate
officers of the Corporation and exercise supervision of the Corporation's
policies which prohibit improper or illegal payments;
(f) Review with the auditors and management any registration statement
which shall be filed by the Corporation in connection with the public offering
of securities and such other public financial reports as the committee or the
Board of Directors shall deem desirable;
(g) Report to the Board of Directors on the results of the committee's
activities and recommend to the Board of Directors any changes in the
appointment of independent auditors which the committee may deem to be in the
best interests of the Corporation and its stockholders;
(h) Monitor the Corporation's policies and practices relating to the
health and safety of employees and customers as well as the ethical standards of
the Corporation; and
(i) Have such other powers and perform such other duties as the board
shall, from time to time, grant and assign to it.
SECTION 3. The compensation and nominating committee shall consist solely of
directors who are independent of management, as defined in Section 2.
(a) The committee shall (1) determine the compensation of officers, other
than the chairman of the board and chief executive officer and advise the board
of such determination, (2) exercise the authority of the board concerning
employee benefit plans, including those plans which are limited in their
application to officers and senior management, (3) serve as the administration
committee of the Corporation's stock option plans, (4) make recommendations to
the board
Page 8
<PAGE>
concerning the compensation of the chairman of the board and chief executive
officer, and (5) advise the board and the chairman of the board and chief
executive officer on other compensation and employee benefit matters.
(b) In addition, the committee shall assist and advise the Board of
Directors in connection with board membership, board committee structure and
membership. To accomplish these purposes, the committee shall:
(1) Develop general criteria for use in selecting potential new board
members and assist the board in identifying and attracting qualified candidates
for election to the board;
(2) Recommend to the board annually a slate of nominees to be proposed by
the board to the stockholders as nominees for election as directors and, from
time to time, recommend persons to fill any vacancy on the board;
(3) Recommend to the board any changes in number, authority and duties of
board committees and the chairmen and members who should serve thereon;
(4) In the event of the death, incapacity, resignation or other absence
(temporary or permanent) of the chairman of the board and chief executive
officer, the committee shall confer and recommend for election by the full board
an acting or successor chairman of the board and chief executive officer; and
(5) Make recommendations to the board concerning compensation payable for
board membership, as well as other benefits available to board members.
The compensation and nominating committee shall have such other powers and
perform such other duties as the board shall, from time to time, grant and
assign to it.
SECTION 4. The following provisions shall apply to all committees of the
Board of Directors:
(a) Any power or authority granted to a committee by these bylaws may also
be exercised by the Board of Directors;
(b) Each member of a committee shall hold office until the next regular
annual meeting of the Board of Directors following his designation and until his
successor is designated as a member of a committee, or until the committee is
dissolved by a majority of the whole board or the member is removed as
hereinafter provided;
(c) Meetings of a committee may be called by any member thereof, the
chairman of the board and chief executive officer, the secretary, or any
assistant secretary upon twenty-four (24) hours notice to each member stating
the place, date, and hour of the meeting, which notice may be written or oral.
If mailed, the notice shall be deemed to be delivered when deposited in the
United States mail, addressed to the member of the committee at his business
address, provided it is mailed four (4) days prior to the meeting. Any member
of a committee may waive notice of any meeting
Page 9
<PAGE>
and no notice of any meeting need be given to any member thereof who attends in
person. The notice of a meeting of a committee need not state the business
proposed to be transacted at the meeting;
(d) The lesser of a majority of the members or two members of a committee
shall constitute a quorum for the transaction of business at any meeting thereof
and action of a committee must be authorized by the affirmative vote of a
majority of the members present at a meeting at which a quorum is present;
(e) Any action that may be taken by a committee at a meeting may be taken
without a meeting if a consent in writing, setting forth the action to be taken,
shall be signed by all of the members of a committee and filed with the minutes
of the committee, which action shall be effective as of the date stated in such
consent;
(f) Any vacancy on a committee may be filled by a resolution adopted by a
majority of the Board of Directors;
(g) Any member of a committee may be removed at any time with or without
cause by resolution adopted by a majority of the Board of Directors;
(h) The chairman of each committee of the Board of Directors shall be
appointed from among the members of such committee by the Board of Directors.
The chairman of the committee shall, if present, preside at all meetings of a
committee. A committee may fix its own rules of procedure which shall not be
inconsistent with these Bylaws. Each committee shall keep regular minutes of
its proceedings and report its proceedings at the next meeting of the Board of
Directors; and
(i) The chairman of the board and chief executive officer shall act in an
advisory capacity to all committees.
ARTICLE IV
OFFICERS
SECTION 1. The officers of the Corporation shall be the chairman of the
board and chief executive officer and the secretary, and may include a
president, one or more executive vice presidents, one or more senior vice
presidents, one or more group vice presidents, one or more vice presidents, a
treasurer, one or more assistant secretaries, and such other officers as may
from time to time be elected or appointed by the Board of Directors. Any number
of offices may be held by the same person.
SECTION 2. CHAIRMAN OF THE BOARD AND CHIEF EXECUTIVE OFFICER. The
chairman of the board and chief executive officer shall be the chief executive
officer of the Corporation and shall have the responsibility for the management
of the Corporation and such other
Page 10
<PAGE>
powers and duties as may be assigned to him from time to time by the board. The
chairman of the board and chief executive officer shall, when present, preside
at all meetings of the stockholders and of the Board of Directors. He shall act
as liaison from and as spokesman for the board. He shall participate in long
range planning for the Corporation. He may sign shares of the Corporation, any
deeds, mortgages, bonds, contracts or other instruments which the Board of
Directors has authorized to be executed, or which are in the ordinary course of
business of the Corporation. He may vote, either in person or by proxy, all the
shares of the capital stock of any company which the Corporation owns or is
otherwise entitled to vote at any and all meetings of the stockholders of such
company and shall have the power to accept or waive notice of such meetings. He
shall in general perform all duties incident to the office and such other duties
as shall be prescribed by the Board of Directors from time to time.
SECTION 3. PRESIDENT. The president shall have such duties and authority as
the chairman of the board and chief executive officer may determine from time to
time. In the absence or disability of the chairman of the board and chief
executive officer, the president shall exercise all powers and discharge all of
the duties of the chairman of the board and chief executive officer, including
the general supervision and control of all the business and affairs of the
Corporation. He may sign any deeds, mortgages, bonds, contracts or other
instruments which the Board of Directors has authorized to be executed or which
are in the ordinary course of business of the Corporation. He may vote, either
in person or by proxy, all the shares of the capital stock of any company which
the Corporation owns or is otherwise entitled to vote at any and all meetings of
the stockholders of such company and shall have the power to accept or waive
notice of such meetings.
SECTION 4. VICE PRESIDENTS. In the absence or disability of the chairman of
the board and chief executive officer and the president, the functions of the
chairman of the board and chief executive officer shall be performed by the
executive vice president who was first elected to that office and who is not
then absent or disabled, or, if none, the senior vice president who was first
elected to that office and who is not then absent or disabled, or, if none, the
group vice president who was first elected to that office and who is not then
absent or disabled, or, if none, the vice president who was first elected to
that office and who is not then absent or disabled. Each executive vice
president, senior vice president, group vice president and vice president shall
have such powers and shall discharge such duties as may be assigned to him from
time to time by the chairman of the board and chief executive officer or the
president and may sign any deeds, mortgages, bonds, contracts or other
instruments which the Board of Directors has authorized to be executed or which
are in the ordinary course of business. Each executive vice president, senior
vice president, group vice president and vice president may vote, either in
person or by proxy, all the shares of the capital stock of any company which the
Corporation owns or is otherwise entitled to vote at any and all meetings of the
stockholders of such company and shall have the power to accept or waive notice
of such meetings.
SECTION 5. SECRETARY. The secretary shall give, or cause to be given,
notice of all meetings of stockholders and directors, and all other notices
required by law or by these Bylaws, and in the case of his absence or refusal or
neglect so to do, any such notice may be given by any
Page 11
<PAGE>
person thereunto directed by the chairman of the board and chief executive
officer or the directors, upon whose requisition the meeting is called as
provided in these Bylaws. He shall record all the proceedings of the meetings
of the stockholders and of the directors in a book to be kept for that purpose,
and shall perform such other duties as may be assigned to him by the Board of
Directors or the president. He shall have the custody of the seal of the
Corporation and shall affix the same to all instruments requiring it, when
authorized by the Board of Directors, the chairman of the board and chief
executive officer or the president, and attest the same. He shall have charge
of the original stock books, transfer books and stock ledgers, and act as
transfer agent in respect of the stock and the securities of the Corporation in
the absence of designation by the Board of Directors of a corporate transfer
agent, and shall perform all of the other duties incident to the office of
secretary. He may vote, either in person or by proxy, all the shares of the
capital stock of any company which the Corporation owns or is otherwise entitled
to vote at any and all meetings of the stockholders of such company and shall
have the power to accept or waive notice of such meetings.
SECTION 6. ASSISTANT SECRETARY. Each assistant secretary shall have such
powers and perform such duties as shall be assigned to him by the directors or
delegated to him by the secretary, and in the absence or inability of the
secretary to act, shall have the same general powers as the secretary.
SECTION 7. TREASURER. The treasurer shall perform such duties as shall be
delegated to him by the Board of Directors.
ARTICLE V
RESIGNATIONS AND FILLING OF VACANCIES
SECTION 1. RESIGNATIONS. Any director, member of a committee or other
officer may resign at any time. Such resignations shall be made in writing and
shall take effect at the time specified therein and, if no time be specified, at
the time of the receipt of such resignation by the chairman of the board and
chief executive officer or secretary. The acceptance of the resignation shall
not be necessary to make it effective.
SECTION 2. FILLING OF VACANCIES. If the office of any member of a committee
or other officer becomes vacant, the vacancy may be filled only by the remaining
directors in office, who, by a majority vote, may appoint any qualified person
to fill such vacancy. Any vacancy on the Board of Directors, resulting from an
increase in the number of directors or for any other reason, may be filled by a
majority of the directors then in office, although less than a quorum, or by a
sole remaining director. A person appointed to fill a vacancy shall hold office
for the unexpired term or until the next election of the class to which the
director has been assigned, and until his successor shall be elected and
qualify.
Page 12
<PAGE>
ARTICLE VI
CAPITAL STOCK
SECTION L. CERTIFICATES OF STOCK. Certificates of stock, numbered and with
the seal of the Corporation affixed, signed by the chairman of the board and
chief executive officer, the president or any vice president, and the secretary
or an assistant secretary or the treasurer, shall be issued to each stockholder
certifying the number of shares owned by him in the Corporation. Any of or all
the signatures on these certificates may be facsimile. In case any officer or
transfer agent who has signed or whose facsimile signature has been placed upon
a certificate shall have ceased to be such officer or transfer agent before such
certificate is issued, it may be issued by the Corporation with the same effect
as if he were such officer or transfer agent at the date of issue.
SECTION 2. LOST, STOLEN OR DESTROYED CERTIFICATES. A new certificate of
stock may be issued in the place of any certificate theretofore issued by the
Corporation, alleged to have been lost, stolen or destroyed, and the directors
may, in their discretion, require the owner of the lost, stolen or destroyed
certificate, or his legal representative, to give the Corporation a bond, in
such sum as they may direct, sufficient to indemnify the Corporation against any
claim that may be made against it on account of the alleged loss, theft or
destruction of any such certificate or the issuance of such new certificate.
SECTION 3. TRANSFER OF SHARES. The shares of stock of the Corporation shall
be transferable only upon its books by the holders thereof in person or by their
duly authorized attorneys or legal representatives, and upon such transfer the
old certificates shall be surrendered to the Corporation by the delivery thereof
to the person in charge of the stock and transfer books and ledgers, or to such
other person as the directors may designate, by whom they shall be canceled, and
new certificates shall thereupon be issued. A record shall be made of each
transfer, and whenever a transfer shall be made for collateral security, and not
absolutely, it shall be so expressed in the entry of the transfer.
SECTION 4. DETERMINATION OF RECORD DATE.
(a) In order that the Corporation may determine the stockholders entitled
to notice of or to vote at any meeting of stockholders or any adjournment
thereof, or entitled to receive payment of any dividend or other distribution or
allotment of any rights, or entitled to exercise any rights in respect of any
change, conversion or exchange of stock or for the purpose of any other lawful
action, the Board of Directors may fix, in advance, a record date, which shall
not be more than sixty (60) nor less than ten (10) days before the date of such
meeting, nor more than sixty (60) days prior to any other action.
Page 13
<PAGE>
(b) If no record date is fixed:
(1) The record date for determining stockholders entitled to
notice of or to vote at a meeting of stockholders shall be at the close of
business on the day next preceding the day on which notice is given, or, if
notice is waived, at the close of business on the day next preceding the day on
which the meeting is held.
(2) The record date for determining stockholders for any other
purpose shall be at the close of business on the day on which the Board of
Directors adopts the resolution relating thereto.
(c) A determination of stockholders of record entitled to notice of or to
vote at a meeting of stockholders shall apply to any adjournment of the meeting;
provided, however, that the Board of Directors may fix a new record date for the
adjourned meeting.
SECTION 5. DIVIDENDS. Subject to the applicable provisions of the
Certificate of Incorporation, if any, and Delaware law, the directors may
declare dividends upon the capital stock of the Corporation as and when they
deem expedient.
ARTICLE VII
AMENDMENTS
SECTION 1. AMENDMENTS OF BYLAWS. The stockholders by the affirmative vote
of at least two-thirds of the Voting Stock (as defined in Article VIII of these
Bylaws), or the directors by the affirmative vote of a majority of the directors
present at any meeting, may amend or alter any of these Bylaws, provided the
substance of the proposed amendment shall have been stated in the notice of the
meeting.
ARTICLE VIII
MISCELLANEOUS PROVISIONS
SECTION 1. CORPORATE SEAL. The corporate seal of the Corporation shall be
circular in form and shall contain the name of the Corporation, and the words
"Corporate Seal, Delaware". Said seal may be used by causing it or facsimile
thereof to be impressed or affixed or reproduced or otherwise.
SECTION 2. FISCAL YEAR. The fiscal year of the Corporation shall be the
calendar year.
Page 14
<PAGE>
SECTION 3. REGISTERED OFFICE. A registered office of the Corporation shall
be established and maintained at the office of The Corporation Trust Company, in
the City of Wilmington and County of New Castle, and such company shall be the
registered agent of this Corporation in the State of Delaware.
SECTION 4. BANK ACCOUNTS, CHECKS, DRAFTS, NOTES. The Corporation shall
maintain such bank accounts and checks upon such accounts shall be signed and/or
countersigned by such officers as may be designated by resolution of the Board
of Directors. Notes or other evidences of indebtedness issued in the name of
the Corporation shall be signed by such officer or officers, agent or agents of
the Corporation, and in such manner as shall from time to time be determined by
resolution of the Board of Directors.
SECTION 5. NOTICE AND WAIVER OF NOTICE. Whenever any notice is required by
these Bylaws to be given, personal notice is not meant unless expressly so
stated, and any notice so required shall be deemed to be sufficient if given by
depositing the same in a post office box in a sealed post paid wrapper,
addressed to the person entitled thereto at his last known post office address,
and such notice shall be deemed to have been given on the day of such mailing.
Any notice required to be given under these Bylaws may be waived by the person
entitled thereto. Stockholders not entitled to vote shall not be entitled to
receive notice of any meetings except as otherwise provided by statute.
SECTION 6. CERTAIN PURCHASES BY THE CORPORATION OF OUTSTANDING SHARES
OF ITS COMMON STOCK.
(a) VOTE REQUIRED FOR CERTAIN PURCHASES. Except as set forth in
subsection (b) of this Section 6, in addition to any vote of the Corporation's
stockholders required by law, the Corporation's Certificate of Incorporation or
these Bylaws, the affirmative vote of the holders of not less than a majority of
the Voting Stock (as defined below) of the Corporation shall be required before
the Corporation may purchase any outstanding shares of Common Stock of the
Corporation at a price known by the Corporation to be above Market Price (as
defined below) from a person known by the Corporation to be a Selling
Stockholder (as defined below). Such affirmative vote will be required
notwithstanding the fact that no vote may be required, or that a lesser
percentage may be specified, by law or any agreement with any national
securities exchange.
(b) WHEN A VOTE IS NOT REQUIRED. The provisions of subsection (a) of
this Section 6 will not apply to:
(i) any purchase or other acquisition of securities made as part of a
tender or exchange offer by the Corporation to purchase securities of the
same class made on the same terms to all holders of such securities and
complying with the applicable requirements of the Exchange Act and the
rules and regulations promulgated thereunder;
(ii) any purchase or acquisition made pursuant to an open market
purchase program approved by the Board of Directors; or
Page 15
<PAGE>
(iii) any purchase or acquisition which is approved by the vote of
a majority of the directors then in office and which is made at no more
than the Market Price, on the date that the understanding between the
Corporation and the Selling Stockholder is reached with respect to such
purchase (whether or not such purchase is made or a written agreement
relating to such purchase is executed on such date), of the shares of the
Common Stock of the Corporation to be purchased.
(c) CERTAIN DEFINITIONS. For purposes of this Section 6, the
following terms are defined as follows:
(i) "VOTING STOCK" means the outstanding shares of capital stock of
the Corporation entitled to vote generally in elections of directors of the
Corporation considered as one class.
(ii) "MARKET PRICE" means the highest closing sale price, during the
30-day period immediately preceding the date of the making of such purchase
agreement, of a share of the Common Stock of the Corporation on the
Composite Tape for the New York Stock Exchange. If such stock is not
quoted on the Composite Tape or is not listed on the New York Stock
Exchange, then such price during the 30-day period on the principal United
States securities exchange registered under the Exchange Act on which such
stock is listed. If such stock is not listed on any such exchange, then
the highest closing bid quotation with respect to a share of such stock
during the 30-day period on the National Association of Securities Dealers,
Inc. Automated Quotations System or any system then in use. If no such
quotations are available, the fair market value on the date in question of
a share of such stock.
(iii) "SELLING STOCKHOLDER" means and includes any person (other than
the Corporation, any of its Subsidiaries, any benefit plan or trust of or
for the benefit of the Corporation or any of its Subsidiaries, or any
trustee, agent or other representative of any of the foregoing) who or
which is the beneficial owner of in the aggregate five percent (5%) or more
of the outstanding shares of Common Stock of the Corporation and who or
which has purchased or agreed to purchase any of such shares within the
most recent two-year period. For purposes of determining whether a person
is a Selling Stockholder, the number of shares of Common Stock deemed to be
outstanding and the number of shares beneficially owned by such person
shall include shares respectively deemed owned through application of
Article VIII, Section 6(c)(v), but shall not include any other shares of
Common Stock which may be issuable to any other person pursuant to any
agreement, arrangement or understanding, or upon exercise of conversion
rights, warrants or options, or otherwise.
(iv) A "PERSON" means any individual, firm, partnership, limited
liability company, corporation or other entity (including, without
limitation, a "group" within the meaning of Section 13(d) of the Exchange
Act and the rules and regulations promulgated thereunder).
(v) A person shall be the "BENEFICIAL OWNER" of any shares of Common
Stock of the Corporation:
Page 16
<PAGE>
(A) which such person or any of its Affiliates or
Associates (as defined below) beneficially owns, directly or
indirectly; or
(B) which such person or any of its Affiliates or
Associates has (1) the right to acquire (whether such right is
conditional or exercisable immediately or only after the passage
of time), pursuant to any agreement, arrangement or understanding
or upon the exercise of conversion rights, exchange rights,
warrants or options, or otherwise, or (2) the right to vote
pursuant to any agreement, arrangement or understanding; or
(C) which are beneficially owned, directly or
indirectly, by any other person with which such person or any of
its Affiliates or Associates has any agreement, arrangement or
understanding for the purpose of acquiring, holding, voting or
disposing thereof.
(vi) The terms "AFFILIATE" and "ASSOCIATE" have the respective
meanings ascribed to such terms in Rule 12b-2 of the rules and regulations
under the Exchange Act.
(vii) "SUBSIDIARY" means any corporation at least a majority of the
outstanding securities of which having ordinary voting power to elect a
majority of the board of directors of such corporation (whether or not any
other class of securities has or might have voting power by reason of the
happening of a contingency) is at the time owned or controlled directly or
indirectly by the Corporation and/or one or more Subsidiaries.
(d) FIDUCIARY DUTY OF SELLING STOCKHOLDER. Nothing contained in this
Section 6 shall be construed to relieve any Selling Stockholder or any other
person from any fiduciary obligation imposed by law.
(e) INTERPRETATIONS. The Board of Directors of the Corporation has
the power to construe and interpret this Section 6, including, without
limitation, (i) whether a person is a Selling Stockholder, (ii) whether a person
is an Affiliate or Associate of another, (iii) whether this Section 6 is
applicable to a proposed transaction, (iv) what is the Market Price and whether
a price is above Market Price, and (v) when or whether a purchase or agreement
to purchase any shares of Common Stock of the Corporation has occurred and when
or whether a person has become a beneficial owner of any shares of Common Stock
of the Corporation. Any decision or action reasonably taken by the Board of
Directors of the Corporation in good faith in connection with the interpretation
of this Section 6 shall not constitute a violation of and shall be deemed to be
in accordance with the terms of this Section 6.
Page 17
